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Abstract
This thesis describes the synthesis and evaluation of compounds designed as isoform- 
selective nitric oxide synthase inhibitors, carrying a 4,5-dihydrothiazole or a thiourea. 
Structural features of the selective iNOS inhibitor 1400W were incorporated into the 
design.
Human tumours have high levels of NO, the main source being iNOS. NO causes 
increased tumour blood flow. Selective iNOS inhibition should cause collapse of the 
tumour vasculature, an antitumour event, but will also increase tumour hypoxia and 
potentiate bioreductively activated drugs.
The principal target compounds were N-benzyl and N-phenylthioureas, 2- 
benzylamino-4,5-dihydrothiazoles and 2-phenylamino-4,5-dihydrothiazoles. 
Isothiocyanates reacted with ammonia giving thioureas. Reaction of 3- and 4- 
methoxybenzylamines with 2-methylthio-4,5-dihydrothiazole at 180°C gave the 
corresponding dihydrothiazoles. Other dihydrothiazoles were synthesised by acid- 
catalysed cyclisation of N’-(2-hydroxylethyl)thioureas. N^-Aminothiocarbonyl-L- 
lysine and its methyl ester were synthesised similarly. Ne-(4,5-Dihydrothiazol-2- 
yl)lysine was synthesised via the N ’(2-hydroxyethyl)thiourea intermediate. The 
benzene rings carried various groups in meta or para positions to explore the 
structure-activity relationships.
The five most potent targets were analysed for time-dependent kinetics, giving an 
optimum pre-incubation time of fifteen minutes. bf-Aminothiocarbonyl-L-lysine 
and its methyl ester were potent, Ne-aminothiocarbonyl-L-lysine methyl ester 
displaying four-fold selectivity for cNOS. Both compounds were more potent than 
the known inhibitor thiocitrulline against the cNOS isoform and equivalent to L- 
NMMA against the iNOS isoform. The dihydrothiazoles were the most potent NOS 
inhibitors. 2-(3-(Aminomethyl)phenylamino)-4,5-dihydrothiazole was more potent 
than the known inhibitor 7NI but showed no isoform selectivity. N-(3- 
aminomethylphenyl)thiourea showed five-fold selectivity for the cNOS isoform, and 
with IC50 = 54 pM. The most potent and selective aromatic targets carried CH2NH2 ,
with the most selective being meta-substituted, which provides an optimum size for 
binding to NOS.
N-(2-Hydroxyethyl)-N’-(3-methoxyphenylmethyl)thiourea stimulated iNOS without 
pre-incubation. After ten minutes pre-incubation, it was weakly inhibitory. Other 
thioureas exhibited similar properties. These compounds may bind at more than one 
site, one site being stimulatory and the other inhibitory.
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Chapter 1: Introduction
Introduction
What is Nitric Oxide?
The potentially toxic free radical nitric oxide (NO*) is currently one of the most 
studied molecules in biomedical sciences. The colourless inorganic gas is 
synthesised by mammals (Nathan 1992), birds (Lee et al 1994), invertebrate (Muller 
and Bicker 1994) and bacteria (Chen and Rossazza 1994). It was first discovered as 
endothelial derived relaxing factor (EDRF) in the vascular system, since then it has 
been identified in a variety of tissues and cells; including macrophages, artery, 
advential nerves and brain. NO also plays a role in plant disease resistance (Cho et 
al 1998).
NO is produced from L-arginine (1) and the reaction is catalysed by the enzyme 
nitric oxide synthase (NOS), of which there are three different isoforms. NO is both 
a chemical messenger and a cytotoxic agent. As a chemical messenger it acts as an 
initiator for biological pathways that are essential to life, such as blood flow (Kerwin 
et al 1995). The role NO plays as a cytotoxic agent can be both beneficial and 
harmful.
NO has been linked to many different disease states, some examples are: 
Alzheimer’s disease, multiple sclerosis, AIDS-associated dementia, asthma, cancer, 
rheumatoid arthritis (Nathan 1997), Duchene’s muscular dystrophy, sickle cell 
anaemia, sepsis, heart failure, erectile dysfunction, diabetes and atherosclerosis 
(Maxwell 2002).
Due to NO being related to many diseases the understanding of the biological effects 
of NO in healthy and disease states has great potential in therapeutic applications.
Physical Properties of NO
It is important to understand the chemical biology of NO in order to appreciate its 
biological roles. NO in the pure state under standard temperature and pressure is a 
gas. However NO acts as a dissolved nonelectrolyte in all its biological activities 
and so, in most biological conditions, NO is not a gas (Kerwin et al 1995). NO can
1
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also have toxic effects by reacting with oxygen in an aerobic environment, producing 
toxic constituents of air pollution and cigarette smoke (Wink et al 1996b).
NO is an uncharged molecule. It is a diatomic radical containing eleven valence 
electrons, one of which makes the molecule paramagnetic. Its electron configuration 
is (g i ) 2 (0 2 ) 2 (0 3 ) 2 (71)4 (71*)1. The extra electron makes NO chemically highly 
reactive. The unpaired electron is in the antibonding molecular orbital and so is 
relatively easily removed to give the nitrosonium cation (NO+). Conversely, the 
addition of an electron to this orbital forms NO'. NO can act as a free radical, an 
electrophile and an oxidizing agent. NO is a relatively stable free radical which 
reacts readily with other free radicals such as dioxygen and superoxide (Stamler et al 
1992).
Reactions with oxygen
NO reacts with O2 in both the gas phase and aqueous solution to form NO2 .
2NO + 0 2 -> 2N02
The reaction is second order with respect to NO and first order with respect to O2 . In 
the gas phase NO2 will react further with NO2 to form dinitrogen tetroxide (N2O4) or 
react with another NO to form dinitrogen trioxide (N2O3).
N O 2 + N O 2  —^ N 2 O 4
n o 2+ n o - > n 2o 3
These species are highly reactive and are considered donors of nitrosonium ion 
(NO+). This ion can react with a variety of nucleophiles, including amines and thiols 
(Kerwin et al 1995).
Reaction with superoxide
The reaction of NO with superoxide is most likely to be the major route for NO 




NO + 0 2’ -> ONOO’
The stable nature of peroxynitrite allows it to diffuse through biological systems and 
across membranes before it reacts (Thomas 2000). Peroxynitrite is a potent oxidant 
which reacts with proteins, lipids and DNA. Peroxynitrite causes DNA damage by 
several mechanisms such as DNA base modifications and DNA single strand 
breakage (Szabo and Ohshima 1997).
Reaction with haemoglobin
NO has a much lower affinity for methemoglobin and other ferric (Fe ) compounds 
than for ferrous (Fe2+) haemoglobin (Kerwin et al 1995). NO reacts with haem 
proteins such as haemoglobin, myoglobin, and cytochrome c to form the 
corresponding nitrosyl-haem protein adduct. NO reacts with oxyhaem to form stable 
compounds in the absence of oxygen, forming met Hb and NO3'. The first order 
dependence on NO concentration and the lack of a limiting rate at high NO 
concentration shows that NO reacts directly with bound 0 2, without displacing it 
from the haem.
Hb-Fell (0 2) + NO-» Hb-Felll + NOT
This reaction limits the transport of NO in the blood, so that free NO does not have 
systemic effects.
Reaction with metals
NO can react with metalloproteins, such as intracellular cytochrome P-450 and 
cytochrome c oxidase. NOS has been found in mitochondria, so the competition 
between NO and 0 2 binding to cytochrome c oxidase may be used to regulate 
respiration (Pfeiffer et al 1999). NO reacts with some (but not all) transition metal 
complexes to give metal-nitrosyl adducts. The rate and stability of these reactions 
depends on the valence state of the metal and the ligands in the coordination sphere 




NO does not react directly with thiols to form S-nitrosothiols (SNTs or RS-NO). It is 
oxidised to the NO+ species, which readily react with thiols and thiolates (RSH/RS'), 
to form nitrosothiols (RS-NO). The major targets for the NO+ species are metal- and 
thiol-containing proteins, in particular Zn-fmger motifs within proteins (Stamler 
1994).
Nitrous acid, alkylnitrites, nitrosyl halides, N2 O3 and N2 O4  all act as carriers for NO+ 
(Pfeiffer et al 1999).
NO as an electrophile
Due to its electronic configuration, NO can act as an electrophile. NO reacts readily 
with primary and secondary amines to form adducts known as NONOates. The first 
step of the reaction involves NO reacting with the amine to form an NO complex. 
This acts as a radical and reacts with another NO molecule to form the NONO-ate 
adduct (scheme 1 . 1 ).
The NONO adduct is unstable and under aqueous conditions yields NO. These 
NONO-ate adducts may have therapeutic applications in conditions that results from 
impaired NO production e.g. angina (Thomas 2000).
R R R
H-N;y ° \  N = 0 ------- ..  H-N R2NH ,  H-N
R - R N=0 .N=0 R N=0
i A )  *•■>
NONO-ate adduct
Scheme 1.1: Mechanism to show the formation o f  a NONO-ate adduct
4
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Nitric Oxide Synthases (NOS)
There are two major groups of NOS; constitutive NOS (cNOS) and inducible 
(iNOS). cNOS can be further sub-divided into endothelial and neuronal forms (eNOS 
and nNOS). These are the more common terminology used, however nNOS was the 
first enzyme to be isolated from brain tissue and is otherwise known as NOS-I. 
Similarly, iNOS was the second type to be isolated and is known as NOS-II and 
eNOS is also known as NOS-III. Soon after nNOS was cloned (Bredt et al 1991), 
the genes encoding all three enzymes were mapped on the human chromosome 
(Nathan and Xie 1994), with a 51-57% homology between the human forms 
(Alderton et al 2001). All three isoforms are found in a variety of tissues and a brief 
summary together with gene locations are given in table 1.1.




Neuronal nNOS, ncNOS, 












Inducible iNOS, macrophage 





Table 1.1: Table illustrating the three isoforms of NOS and their gene location and 
tissue expression (Nathan and Xie 1994).
Both types are dependent on the reduced form of the coenzyme nicotinamide adenine 
dinucleotide phosphate (NADPH). cNOS is Ca2+/calmodulin-dependent; only the 
calcium-bound form of calmodulin (CaM) can bind and activate the enzyme. cNOS 
is unaffected by glucocorticoids and gives a short-lasting release of picomolar 
concentrations of NO. In contrast, iNOS is calcium-independent; this is because
5
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iNOS already binds to CaM and is fully active at such low calcium concentrations 
that its activity can never be limited by calcium. iNOS is inhibited by 
glucocorticoids and sustains a long lasting release of nanomolar concentrations of 
NO (Pfeiffer et al 1999). The function of each of the isoforms will be discussed in 





Evidence for mammalian nitric oxide synthesis was reported as early as 1916 but it 
was not until 1986 that Furchgott and Ignarro independently reported that EDRF and 
NO might be identical. At the same time, Ferid Murad was investigating the 
effectiveness of nitroglycerin as a treatment for heart attack. Nitroglycerin was 
shown to cause blood vessel relaxation once it had been converted to NO. NO 
relaxes muscles by instigating the formation of cyclic GMP in the same way that 
EDRF does (Snyder and Bredt 1992). Palmer et al, in 1987, showed that NO 
released from endothelial cells had identical chemical and biological properties to 
EDRF by stimulating the release of EDRF from endothelial cells and monitoring the 
relaxing effect on smooth muscle cells. At the same time the amount of NO released 
from the endothelium was monitored and was shown to fully account for the 
relaxation of muscle cells (Moncada et al 1991). These findings were later 
confirmed by Ignarro (Ignarro et al 1990).
In 1998, the Nobel Prize for physiology/medicine was awarded to Robert Furchgott, 
Louis Ignarro and Ferid Murad for their discoveries concerning nitric oxide as a 
signalling molecule in the cardiovascular system (Physiology or Medicine for 1998).
The biological actions of NO are directly related to the cell type and tissue that 
produce it. NO is produced by a wide variety of cells and tissues such as endothelial 
cells, the central nervous system, peripheral nervous system, platelets and certain 
activated cells of the immune system. The actions of NO derived from the three 
different isoforms will be discussed separately.
eNOS
NO produced by cNOS acts as a chemical messenger and is unique because it relies 
on its redox reactivity to convey information to neighbouring cells, and is 
synthesised when required, unlike other chemical messengers which transmit 
information by changing their conformation and ability to bind to a receptor, are 
stored in situ and are released under specific stimulation (Thomas 2000). NO has a 
short biological life and, therefore, target cells must be close before NO is
7
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metabolised to nitrate, nitrite and other reactive species. NO produced by cNOS 
isoforms is delivered to target cells in short bursts without damaging target cells and 
so is beneficial to biological processes.
eNOS is Ca /CaM-dependent and is expressed in endothelial cells. Synthesis of NO 
by eNOS in vascular endothelial cells is stimulated by acetylcholine receptors (ACh). 
NO diffuses into smooth muscle cells of the blood vessel wall and elicits a cGMP- 
dependent relaxation, which results in an increased blood flow through the vessel 
(Gross 2001) (figure 1.1). The key role of eNOS is in maintaining a normal blood 
pressure (Knowles and Moncada 1994). Endothelial dysfunction is believed to be 
due to an increase in superoxide production within the endothelium. Superoxide 
reacts with NO to form peroxynitrite. This reduces the amount of NO diffusing into 
the smooth muscle cells making these cells less likely to relax, leading to an increase 
in blood pressure and endothelial damage (Thomas 2000).
NO inhibits platelet aggregation via the soluble guanylate cyclase cyclic GMP 
dependent pathway (sGc-cGMP). NO binds to a haem cofactor within the guanylate 
cyclase enzyme and activates it. This leads to intracellular accumulation of cGMP 
which then activates a cascade of intracellular enzymes to bring about biological 
effects. NO, together with prostacyclin, provides a defence against platelet 
aggregation and adhesion to the endothelium (Kerwin et al 1995).
The correct balance of NO produced by eNOS is extremely important. Excessive 
NO production within the blood vessel wall is thought to be the basis for conditions 
such as septic- and cytokine-induced circulatory shock. In these conditions, the sGc- 
cGMP pathway is excessively activated, which leads to high levels of NO and so 
contributes to profound vasodilatation and hypotension (Gross and Wolin 1995). 
However, if too little NO is produced, this can lead to conditions such as high blood 
pressure, angina and impotence. Recently, it has been shown that a reduction in the 
activity and synthesis of NO within the endothelium may contribute to the initiation 
and progression of atherosclerosis (Napoli and Ignarro 2001).
8








Figure 1.1: The pathway showing the production of NO by eNOS in a vascular 
endothelial cell which has been stimulated by Ach.
nNOS
nNOS is Ca2+/CaM-dependent and is constitutively expressed at a high activity in the 
brain. It is expressed in postsynaptic terminals of neurons in the brain. Binding of 
neurotransmitter glutamate to receptors in the cell membrane causes calcium ions to 
influx and so activate the enzyme.
Activation of synapse begins with the impulse spreading to the presynaptic terminal, 
depolarising the terminal membrane and activating voltage gated calcium channels. 
This leads to exocytosis of synaptic vesicles and release of glutamate. Glutamate 
binds to receptors and calcium is carried into the cells. Here it acts as a second 
messenger and activates several kinds of kinases. Protein kinase C (PKC) is believed
9
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to activate NO synthase, releasing NO. This diffuses to neighbouring terminals, 
including presynaptic terminals, where it activates guanylate cyclase to produce 
cGMP (figure 1.2). Memory function and learning is linked to a term known as 
long-term potentiation (LTP) which means that the synaptic response has greater 
amplitude and persists for a longer time. NO may provide the link which appears to 
be necessary for co-ordinating, the enhancement of both pre- and post-synaptic 
mechanisms which contribute to LTP (Shepherd 1994).
NO release from the pelvic nerve neurons located in the human corpus cavemosium 
is known to cause penile erection. NOS inhibitors have been shown to prevent this 
action while nitric oxide sources mimic the effect (Kerwin et al 1995). Nitric oxide 
activates guanylyl cyclase which forms GTP and activates cGMP which in turn cause 
penile erection, the activity is terminated by cGMP being converted to 5’-guanosine 
monophosphate by the action of phosphodiesterase type 5 (PDE5). The drug Viagra 
(Sildenafil) is a PDE5 inhibitor which compensates for the low levels of NO by 
allowing cGMP levels to accumulate (Thomas 2000).
Recently the over-expression of nNOS in circulating neutrophils has been found in 
patients with Parkinson’s disease (Gatto et al 2000). Also nNOS levels are thought 
to be linked to migraine headaches. These headaches are believed to be a result of 
abnormal activity in large cerebral blood vessels and high levels of nNOS occur in 








Figure 1.2: The pathway showing the production of NO by nNOS in a neuronal 
denrite which has been stimulated by glutamate (Glu).
iNOS
iNOS is Ca2+/CaM-independent. This is because (as mentioned earlier) iNOS binds
9 -4-
CaM already and is active at low Ca concentration and so its activity is never 
limited by Ca2+ iNOS is expressed in macrophages in response to cytokines and 
other stimuli associated with infection (figure 1.3). Expression typically begins 4-12 
h after infection (Pfeiffer et al 1999).
NO production from iNOS reacts in conjunction with superoxide (also produced by 
activated immune cells). Immune cells congregate around the target cell and 
increase in number. NO is released from these cells and attacks copper and iron 
complexed proteins in the target cell. Copper and iron ions are released along with 
hydroxyl free radicals and molecular oxygen which leads to the destructive oxidative
11
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injury to target cells (Thomas 2000).
The major function of NO from iNOS is the cytostatic and cytotoxic effects on 
invading microorganisms or tumour cells. The mechanism of NO induced 
cytotoxicity is in two categories. First is the inhibition of mitochondrial respiration. 
NO interacts and inhibits cytochrome c oxidase, the terminal acceptor of the electron 
transport chain (Cooper 2002). This is because these enzymes contain iron-sulphur 
centres in their catalytic sites. Second is the direct modulation of DNA synthesis due 
to inhibition of some enzymes e.g. ribonucleotide reductase. NO production by 
iNOS is essential for the defence mechanism of an organism, however NO produced 
by iNOS has been related to several pathological conditions. Unregulated NO 
synthesis becomes self-destructive and is known in autoimmune disease (Schmidt 
and Walter 1994); examples of such pathological conditions are diabetes (Corbett et 
al 1992), rheumatoid arthritis, Alzheimer’s disease, impotence and schizophrenia 
(Lee et al 1999).
Poly (ADP-ribose) polymerase (PARP) is a DNA repair enzyme found within the 
nucleus of the cell which is activated by nicks and breaks in DNA. Breaks in DNA 
strands are caused by a number of different factors including environmental stimuli 
and free radical or oxidant attacks. NO produced from iNOS in response to pro- 
inflammatory conditions combines with superoxide to yield peroxynitrite. 
Peroxynitrite then induces single-strand breaks in DNA, which in turn activates 
PARP. PARP has been identified as a key final mediator of cellular injury in a 
variety of pathophysiological conditions such as diabetes, liver damage and 
ischemia-reperfusion (Szabo and Dawson 1998).
The understanding of the chemical and biological properties of NO is important to 
comprehend and appreciate the diversity of roles of NO and so lead to discovering its 











Figure 1.3: The pathway showing the production o f NO by iNOS in a macrophage 




Each of the three isoforms contains four prosthetic binding domains for flavin- 
dinucleotide (FAD), flavin mononucleotide (FMN), tetrahydrobiopterin and haem 
complex; iron protoporphyrin IX (haem) per monomer (Bredt et al 1991). All four 
of these cofactors are widely distributed in biological systems and help catalyse a 
number of oxidative and reductive reactions. However, the NOS isoforms are the 
only enzymes known to use all four simultaneously.
The active form of the NO synthase enzyme functions as a homodimer. This 
comprises of two oxygenase domains which are linked through interactions between 
haem domains and one reductase domain (Siddhanta et al 1996). The C-terminal 
reductase domain and the N-terminal oxygenase domain both fold independently of 
each other. The reductase domain is monomeric and contains one molecule each of 
bound FAD and FMN and also has a binding site for NADPH. The function of the 
reductase domain is to shuttle the five electrons from NADPH to the oxygenase 
domain. This electron transfer requires the binding of CaM. Studies have shown 
that only one haem unit per heterodimer is reduced and, in particular, the reduction 
will only occur when the arginine binding site and the reductase domain are on 
opposite subunits (Pfeiffer et al 1999). The oxygenase domain is homodimeric and 
contains a haem group and one binding site each for both the pteridine cofactor 
tetrahydrobiopterin and the substrate 1. On the N-terminal side of the oxygenase 
domain, there is an extension which may play a role in positioning the enzyme 
correctly within the cell.
Between the two domains, there is a binding site for CaM. NOS is the only P-450 
haem-containing enzyme in animals that has a dedicated reductase as an integral part 
of the protein; this suggests that the oxygenase-reductase interface is a crucial part of 
the function of the enzyme (Pfeiffer et al 1999). The CaM binding region acts as a 
hinge between the reductase and oxygenase domain. When Ca2+/CaM is bound, the 
domains align and so the enzyme is active (Griffith and Stuehr 1995) (Figure 1.4). 
Binding of CaM accelerates both interdomain (from the reductase to the oxygenase 
domain) and intradomain (from NADPH through the reductase domain) electron 
transfer (Perry et al 2000).
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The role of the tetrahydrobiopterin has been found to be essential in the reaction 
mechanism as the absence of the fully reduced form generates an excess of 
superoxide. One possible role for tetrahydrobiopterin is to act as a one-electron 
donor to the haem iron which is required for the cleavage of the oxygen-oxygen 
bond in the second step of the reaction mechanism.
Oxygenase domainReductase dom ain
L-A rg O,
N ADPH





Figure 1.4: Domain structure of NOS. The dashed arrow represents the path of 
electron transfer (Pfeiffer et al 1999).
P450 Homology
Cytochrome P-450 enzymes contain a haem prosthetic group, an iron-sulphur 
cluster-containing protein and a flavoprotein reductase. These enzymes catalyse 
hydroxylation reactions. The flavoproteins and iron-sulphur proteins supply 
electrons from NADPH to cytochrome P-450 via a reductase which contains FAD 
and FMN (Poulos et al 1998). The P-450 part corresponds to the most intense 
absorption band of the carbon monoxide-liganded haem on the inhibited form. NOS 
appears to be the first self-sufficient mammalian P-450 enzyme (self-sufficient 
means that there is no need for a separate reductase). It is also unique in the fact that 
the reductase and haem domains are part of the same polypeptide (White and 
Marietta 1992). The flavin reductase is covalently linked to the haem domain via a 
linker that binds CaM (figure 1.5).
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In both NOS and the homologous protein cytochrome P-450 reductase, the reductase 
domain is made up of nucleotide-binding molecules that bind NADPH, FAD and 
FMN. The only difference in their structure is an insert of approximately 45 amino 
acid residues within the FMN binding region. This insert is present in eNOS and 
nNOS but absent in iNOS (Pfeiffer et al 1999) (figure 1.5).












Cytochrome P-450 reductase HoN C 0 2H
Figure 1.5: Structure of the NOS isoforms and cytochrome P-450 redcuctase cDNA. 
The gap in the iNOS sequence represents a 40 amino acid deletion (Ogden and 
Moore 1995).
It was first thought that NOS had significant homology to cytochrome P-450. Some 
of the chemistry that NOS displays is typical cytochrome P-450 chemistry. The P- 
450 reductase domain (C-terminal) the binding sequence for NADPH, FAD and 
FMN, is present in all isoforms. NOS also contains a cytochrome P-450 type iron 
protoporphyrin IX haem. This haem domain is most likely to be located near the N- 
terminus as it lacks the homology found in the C-terminal.
Common P-450 structural elements are missing from NOS, which suggests that it is 
most likely to be an example of convergent evolution and does not belong to the 
cytochrome P-450 superfamily (Marietta 1994a).
16
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N O S R eaction  M ech an ism
NO is synthesised from the amino acid 1 by the enzyme nitric oxide synthase (NOS). 
Compound 1 undergoes a five-electron oxidation reaction to form L-citrulline (2) and 
NO (Marietta 1994b). Stable-isotope studies have provided the best evidence in 
understanding the mechanism of NO formation (Stuehr et al 1991). 15N-labelled 
arginine showed that NO2 ' and NTV (the breakdown products of NO) were derived 
from one of the guanidino nitrogens (Marietta 1993), and the ureido oxygen of 2 is 
derived from O2 and not H2 O (Griffith and Stuehr 1995).
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Scheme 1.2 NOS catalysed conversion of 1 to 2 and NO (Steuhr et al 1991). 
Tetrahydrobiopterin (BH4).
The reaction is a five-electron oxidation of one of the guanidino nitrogen atoms of 1. 
The first step is a two-electron oxidation to form the intermediate A^-hydroxy-L- 
arginine (NOH-Arg). The second step involves an electron removal, oxygen 
insertion and a carbon-nitrogen bond scission to form 2 and NO in an overall three- 
electron oxidation. The electrons required for both steps in the reaction are provided 
by NADPH (scheme 1.2).
The reactions occur on the oxygenase domain of the enzyme. Compound 1 is bound 
near the haem co-factor (tetrahydropterin). The tetrahydrobiopterin is ligated to 
NOS through a sulphur atom on active site of a cysteine residue. The binding of 1 in 
the active site places both the oxidisable nitrogen and the guanidino carbon in close 
proximity to the haem iron (Babu and Griffith 1998a). The enzyme is in the ferric 
state and is firstly reduced to Fe2+ by an electron provided by NADPH via the 
flavins. The ferrous form then binds oxygen to give a stable complex. It is the
17
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dissociation of this species that is likely to be the source of superoxide ion formation. 
Simultaneous addition of an electron delivered from NADPH via the flavins FAD 
and FMN and a proton from the BH4 complex reduces the bound superoxide to 
hydroperoxide. The breaking of the oxygen-oxygen bond results in water being 
released and the perferryl haem species is formed (Alderton et al 2001). The 
perferryl haem species is a potent hydroxylating agent and so rapid hydroxylation 
occurs in which 1 is oxygenated to the intermediate NOH-Arg and the ferric haem is 
regenerated (Babu and Griffith 1998a).
The second stage in the reaction is unique to NOS. The original haem cofactor 
receives an electron from NADPH and binds a second molecule of oxygen. This 
ferric-oxy haem complex may act as an oxidant, by removing an electron from the 
bound NOH-Arg as an H* radical. The peroxy-iron species carries out a nucleophilic 
attack at the cation radical to generate a tetrahedral intermediate. This rearranges to 
give 2, NO, water and ferric haem(Korth et al 1994) (scheme 1.3).
18
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Little has been known about the structure of the NOS active site until recently. By 
understanding the structure of each domain, more information can be gained about 
NOS activity and the mechanism of action both of which are important in developing 
new NOS inhibitors.
Since the publication of NOS crystal structures, more information has been available 
about binding of inhibitors to these active sites and, indeed, where they bind. 
Although, as expected there is much homology between the active sites in the three 
isozymes, there are subtle differences, particularly in the distal pockets.
The haem and tetrahydrobiopterin cofactors together with the oxygenase domain 
form the active site of the enzyme (Perry et al 2000). The oxygenase domain of 
iNOS appears like a baseball catcher’s mitt with the haem group in the palm of the 
mitt. Dimerisation creates a 30 A deep funnel-shaped active centre. The distal pocket 
of NOS differs from other haem-based oxygenases in the fact that it is mainly 
comprised of p-sheets, whereas other haem-based oxygenases are helical (Crane et al 
1998). Each of the isozymes have slightly different structures in these distal pockets, 
which influences the catalytic and ligand binding properties. At the centre of the 
dimer interface, there is a zinc tetrathiolate which aids in dimerisation stability and 
also in the formation of the pterin binding site (Li et al 2001). The binding of 
tetrahydrobiopterin, haem and 1 all promote and stabilize the active dimeric forms of 
all three isoforms of NOS.
Many of the arginine analogue inhibitors bind in the substrate binding site. 
Imidazoles act in a different way, by preventing the formation of 2. The unbonded 
electron pair on position three of the imidazole ring acts as a sixth ligand to the haem 
iron and prevents oxygen binding (Wolff et al 1993). Crystallographic studies allow 




Therapeutic potential of NOS inhibitors
The development of NOS inhibitors has immense potential in the medical world, as 
NO is linked to many disease states. NO produced from iNOS has been linked to 
autoimmune disease states such as arthritis (Evans and Stefanovic-Racic 1997) and 
diabetes (McDaniel et al 1996). nNOS-derived NO is linked with diseases related to 
the brain, such as Parkinson’s disease (Gatto et al 2000), Huntington’s disease (Bryk 
and Wolff 1999) and migraine headaches (Babu and Griffith 1998a). NO is not only 
involved in disease states but is also essential for human health; for example, eNOS 
is tightly regulated and plays a critical role in the maintenance of blood pressure 
(Babu and Griffith 1998a) and so the design and synthesis of highly selective NOS 
inhibitors is paramount. Failure to achieve selectivity can lead to many systemic side 
effects and so therapeutic applications of the inhibitor become limited. Inhibition of 
eNOS is not ideal as it may lead to a large increase in blood pressure with many 
profound side effects and so selective eNOS inhibitors do not appear to have such a 
great potential in drug development.
Several inhibitors have been tested in vivo and have produced encouraging results, 
e.g. the iNOS selective inhibitor 1400W has been shown to reduce the rate of solid 
tumour growth in mice (Thomsen et al 1997). The administration of other NOS 
inhibitors has shown significant effects in other disease states such as arthritis and 
septic shock. L-NAME was administered to rats induced with adjuvant arthritis. 
Adjuvant arthritis in rats is an experimental immunopathy which involves a T- 
lymphocyte-mediated delayed hypersensitivity reaction. Rats receiving the L- 
NAME therapy showed a marked decline in their T-lymphocyte response (Ialenti et 
al 1993). The cardiovascular collapse that is associated with septic shock is largely 
due to endotoxin. L-NMMA has been shown to have a rapid and strong anti­
hypotensive effect in endotoxin-induced dogs (Kilboum et al 1990).
NOS inhibitors can generally be divided into two categories, amino-acid derivatives 





The arginine analogues include the first NOS inhibitors synthesised. Studies have 
shown that the L- configuration is a requirement for the inhibitor as D-arginine is not 
a substrate and does not inhibit the NOS reaction (Narayanan and Griffith 1994).
The arginine analogues include NG-monomethyl-L-arginine (L-NMMA (4)), N8- 
(iminoethyl)-L-lysine (L-NIL (5)) and its lower homologue N8-(iminoethyl)-L- 
omithine (L-NIO (6 )), N^-nitro-L-arginine (L-NNA (7)) and its methyl ester (L- 
NAME (3)). The mechanism of NOS inhibition by these compounds varies, but they 
all bind to the oxygenase domain of NOS and interact with the guanidinium region of 
the arginine binding site (Moore et al 1994). Compounds 3, 4 and 6  are reversible 
competitive inhibitors, which show potency but no particular selectivity for any type 
of NOS (Ogden and Moore 1995), the effects of which are reversed by the addition 
of arginine. IC50 values for arginine analogues are given in table 1 .2 . Lead target 
inhibitors should display at least 1 0 0 -fold isoform selectivity.
The arginine analogues differ in their influences on electron transfer and in the 
reduction of the haem iron in the NOS enzyme. Compound 4 binds with its 
unsubstituted guanidinium nitrogen in the distal, non-reactive guanidinium nitrogen 
pocket (Babu et al 1999), and has been found to be a mechanism-based inhibitor. It 
is first hydroxylated to N^hydroxy-N^-methyl-L-arginine which is then 
demethylated to intermediate in the NOS reaction N^hydroxy-L-arginine and finally 
metabolised to 2 and NO (Klatt et al 1994).
Table 1.2 shows that compound 7 displays selectivity for the eNOS isoform. This is 
due to the higher affinity of 7 for the nNOS isoform (Furfine et al 1993). The methyl 
ester of compound 7 (3) is a much less potent NOS inhibitor (IC50 70 pM brain 
NOS). The inhibitor only inhibits eNOS in pharmacological experiments with 
animals or tissues following its hydrolysis to the free acid 7 (Pfeiffer et al 1996). 
Compound 3 acts by inhibiting NADPH consumption by interrupting electron flow 
immediately prior to reduction of the haem iron (Southan and Szabo 1996). The 
electron flow is blocked by inhibiting haem iron reduction which involves a lowering
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of the haem iron reduction potential (Abu-Soud et al 1994).
Compound 5 shows selectivity for the iNOS isoform while its lower homologue 6 
shows potency but no isoform selectivity. Compound 6 binds to the guanidium 
region of the arginine binding site and is thought to be oxidised in a similar way to 1 
(Fast et al 1999).
Compounds 4, 6 and 3 have been shown to increase blood pressure and so inhibit NO 
production from endothelial cells both in vivo and in vitro (Rees et al 1990). 
Unfortunately, due to the modest selectivity displayed by these compounds, many 
undesirable side effects have occurred in animal studies, indicating the need for more
selective NOS inhibitors (Babu and Griffith 1998b).
ICso (uM)













Table 1.2: IC5 0  Values for arginine analogues. Values taken from Moore et al 1994
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The most potent and selective of the N®- substituted arginine analogues is N^-propyl- 
L-arginine. It was found to be a competitive inhibitor of all three isoforms. The Kj 
values show that there is substantial degree of selectivity for the nNOS isoform (from 
bovine brain). Selectivity for nNOS/iNOS is the ratio of the inverse of the Ki values. 
N“-propyl-L-arginine shows a potency of inhibition for nNOS which is 3158 times 
that for iNOS (mouse murine recombination (Hevel et al 1991)) and 149 times that 
for eNOS (bovine endothelial recombinant (Martasek et al 1996)). The propyl chain 
length (compared to methyl, ethyl, allyl and propargyl) gives rise to the optimum size 
and geometry for nNOS selective inhibition for this class of compounds (Zhang et al 
1997). This suggests that the binding region for the guanidinium nitrogen which is 
located near the haem iron can accommodate substituents extending about 4-5 A 
from the guanidinium carbon (Babu et al 1999).
L-Citrulline analogues 
Thiocitrulline
Compound 2 (Scheme 1.2), the amino acid product of the NOS reaction is not a 
useful inhibitor. However, when the ureido oxygen is replaced by sulphur, this gives 
rise to potent inhibitors. Thiocitrulline (8 ) competitively inhibits NOS showing a 
degree of selectivity for the iNOS isoform (table 1.3). Compound 8  acts by 
decreasing the electron flux through NOS and NADPH oxidase activity of NOS by 
lowering the reduction potential of the haem iron (Ware and King 2000).
X-ray crystallographic studies of iNOS oxygenase domain show that 8  binds with its 
sulphur atom positioned directly above the haem iron. Compound 8  binds to the 
active site in a similar conformation as does L-arginine. It binds in the distal pocket 
(which is adjacent to the haem) by interacting directly with Glu371 (Crane et al 
1997). The inhibitor is held in place by hydrogen bonds being formed between the 
carboxyl oxygen atom of Glu371 and the sulphur atom in the thiourea group of 8  
(Ware and King 2000). Frey et al 1994 have shown that the interaction between the 
haem iron and homothiocitrulline (9) are not as strong as in 8 . This is because the 
sulphur atom is further away from the haem iron and so the ability to alter the 
reduction potential of the haem iron is affected. However, the percentage inhibition 
results indicate that 9 is a reasonable NOS inhibitor and so other binding interactions
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must be occurring between NOS and the thioureido unit (Frey et al 1994).
5-methylthiocitrulline (8a) and 5-ethylthiocitrulline (8b) are potent reversible slow- 
binding inhibitors of NOS (Furfine et al 1994). They bind to the enzyme active site 
in the same way as 8 and 9. Compound 8a displays a degree of selectivity for nNOS 
(table 1.3). The alkylation of the sulphur atom in 8 increases the strength of the 
interaction with the enzyme this is evident from the IC5 0  values given in table 1.3. 
The alkyl functionality attached to the sulphur atom increases the potency of the 
inhibitor; this is also seen in isothiourea compounds, as synthesised by Garvey et al 
1994. The alkyl group may give rise to an increase in potency by binding into a 
small hydrophobic pocket region within the arginine binding site.
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Non-amino-acid inhibitors are another class of NOS inhibitor. These include 
isothioureas, 1400W (10), aminoguanidine (11), 7-nitroindazole (7NI (12)) and 
imidazoles. Many of the non-amino-acid inhibitors show isoform-selectivity, 
particularly for iNOS and so important structural features can be determined in order 
to design and synthesise potent selective inhibitors and also gain information about 
binding to the NOS active site.
Aminoguanidine
Aminoguanidine (11) is one of the first non-amino-acid inhibitors to be identified 
and inhibits NOS in a time-dependent manner (Wolff and Lubeskie 1995). Other 
aminoguanidine analogues have been studied, but 11 displays the greatest selectivity 






Aminoguanidine 5.0 41.0 255
(11)
Table 1.4: IC5 0  Values for aminoguanidine. Values taken from Wolff et al 1998.
Due to its low acute toxicity, 11 has been used in clinical therapeutics including 
various experimental models of inflammation and shock (Southan and Szabo 1996). 
Compound 11 has also been shown to inhibit vascular changes in diabetic rats which 
cause increase blood flow (Corbett et al 1992).
Isothioureas
The isothioureas are a group of inhibitors which have been shown to be competitive 
with arginine and therefore are known to bind to the arginine binding site on the 
haem-domain. Several of the inhibitors within this group are selective for iNOS. S- 
ethylisothiourea (EIT (13)) and 2-amino-5,6-dihydro-6-methyl-4H-l,3-thiazine 
(AMT (13a)) inhibited murine iNOS in vitro with IC5 0  results of 13 and 4 nM,
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respectively (Nakane et al 1995).
S-alkylisothioureas have been shown to be potent NOS inhibitors. In particular, 13 
shows potency and selectivity for iNOS. The potency is believed to be directly 
related to the steric bulk of the S-alkyl substituent. Shearer et al (1997) showed that 
optimal potency is observed for S-ethylisothiourea. The introduction of the phenyl 
ring in S-ethyl-N-phenylisothiourea (14) led to nNOS selectivity. The type of 
substituents bonded to the aromatic ring as well as the position play an important role 
in the selectivity of the inhibitor, with para electron-withdrawing groups giving rise 
to the most selective inhibitors (Shearer et al 1997).
Garvey et al have developed a series of bisisothioureas, which have produced 
encouraging results in vitro. In particular S ,5” -(1.3 -phenyl enebis-( 1,2- 
ethanediyl))bisisothiourea (PBITU (14a)) and S,^’-(1.4-phenylenebis-( 1,2-
ethanediyl))bisisothiourea (14b) showed potency and selectivity for human iNOS 
giving Kj values of 0.047 pM  and 0.0074 pM respectively. However their poor 
cellular penetration and toxicity may limit their therapeutic use (Garvey et al 1994).
1400W
N-(3-(Aminomethyl)benzyl)acetamidine, known as 1400W, (10) is the most 
selective inhibitor of iNOS to date. Compound 10 was shown to be 5000 and 200- 
fold selective for human iNOS against eNOS and nNOS respectively (Garvey et al 
1997). (As mentioned earlier selectivity can be defined as the ratio of Kj eNOS or Ki 
nNOS to Kj iNOS). The selectivity of 10 towards iNOS may be partly attributed to 
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0.23 7.3 1000
Table 1.5: IC5 0  values for 1400W (Alderton et al 2001)
Compound 10 binds competitively with 1. Both 6 and 10 share the same amidine 
group which is structurally similar to guanidine and so the amidine binds in the 
guanidine-binding pocket of the substrate site, H-bonding with Glu363. Inactivation 
of iNOS is believed to occur after the oxidation step but before hydroxylation 
(scheme 1.3). Compound 10 is unable to donate a proton to the ferric-hydroperoxy 
intermediate which leads to an excess production of peroxide and haem destruction 
(Li et al 2001).
Compound 10 is a time-dependent inhibitor of iNOS and most of the selectivity of 
iNOS was seen when the interactions develop slowly. When the enzyme was pre­
incubated with 10, an optimum pre-incubation time of ten minutes was obtained 
(Garvey et al 1997). The progressive nature of inhibition for iNOS (not eNOS or 
nNOS) accounts for the underestimated IC5 0  value for iNOS given in table 1.5. This 
also explains why the selectivity seen in table 1.5 is much lower than that observed 
by Garvey et al 1997.
The removal of the methylene unit from 10 to give N-(3- 
(aminomethyl)phenyl)acetamidine (15) reversed the selectivity of the compound to 
give rise to a nNOS selective inhibitor, which displays no time dependence kinetics 
but binds reversibly (Collins et al 1998). As seen in the isothiourea group, the 
position of the substituents on the aromatic ring plays a role in the selectivity of the 
inhibitor. This was also demonstrated by Collins et al as shifting the aminomethyl 
functionality from the meta to the para position resulted in a reduction in nNOS and
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eNOS inhibition but not in iNOS inhibition (Collins et al 1998).
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Figure 1.6: Proposed binding of the iNOS selective inhibitor 10 and the nNOS
selective inhibitor 15, illustrating the co-ordination of the amidine head group to the 
haem and the bridge length of the compound which may play an important role in the 
selectivity of the inhibitor.
Compound 10 was shown to be highly selective both in vitro and in vivo. It shows a 
similar toxicity profile to another selective iNOS inhibitor 14a and so use of this 
drug in human therapeutics is unsafe, but can be used effectively in animal models. 
However, dose-limiting toxicity has been observed for this compound (Thomsen et al 
1997). Compound 10 has been shown to reduce the rate o f growth in solid tumours in 
mice.
Imidazoles
The imidazoles are a group of non-selective inhibitors. Imidazoles have been shown 
to be non-competitive inhibitors of iNOS and nNOS while being competitive 
inhibitors of eNOS (Aktinson and King 1999).
The consensus for the mode of action for the imidazoles is that they block the 
formation of the reaction product (2). The unbonded electron pair on position three 
of the imidazole ring acts as a sixth ligand to the haem iron. The binding of the 
imidazole prevents oxygen binding and therefore prevents the formation of citrulline
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(Wolff et al 1993).
The selectivity and potency of the imidazole inhibitors is closely linked to the amino 
acid chain length attached to the head group. Atkinson and King (1999) and also Lee 
et al (1999) found that the longer chain lengths decrease the potency of the inhibitor. 
Substitution of the imidazole head group also affects the potency of this class of 
inhibitors. Substitution at positions two and four on the ring have been shown to 
diminish the potency. This may be due to steric hindrance (Ulhaq et al 1998), 
whereas substitution at position one in particular with an alkyl or aromatic group is 
favoured (Salerno et al 2002).
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Table 1.6: IC5 0  values for imidazoles, a Ulhaq et al 1998 rat iso forms used, b
Chabin et al 1996 human isoforms used, c Lee et al 1999 mouse iNOS, bovine eNOS




Compound 12 is the most studied nNOS-selective inhibitors (Southan and Szabo
1996). However, the selectivity seen in 12 for nNOS remains low in vitro (Schumann 
et al 2001). Indoles are believed to bind to the NOS haem iron in the same way as 
the imidazoles by binding to the haem iron instead of oxygen and preventing the 


















Table 1.7: I C 5 0  values for Indoles, a bovine brain NOS




As table 1.7 shows, the nitro group at position seven gives rise to the optimum 
potency for this particular series. By moving the nitro group to either position six or 
five, the potency of the inhibitor decreases. The nitro group on an aromatic ring is 
strongly electron-withdrawing and decreases the electron density of the aromatic 
ring. Also, the nitro group contains a semipolar bond that leaves the nitrogen atom 
with a positive charge and the oxygen atoms with delocalised negative charges. It is 
unclear whether the potency seen in 12 is due to the change in electron charge 
distribution of the aromatic ring or if the positively charged nitrogen atom interacts 
in some way with NOS. However the potency displayed by 7-methoxyindazole (7MI 
12d) contradicts the theory that potency displayed by 12 is due to the electron 
withdrawing effect of the nitro group at position seven (Schumann et al 2001).
Other non-amino acid inhibitors
Another class of potent NOS inhibitors include the cyclic amidines. 2- 
Iminopiperidine (16d) is one of the most potent inhibitors within this series; IC50 1.4, 
4.7, 1.1 pM against human iNOS, eNOS, nNOS respectively. The potency of the 
inhibitor depends greatly on the position and functionality of the groups substituted 
around the ring. The effect of methylation at the different ring positions has been 
investigated and positions four and six increased the potency of the inhibitor relative 
to 16d whereas positions three and five showed a decline in NOS inhibition (Webber 
et al 1998). The size of the piperidine ring also affects the potency of the inhibitor 
with seven membered rings giving rise to similar potency to that seen in six 
membered rings values whereas five, eight and nine membered rings decreased the 
potency of the inhibitor (Moore et al 1996).
NH
2-iminopiperidme (16d)
Other non amino acid inhibitors include porphyrins (Wolff et al 1996), pyrazole N- 
carboxamidines (Southan et al 1997 and Lee et al 2000). All of these three classes of 




Normal cells reproduce when instructed to do so by other cells, this process is known 
as the cell cycle. Cancer cells arise when alterations occur in the control mechanisms 
of the cell cycle causing cancer cells to undergo their own reproduction.
The cell cycle is a complex assembly of stimulatory and inhibitory pathways. There 
are four stages to the cycle; Gi pre-replication stage in which the cell enlarges and 
prepares to copy DNA. Go is the resting phase, S is the synthesis phase and M is 
mitosis (cell division). The critical stage in the cycle is the restriction point (R), 
which occurs late in the Gi phase. At this point, the cell decides whether or not to 
commit itself to completing the cycle (Weinberg 1996) (figure 1.7).
Figure 1.7: The four stages of the cell cycle; G] pre-replication stage, Go is the 
resting phase, S synthesis and M is mitosis (cell division).
There are two gene classes that control the life cycle o f the cell; proto-oncogenes 
which encourage cell growth, while tumour suppressor genes inhibit it. For a
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cancerous tumour to develop, mutations must occur in at least six of the controlling 
genes. Mutated proto-oncogenes (oncogenes) cause excessive cell multiplication 
while mutations in tumour-suppressor genes result in a loss of a functional tumour 
suppressor protein and so deprive the cell of brakes that prevent inappropriate 
growth.
In order for a cancer cell to metastasise successfully, they must detach from their 
original location and invade the blood or lymphatic system. The survival of the 





The current main therapies available for internal tumours are; surgery, chemotherapy 
and radiotherapy. These therapies often have such harmful side effects and so their 
administration often compromises the benefits of treatment. The need for safe and 
effective therapies that act only on cancer cells is paramount.
Surgery
Surgery is the earliest established therapy for tumours and is still the most widely 
used. The removal of the tumour and eradicating the cancer from the body is often 
the most effective way. However there are several pitfalls from this type of 
treatment. The physician may be able to remove the tumour with the scalpel but 
often microscopic parts of the tumour are left behind and so the tumour is able to 
metastasise again. Surgery often involves the removal of healthy tissue to ensure 
that the tumour has been fully excised; however; this can leave the patient with 
severe damage and discomfort (Heilman and Vokes 1996).
Chemotherapy
Chemotherapeutic drugs act by interfering with the cells DNA and so preventing the 
tumour cells from replicating. Some of these drugs act directly on tumour cells 
whereas others must be activated by metabolic processes, either in the tumour cells 
or in organs (Franks and Teich 1995). Chemotherapeutic drugs can be divided into 
three groups according to their site of action. The first group are only active on 
dividing cells. The second group are active on dividing cells and affect a particular 
phase of the cell cycle; an example is methotrexate which is active in the S phase of 
the cell cycle. The final group are those drugs which affect all or most of the phases 
of cell division; an example is nitrosourea (Franks and Teich 1995).
Chemotherapy affects both tumour cells and normal cells; the feasibility of 
chemotherapy is based on the fact that normal tissue cells may recover at a faster rate 
than tumour cells. During the 1940s when chemotherapeutic drugs were first 
developed their effectiveness often proved inadequate when administered alone. By 
the 1960s physicians discovered that the success rate increased when several drugs 
were given at the same time. Leukemias and testicular cancer are two examples that
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are now successfully treated with combination therapy (Heilman and Vokes 1996).
Besides killing normal cell tissue chemotherapeutic drugs often cause many serious 
side effects such as damage to the growing cells of the bone marrow causing anaemia 
due to the patient being unable to produce adequate number of red blood cells, white 
blood cells and platelets. Other side effects include diarrhoea, nausea, and vomiting 
and hair loss. Probably the major problem with the failure of chemotherapy is drug 
resistance by the cancer cells. Tumours can develop a resistance to multiple drugs 
after the administration of one drug (Franks and Teich 1995).
Radiotherapy
Radiation therapy involves the use of powerful X-rays or gamma rays to irradiate the 
tumour. Radiation treatments act in two ways; either by inflicting sufficient genetic 
damage to kill the cells directly or by inducing apoptosis. Radiation enables the 
microscopic amounts of tumour that surgery may leave behind to be destroyed; also 
healthy tissue is able to recover more easily. One of the factors that limits the 
effectiveness of radiotherapy is the presence of radioresistant hypoxic tumour cells 
(Wink et al 1998). These cells have PO2 levels of < 10 mm Hg and so much effort 
has been made to exploit these regions of tumour cells to develop drugs that are 
effective hypoxic cell radiosensitizers (Sutherland et al 1988) (figure 1.8).
Anti-angiogenic therapy
Angiogenic therapy does not aim to destroy the tumour but exploits the fact that 
tumours require their own blood supply to survive. Angiotherapeutic drugs act by 
limiting the blood supply and so shrinking the tumour and preventing it growing. 
The main advantage of this type of therapy is the fact that the drugs are specially 
designed to be specific for tumour cells and so prevent healthy cells being destroyed. 
This type of therapy is relatively new and as yet no drugs have been approved for use 
in patients but many are now in clinical trials (Folkman 1996).
The type of treatment a patient receives depends on the tumour and the stage of 
progression. Many physicians combine the use of surgery, radiotherapy and 
chemotherapy to provide the most effect way to eradicate the tumour.
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NOS and Cancer Therapy
NO is generated by a variety of cell types including several tumour cell lines and 
solid human tumours (Edwards et al 1996). The production of NO is carried out 
either by the tumour cells themselves, by the endothelial cells in the tumour 
vasculature or by the macrophages and stromal cells within the tumour (Lala and 
Orucevic 1998). The effects of NO production by tumour cells include; tumour cell 
growth, differentiation, metastatic capability, chemosensitivity, radiosensitivity and 
tumour-induced immunosupression (Edwards et al 1996).
NO may play a dual role within the tumour cells. High concentration of NO may 
participate in antitumour events (Edwards et al 1996) such as the induction of tumour 
apoptosis and the inhibition of tumour growth. However, when NO concentrations 
are low tumour growth and angiogenesis may be stimulated (Jenkins et al 1995). 
Another factor affecting the dual role of NO within tumour cells is NO sensitivity. 
Different tumour types may have different sensitivities to NO (Buttery et al 1993).
The role(s) that NO plays within the tumour remain unclear and conflicting. 
However, it is believed that the function of NO within tumour cells depends on the 
stage and type of tumour and also the genetic make-up within the cell (Doi et al 
1996). The activity of NO has been positively correlated to the degree of malignancy 
in human ovarian (Lala and Orucevic 1998), uterine, breast (Thomsen et al 1995, 
Jenkins et al 1995) and gynaecological tumours (Thomsen et al 1994). Tumours of 
the central nervous system have been found to have high expression of cNOS and 
nNOS (Cobbs et al 1995).
The administration of the non-competitive arginine analogue NOS inhibitors 3, 4 and 
7 have been shown to decrease the blood flow to lung metastases (Edwards et al
1996), murine adenocarcinoma (Andrade et al 1992) and rat carcinoma (Tozer et al
1997). However, there is conflicting evidence that these effects are reversed by the 
addition of L-arginine (Meyer et al 1995). The growth rate of tumours has been 
shown to decrease with the administration of 3 and 4 in C3L5 tumour-bearing mice 
(Lala and Orucevic 1998). These results are very encouraging but it is important to 
remember that these inhibitors are non-selective and so caution must be exercised
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when interpreting this data.
The administration of the iNOS selective inhibitor 10 has been shown to reduce the 
rate of solid tumour growth in mice; however, the murine colon adenocarcinoma 
showed no reduction in growth rate after treatment with 10 (Thomsen et al 1997).
The mechanism of how NO affects tumour proliferation is unclear but there are 
several possibilities, i) The breakdown of the extracellular matrix is believed to be 
an important process in the invasion and metastasis of solid tumours. The enzymes 
responsible for the breakdown of the matrix are known as metalloproteinases. One 
mechanism for the role of NO in tumours is through the activation of 
metalloproteinases (Thomsen et al 1997). ii) the direct stimulation of tumour cell 
proliferation, iii) promotion of tumour cell invasiveness iv) promotion of tumour 
angiogenesis v) promotion of microcirculation in tumour vasculature and vi) the 
suppression of host cell defence (Lala and Orucevic 1998).
Although more detailed understanding of the mechanism of action is required, the 
potential for selective iNOS inhibitors in the treatment of cancer therapy is immense.
Many solid tumours have regions of low oxygen tension, which are known as 
hypoxia (figure 1.8). These areas are thought to be a result of poor and disorganised 
blood supply. These cells are generally radio- and chemoresistant and so can cause a 
relapse of the cancer after such therapy. Severe hypoxia is unique to tumours and 
therefore has great potential to be exploited in cancer drug development (Chinje and 
Stratford 1997). Hypoxia is known to provide a stimulus for angiogenesis and one 
such pathway for this action may be through the activation of the iNOS promoter via 
the hypoxia response element (HRE) (Lala and Orucevic 1998). Inhibition of NOS 
has been shown to decrease tumour size, which correlates with an increase in the 
level of tumour hypoxia sufficient enough to enhance the efficiency of bioreductively 







T u m o u r  d i a m e t e r
Figure 1.8: Diagram to show the hypoxic regions within a solid tumour.
As mentioned earlier NO inhibition reduces blood flow to the tumour. The levels of 
hypoxia have been shown to increase in those tumours which have received NOS 
inhibition. This evidence provides an approach to developing selective NOS 
inhibitors which will reduce blood supply to the tumour and cause vascular shut­
down of the tumour and also potentiate the use of bioreductive anti-cancer drugs.
This is the main objective of the project and will be discussed in detail in chapter 
two.
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Aims, Objectives and Research Proposal
Aims
The potential for the use of selective NO inhibitors in diminishing tumour blood flow 
is immense. The arginine analogues, 4, 3 and 7 are potent but non-selective 
inhibitors and so are likely to cause systemic side effects. The most potent NOS 
inhibitor to date is 10, which is selective for the iNOS isoform (Garvey et al 1997). 
It remains uncertain whether the selectivity shown by this compound is partly due to 
the high turnover rate of iNOS when compared with eNOS and nNOS (Li et al 
2001). Also 10 is highly toxic, so the need for potent non-toxic NOS inhibitors still 
exists.
The aim of this research project was to synthesise inhibitors of the inducible and 
constitutive isoforms of NOS, which would be highly selective and so eliminate side 
effects associated with non-selective inhibitors. Selective inhibition in tumours 
should achieve collapse of the tumour and shutdown the tumour vasculature. Such 
selective inhibitors may alone cause an anti-tumour event. However it could also 
increase tumour hypoxia and potentiate the cytotoxicity of bioreductively activated 
drugs.
Objectives
The objectives of this research project are as follows;
i) Modify the structures of N -(4,5-dihydrothiazol-2-yl)-L-omithine (17) and 
10; a lead but non-isoform selective inhibitor, and a highly selective iNOS 
inhibitor respectively.
ii) Synthesise lead compounds.
iii) Evaluate compounds for potency and isoform selectivity of NOS inhibition.
iv) Design, synthesise and test analogues of lead compounds in order to 
determine their structure activity relationships.
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Research Proposal
Introduction
Target compounds have been designed to possess either the 4,5-dihydrothiazole head 
group or the thiourea head group and to incorporate molecular features of 10 to 
increase isoform selectivity.
Important features can be gained by examining the structures and possible modes of 
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Figure 2.1: Proposed binding of the substrate 1, a lead non-isoform selective 
inhibitor 17, iNOS selective inhibitor 10 and an analogous nNOS selective inhibitor 
15. The diagram illustrates the bridge length theory and shows how the inhibitors 
may bind to the haem.
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The incorporation of the isothiourea into a five-membered dihydrothiazole ring (as 
seen in 17) gave rise to potent but non-selective inhibitors when compared to other 
aromatic and non-aromatic heterocyclic head groups of L-citrulline analogues (Ulhaq 
et al 1999). The thiourea head group has been shown to give rise to potent NOS 
inhibitors e.g. thiocitrulline.
Compound 10 is a slow, tight-binding inhibitor, which is highly selective for iNOS 
and has 7 atoms in the bridge between the remote amidine N and N^T^, whereas the 
lower homologue of 10 (15) has six atoms and displays selectivity for the nNOS 
iso form. Compound 17 possesses a six atom bridge and displays no isoform 
selectivity; therefore bridge length appears to be important in the selectivity of the 
inhibitor.
The benzene ring in compounds 10 and 15 is believed to help the inhibitor maintain 
the correct conformation of the acetamide that binds to the haem iron and the amine, 
which binds in the cation pocket (figure 2 .1 ).
The proposal was to synthesise various target compounds related to the structure of 
17 and 10. The following describe the proposed compounds.
Analogues of ̂ - (4 ,5  dihydrothiazol-2-yl)-L-ornithine
A/€-(4,5-Dihydrothiazol-2-yl)lysine 131 is the chain-extended homologue of the non- 
selective potent inhibitor 17 and 129 is the chain-extended homologue of the known 
inhibitor 8 . Both targets were designed to determine whether extending the bridge 
length to seven atoms would increase the selectivity and potency of the target.
H3̂  ULY tl3IN u u 2~
129 131
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It is proposed that both 129 and 131 will bind in a similar conformation to arginine in 
the binding site with the sulphur atom in the head groups co-ordinating to the iron 
atom in the haem. The synthesis of the two lysine derivatives allows a direct 
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In target 31, the 4,5-dihydrothiazole head group replaces the acetamidine of 10, and 
so should hopefully give rise to a potent iNOS inhibitor. The lower homologue of 
10; (15) showed a reversal in isoform selectivity and exhibited selectivity towards 
nNOS. Target 50 is the lower homologue of 31 and, therefore, should be a nNOS 
selective inhibitor and so was synthesised to see whether the understanding of the 
SAR could be applied to this series of compounds. Corresponding targets 35 and 48 
were synthesised with the thiourea head group to compare the effects of the head 
group on the potency and selectivity of the inhibitor.
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The properties and the position of different functional groups around the aromatic 
ring play important roles in determining potent and selective NOS inhibitors. To 
examine these effects targets were synthesised with OMe, NH2 or CO2H 
functionality in both meta and para relationships between the groups. The synthesis 
of the above targets will allow direct comparisons to be made between the functional 
groups, the ring positions and the head groups and help understand more about the 
SAR.
The reason behind the synthesis of 143 was that it possesses the dihydroxyethyl 
motif, which was shown to increase selectivity for iNOS by 700 fold in N-(5(S)- 
amino-6,7-dihydroxyheptyl)ethanimidamide dihydrochloride (18) versus L-NIL (5) 
(Hallinan et al 1998). Hallinan et al have shown that chirality plays a direct role in 
the activity of the inhibitor. The diasteroisomer of 18 showed a reduction of four 
times the potency as an iNOS inhibitor. Compound 143 was synthesised to 
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The target compounds above were designed to retain the dihydrothiazole head group 
as Ulhaq et al 1999 showed that target NOS inhibitors with this head group showed 
increased potency compared to those with the thiazole head group and other atom 













Table 3.1: I C 5 0  values for different ornithine derivatives. Values taken from Ulhaq 
et al 1999.
Table 3.1 clearly shows that the dihydrothiazole head group is twenty-five-fold more 
potent than the aromatic thiazole. The addition of the methyl substituent on the 
thiazole diminishes the potency of the inhibitor quite considerably, as does the 
replacement of the sulphur atom with oxygen. The results show that sulphur plays an 
important role in the head group functionality of the NOS inhibitor; this may be due 
to the binding interactions with the haem iron. The sulphur atom in 17 is a softer
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nucleophile and therefore, a better ligand for binding to iron than the oxygen in the 
oxazoline.
Compound 17 showed potency but not isoform selectivity for either cNOS or iNOS 
(IC50 1.3 pM and 8.1 pM, respectively). The chain length is an important 
characteristic of selective NOS inhibitors, as shown by the two arginine analogues 5 
and 6. Compound 5 has a four-carbon chain between the amino acid moiety and the 
acetamidine head group and displays selectivity for iNOS over cNOS while 6 
exhibits no selectivity for either isoform. A/8-(4,5-Dihydrothiazol-2-yl)lysine 
dihydrochloride (131) was synthesised to retain the dihydrothiazole head group while 
increasing the carbon chain length to four atoms and so give rise to a potentially 
selective and potent iNOS inhibitor.
The aromatic targets (31, 50, 68,42, 58, 75,112,119, 21,123, 82, 99,107, 89) were 
based on the known selective iNOS inhibitor 10. The benzene ring is believed to 
help maintain the inhibitor in the correct conformation for binding to the active site. 
As mentioned above, the number of atoms between the head group and either the 
remote amine (as in 10) or the amino acid functionality (as in 5 and 6) appears to be 
highly significant in the synthesis of selective NOS inhibitors. Target 31 was 
synthesised to maintain the seven-atom bridge and the same remote amine 
functionality as seen in 10 but possessing the dihydrothiazole head group. The 
lower homologue of 10 (15), which has a six-atom bridge length between the head 
group, and the remote amine group gave rise to a nNOS selective inhibitor (Collins et 
al 1998). Target 50 was synthesised to be the lower homologue of 31, testing this 
theory of the bridge length on the selectivity of NOS inhibition.
Targets 42 and 31 are analogous to 58 and 50. These targets were synthesised to 
compare the effects of the potency and selectivity in NOS inhibition in relation to the 
head group functionality. Both targets 75 and 68 have the same bridge length as 58 
and 50, but with the remote amine group directly attached to the benzene ring. These 
four targets could then be evaluated to ascertain whether the optimum position for 
the methylene unit was directly attached to the ring or to the dihydrothiazole head 
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Different functional groups were synthesised onto these targets e.g. NO2 , NH2 , OMe, 
CO2 H, to examine the different roles played by electron-withdrawing groups, 
electron-donating groups and the size of the group on the potency and selectivity of 
the targets. Targets were synthesised with both the meta and para relationships 
between the groups so that a direct comparison could be made between both the 
functional groups and the ring positions.
The second group of targets (illustrated above) were designed to be analogous with 
the dihydrothiazole targets but with differences in the head group functionality. 
Citrulline (one of the products of the NOS reaction) is not a good inhibitor of the 
reaction but, when the ureido oxygen is replaced by sulphur to give 8 , the 
characteristics of the inhibitor change dramatically. Compound 8  is fairly potent but 
non-selective inhibitor of NOS (table 3.2). Other NOS inhibitors have been 
synthesised with the thiourea head group these include S-ethylisothiourea and S- 
isopropylisothiourea (Garvey et al 1994) and aromatic targets such as S-ethyl N- 
phenylisothiourea (Shearer et al 1997a).
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IC,n UM Ki uM
iNOS cNOS eNOS nNOS
Thiocitrulline 4.6a 1.7a
S-ethyl N- 0.87 (Ki pM)b - 0.40b 0.12b
phenylisothiourea
S-ethylisothiourea 0.019c 0.039c 0.029c
Table 3.2: IC50 values for different thiourea derivatives, a Ulhaq et al 1999, b 
Shearer et al 1997a, c Garvey et al 1994.
The lysine target 129 is an analogue of 8 possessing the extra CH2 unit in the chain 
length, which will hopefully increase the selectivity of the target but retain the 
potency seen in 8. Target 128 is the methyl ester of 129 and was synthesised to see if 
increasing the steric bulk around the carboxylate had any affect on the potency and 
selectivity of the inhibitor as seen in 7 and 3. Compound 7 being more selective for 
cNOS over iNOS (ref. table 1.2 chapter 1). Also the effect of changing the overall 
charge of the inhibitor from negative (without the methyl ester) to neutral can be 
examined.
The same hypotheses (explained earlier) that were applied to targets 31, 50, 68, 42, 
58, 75,112,119, 21,123, 82, 99,107, 89 about the benzene ring being important for 
the inhibitor conformation and the bridge length between the head group and the 
functional group were applied to targets 35, 48, 64, 40, 56, 71, 110, 117, 114, 121, 
80, 96,104, 87. Comparisons between functional groups and the position around the 
aromatic ring can be made as before with the dihydrothiazole targets but also the 
effects that the different head groups have on NOS inhibition can be examined.
The first step in the synthesis of all the targets was to devise an efficient and high 




Strategies towards the synthesis of the dihydrothiazole head group
Target 21 was the first target to be synthesised. Stokker et al 1982 have reported a 
method for preparing 2-amino-4,5-dihydrothiazoles from primary amines by an 
addition-elimination reaction with 2-methylthio-4,5-dihydrothiazole in ethanol at 
reflux. This procedure would be extremely beneficial to the synthesis of these 
targets as the head group functionality would be added in a one-step reaction, 
dramatically decreasing the number of steps in the overall synthesis. The starting 
material 4-methoxybenzylamine (19) was chosen as a model for 21. However, when 
this procedure was applied to the model no reaction took place. It was necessary to 
heat a mixture of the reagents at 180°C for 4 h in the absence of solvent to achieve a 
30% yield of the desired model product 21 as a crystalline solid.
Retrosynthetic analysis suggested that a common starting material for target 31 
would be l,3-bis(aminomethyl)benzene (22). Since only one of the amines needed 
to be converted into the various head groups, the other needed to be protected. The 
Boc group is one of the most frequently used groups to protect amino compounds. It 
is inert towards catalytic hydrogenolysis and resistant towards basic and nucleophilic 
reagents but is readily cleaved in high yield by strong acids. Therefore, this makes it 
a very suitable protecting group for the later steps in the synthesis. Diamine 22 was 
treated with 0.3 equivalents of di-tert-butyl dicarbonate, giving a mixture of the 
mono-Boc diamine 23 and the starting material. These were readily separated, as the 
diamine 22 is highly soluble in water; the crystalline product 23 was obtained in 
excellent yield (78%). The selectively Boc protected amine was then treated with 2- 
methylthio-4,5-dihydrothiazole at reflux for 4 h at 180°C. However, the conditions 
were obviously too harsh for this compound, as no products could be identified from 
the ]H NMR spectrum of the crude reaction mixture. This method was then applied 
to a different starting material: 3-cyanobenzylamine with the expectation that the 
cyano group would be able to withstand the harsh conditions. Once again !H NMR 
results showed extensive decomposition. Therefore, another method was needed to 














Scheme 3.1: Synthetic routes for the dihydrothiazole head group.
Another approach to the synthesis of 2-substituted dihydrothiazoles is the classical 
Gabriel synthesis (Metzger 1984), which involves condensation of the thioamide 
with 1,2-dibromoalkanes to give the corresponding 4,5-dihydrothiazoles. This 
method of synthesising the dihydrothiazole targets would be advantageous because 
one of the intermediate steps involves the synthesis of thioureas.
The dihydrothiazoles can be synthesised from thioureas which in turn can be 
synthesised from thiocyanates. The isothiocyanate can easily be prepared from the 
mono-Boc protected diamine (23) by treatment with thiophosgene in the presence of 
CaCCb to prevent the mixture from turning acidic and therefore cleaving the
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protecting group. The unprotected amine acts as the nucleophile and attacks the 
carbon of the thiophosgene and the reaction proceeds by an addition elimination 
mechanism. The thiourea can be disconnected by the “cleavage” of the terminal C-N 
bond. Ammonia represents the strong nucleophile, which is bubbled through a 
solution of the electrophilic isothiocyanate in chloroform to give the thiourea in 
excellent yield (97%). The mechanism for the next step in the reaction is proposed 
in scheme 3.2. This involves nucleophilic attack by the sulphur on 1,2- 
dibromoethane, which displaces one of the bromine atoms. The initial step is 
followed by cyclisation and the loss of the other bromine atom. Ulhaq et al 1999 
used this method for the addition of the C2 unit on ornithine derivatives and only 
achieved moderate yields (35%) for the target dihydrothiazole. When this procedure 
was carried out on the thiourea 28 even after repeated attempts, the yields was 









Scheme 3.2: Synthetic route to the dihydrothiazole head group using the Gabriel 
synthesis.
An alternative method for the synthesis of dihydrothiazoles has been reported by 
Caujolle et al 1989. An isothiocyanate in acetone added dropwise over 30 min to a 
solution of 2-aminoethanol in acetone and refluxed for 4-5 h produces a thiourea 
intermediate. The N’-(2-hydroxyethyl)thiourea intermediate is then cyclised by 
treatment with boiling aq. hydrochloric acid ( 6  M) for 40 h to give the corresponding 
dihydrothiazole.
This procedure was tried on the isothiocyanate intermediate 27. The amine of the 2- 
aminoethanol is more nucleophilic than the oxygen and so readily reacts with the 
electrophilic carbon to add the two-carbon unit onto the thiocyanate. This method 
successfully gave the intermediate 30 in a reasonable yield (37%).
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Cyclisation of 30 was achieved by treatment with boiling aq. hydrochloric acid (6 M) 
for 40 h. The progress of the reaction was monitored by lK  NMR. The crude *H 
NMR spectrum after 24 h showed complete removal of the Boc protection but a 
mixture of dihydrothiazole and 2-hydroxyethyl units. Protonation of the OH group 
makes it a good leaving group; nucleophilic attack by the sulphur at the terminal CH2 
and expulsion of water leads to cyclisation. Yields in repeated runs were ca. 70%. 
An advantage of this method is that the target 31 is isolated directly by evaporation 
as the hydrochloride salt, so achieving two steps in one; the cyclisation and the 
removal of the Boc protecting group. 3-Cyanobenzylamine would also have been a 
suitable starting material for this synthesis, with the reduction of the cyano group 
(with Pd/C) being the last step in the synthesis. However, there is the risk that the 
cyano group would be hydrolysed to a carboxamide or a carboxylic acid under these 
conditions. The addition and removal of the Boc protecting group were high 
yielding steps in the synthesis and so 22 was deemed the more appropriate starting 
material.
Subsequently, it was found that treatment of the N’-(2-hydroxyethyl)thiourea with 
trifluoroacetic acid also produced the cyclised trifluoroacetic acid salt in 
approximately ten minutes (Kocienski 1994) (Scheme 3.3). Trifluoroacetic acid is a 
stronger acid than hydrochloric acid due to the electron-withdrawing properties of 
fluorine; but the differences in their dissociation constants alone would not be 
enough to increase the rate of reaction sufficiently to complete the cyclisation in ten 
minutes; therefore there must be other factors involved. An additional explanation is 
that trifluoroacetic acid reacts with the hydroxyethyl thiourea (30) to form the 
trifluoroacetate ester which is a much better leaving group that OH and so the 
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Scheme 3.3: Reaction mechanism for the formation of 31.
Strategies towards the synthesis of the thiourea head group
Retrosynthesis shows that the thiourea head group can be disconnected by the 
cleavage of either the terminal C-N bond or the other C-N bond. Disconnection of 
the terminal C-N bond would require a strong electrophile and a nucleophile. An 
ideal compound for the electrophile would be an isothiocyanate with ammonia 
representing the nucleophile. As seen in scheme 3.2, these reactions have already 
been achieved in high yields in the synthesis of the dihydrothiazole head group, 
using 22 as the starting material. The advantage of using this synthetic route is that 
the intermediate thiocyanates generated can be used in the synthesis of the 
dihydrothiazole targets as well. This was the method chosen to synthesise targets 
with the thiourea head group.
Disconnection of the other C-N bond would require benzoyl isothiocyanate (32) as 
the electrophile which reacts with the mono-Boc protected diamine 23 to give the 
intermediate 1,1-dimethylethyl N-(3-(N’-benzoylthioureidomethyl)
phenylmethyl)carbamate. Treatment of the intermediate with alkaline hydrolysis 
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Scheme 3.4: Alternative synthetic pathway for the synthesis of 28.
The above targets were designed and synthesised so that a range of structural effects 
could be correlated to NOS inhibition. This would enable conclusions to be drawn 
about the effects of the head group (dihydrothiazole and thiourea), the position, type 
and size of the functional group on NOS potency and selectivity. Also information 
can be gained about the structural features, which are important for the inhibitor to 




Synthetic routes to targets 31, 35, 40 and 42
BocHNBocHN
BocHN BocHN
Scheme 3.5: Synthesis of targets 31, 35, 40 and 42. Reagents and conditions: i) 
B oc20 ,  CH2 C12, Et3N, 16 h; ii) CSC12, CHCI3 , 16 h; iii) NH3, CH2 C12; iv) CF3 C 0 2 H, 
5 min; v) 2-aminoethanol, acetone, reflux; vi) aq. HC1 6  M, reflux 40 h.
Synthetic routes to targets are given in scheme 3.5. Retrosynthetic analysis 
suggested that a common starting material for the meta-substituted targets would be 
l,3-bis(aminomethyl)benzene (22) and l,4-bis-(aminomethyl)benzene (36) for the 
para-substituted targets. For both targets, selective protection of one of the amine 
groups was required and this was again carried out using the Boc protecting group. 
The Boc protecting group is inert towards catalytic hydrogenolysis and resistant 
towards basic and nucleophilic reagents but is readily cleaved in high yield by strong 
acids.
A surprising result from the *H NMR spectral analysis of 23 is that the C //2NH2 
singlet peak was seen at 6  4.34, while the CH2NHBoc doublet peak appeared at 5 
3.90. The electron-withdrawing properties of the carbonyl usually influence the CH2 
next to the NHBoc, pushing the signal further downfield so that the C //2NH2 is 
usually seen further upheld of 8  4.34. The !H NMR spectrum peaks must be 
correctly assigned as the NH attached to the Boc protecting group is coupled into the 
CH2  and therefore seen as a doublet and not a singlet. Protons belonging to free
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amine substituents do not usually couple to neighbouring groups, which explains 
why the signal seen is a singlet and not a doublet.
The reaction of 23 with thiophosgene gave the desired isothiocyanate 27, this was 
achieved in reasonable yield (37%). The mechanism of this (and subsequent steps) 
reaction were explained earlier in the chapter. IR spectral analysis showed that the 
characteristic strong peak of the isothiocyanate had been formed at 2060 cm'1. The 
formation of the novel thiourea 28 was characterised by the disappearance of the 
isothiocyanate peak in the IR spectrum and the appearance of the C=S peak at 1164 
cm'1. Deprotection of the thiourea 28 was carried out in trifluoroacetic acid. 
Compound 27 was stirred in trifluoroacetic acid for five minutes to give the 
corresponding bis(trifluoroacetate) salt in a quantitative yield. The cyclisation of the
2-hydroxyethyl thiourea intermediate 30 was carried out under reflux for 36 h in aq. 
hydrochloric acid ( 6  M). The novel highly polar product 31 was achieved in good 
yield (47%). !H NMR spectra analysis showed that the dihydrochloride salt had 
formed as an > ^ 3  peak and two NH peaks were seen at 5 8.70 and 10.89, 
respectively.
Para-substituted target compounds 40 and 42 were synthesised in the same way as 
the meta-substituted targets. Boc protection of 36 was achieved in 80% yield. !H 
NMR spectra analysis showed that the doublet signal corresponding to CH2NHB0 C 
was seen further downfield of the CH2NH2 as expected. The novel isothiocyanate 
and thiourea intermediates 38 and 39 were achieved in good yields of 80% and 71% 
respectively as crystalline solids. The removal of the Boc protecting group from 39 
was carried with trifluoroacetic acid giving rise to the corresponding target salt in a 
quantitative yield.
Cyclisation of 41 was carried out under the same conditions as 31 (reflux for 36 h in 
aq. hydrochloric acid ( 6  M)), but difficulties occurred with the purification of 42. 
Attempts were made to purify the product by recrystallisation and the re-addition of 
the protecting group to the cyclised product in the hope that the compound could
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then be purified by column chromatography. After repeated attempts target 42 was 
achieved by recrystallisation from propan-2-ol.
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Synthetic routes to targets 48, 50, 56, 58,64, 68, 71 and 75
The synthetic routes to target compounds 48, 50, 56 and 58 are given in Scheme 3.6.
BocHN BocHNNO NH










Scheme 3.6: Synthesis of targets 48, 50, 56 and 58. Reagents and conditions: i) 
B oc20 ,  CH2 C12, Et3N, 16 h; ii) SnCl2 .2H2 0 , EtOH, reflux; iii) CSC12, CHC13, 16 h; 
iv) NH3, CH2 C12; v )  CF3 C 0 2 H; vi) 2-aminoethanol, acetone, reflux; vii) CF3C 0 2 H.
Retrosynthetic analysis suggests that a common starting material for the meta­
substituted targets would be 3-nitrobenzylamine (43) and 4-nitrobenzylamine (51) 
for the para-substituted targets. Before the synthesis of the head groups could be 
carried out, the amine needed to be protected and the nitro group reduced to the 
amine. Initially, the reduction was carried out with hydrogen and Pd/C but, after 
repeated attempts, no significant yields were achieved, and so another method was 
needed (Scheme 3.7). Bellamy et al 1984 proposed another approach to the 
reduction of the nitro group, in which the reduction could occur under neutral
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conditions. This was essential to the reaction otherwise the Boc protecting group 
would be cleaved. The protected nitro compound 52 was added to 2.8 equivalents of 
SnCb in ethanol and boiled for 30 min. The mixture was made basic, subsequently 
extracted and evaporated to give the amine 53 in moderate yield (31%).
B o c H N ^ ^  n 0 2  B o c H N ^  ^
52 2 53 2
Scheme 3.7: Synthesis of 53. Reagents and conditions: i) Pd/C, H2 .
The synthetic route for targets 64, 68, 71 and 75 is given in scheme 3.9. The first 
steps in the synthesis was to orthogonally protect the amine groups in the starting 
material 3-(aminomethyl)benzylamine (59). The proposal was to use the Cbz and 
Boc protecting groups. The Boc protecting group would be cleaved under mild 
acidic conditions to add the head functionality to the target and the Cbz group would 
be removed in the final step. Failed attempts were made to add the Cbz protecting 
group to 1,1-dimethylethyl N-(3-aminophenylmethyl)carbamate (60) (this is shown 
in scheme 3.8). An alternative method was required to achieve target compounds 64, 
68, 71 and 75.
NHBoc
NH2
Scheme 3.8: Synthesis of 61. Reagents and conditions: i) B0 C2 O, CH2 CI2 , 16 h; ii) 
Benzyl chloroformate, CH2 Cl2 ,Et3N, 16 h; iii) aq. HC1.
As mentioned earlier nitro groups can be reduced in the absence of base or acid using 





be carried out in the presence of the sulphur atom. As a consequence the reduction 
of the nitro group could be the final step in the synthesis after the head group 
functionality had been assembled. The starting materials were changed to 3- 
nitrobenzylamine (43) and 4-nitrobenzylamine (51) and the targets were synthesised 
as shown in scheme 3.9.
©
cf3co2
Scheme 3.9: Synthesis of targets 64, 68 71 and 75. Reagents and conditions: i) 
CSCI2 , CHCI3 , 16 h; ii) NH3, CH2 C12; iii) SnCl2 .2H2 0 , EtOH, reflux; v) CF3 C 0 2 H; 
iv) 2-aminoethanol, acetone, reflux; v) CF3 C 0 2 H; vi) SnCl2 .2H2 0 , EtOH, reflux.
Additional compounds (65 and 72) were isolated when 2-aminoethanol was added to 
the intermediates 62 and 69 respectively. The minor tetrahydrooxazole products 
were less polar than the desired major products 66 and 73 and so were easily 
separated by column chromatography. Confirmation of the oxazole products was 
achieved with *H NMR spectra and FAB+ mass spectra. The *H NMR spectrum 
showed triplet signals corresponding to the oxazole CH2 groups at 5 3.82 and 4.05, 
and the appearance of the two methyl signals at 8  1.80. The FAB+ve ion mass 
spectrum showed the [M + H] peak at 296.
Tetrahydrooxazoles 65 and 72 were only formed when the nitro functionality was 
directly attached to the benzene ring. The nitro group is a very strong electron
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withdrawing group and so pulls electrons away from the benzene ring, making the 
isothiocyanate carbon more electrophilic. The proposed mechanism for this reaction 
involves the reaction solvent (acetone) and 2 -aminoethanol reacting together to form 
the nucleophilic species, which then attacks the electrophilic carbon (scheme 3.10).
OH
OH
n N= C= S
yMe
Me
Scheme 3.10: Mechanism for the synthesis of oxazole compounds 65 and 72
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Synthetic routes to targets 80, 82, 87, 89, 96, 99,104 and 107
The starting materials used for the targets with the head group directly attached to the 
ring (89, 82, 87, 80) were 3-aminophenylacetic acid (76) and 4-aminophenylacetic 
acid (83) (scheme 3.11).
NH NCS

























Scheme 3.11: Synthesis of targets 80, 82, 87 and 89. Reagents and conditions: i) 
SOCI2 , MeOH, 4 d; ii) CSC12, CHCI3 , 16 h; iii) NH3, CH2 C12; iv) aq. HC1 1 M, 9 d 
(80) aq. HC1 6  M 16 h (87); v) 2-aminoethanol, acetone, reflux; vi) aq. HC1 6  M, 40 
h, reflux (82), aq. HC1 6  M, 16 h (89).
The initial step in the synthesis of these targets was to protect the carboxylate 
functionality. This was carried out for two reasons; i) to increase the solubility of the 
products ii) to prevent any minor compounds being formed. This is especially 
important when treating the unprotected starting material with thiophosgene as acid 
chlorides may be formed. The carboxylate in both starting materials were protected 
with a methyl ester and the products (77 and 84) were achieved in quantitative yields.
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Methyl 3-isothiocyanatophenylacetate (78) and methyl 3-thioureidophenylacetate 
(79) are both novel compounds and were made in very good yields 77% and 99% 
respectively. The removal of the methyl ester from 79 was carried out in aq. 
hydrochloric acid 1 M and the known product 80 was achieved in a good crystalline 
yield (86%).
Cyclisation of 81 was carried out in reflux with aq. hydrochloric acid. The removal 
of the methyl ester from 86 to achieve the thiourea target 87 was achieved by stirring 
in aq. hydrochloric acid (6 M) for 16h. Interestingly, the removal of the methyl ester 
to achieve the other dihydrothiazole target (89) was carried out in aq. hydrochloric 
acid (6 M) at room temperature.
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3-Cyanobenzoic acid (90) was the most suitable starting material for targets 96 and 
99 (scheme 3.12).



















Scheme 3.12: Synthesis of targets 96 and 99. Reagents and conditions: i) SOCI2 , 
MeOH, 4 d; ii) Pd/C H2, MeOH, 16 h; iii) CSC12, CHCI3 , 16 h; iv) NH3, CH2 C12; v) 
hydrobromic acid (50%), 16 h; vi) 2-aminoethanol, acetone, reflux; vii) aq. HC1 6  M, 
40 h, reflux, MeOH, S0C12, 4 d; viii) CF3 C 0 2 H.
Reduction of 91 with Pd/C (10%) gave rise to both the desired product 92 in 
reasonable yield and a dimerized side product 93 in an exceptionally low yield. 
During the reaction a partially reduced intermediate is formed which reacts with the 
amine to produce an imine. The nitrogen double bond in the imine is then reduced 
forming 93 (scheme 3.13). Confirmation of the dimer came from mass spectra. 






Scheme 3.13: Mechanism for the synthesis of the dimerized side product 93.
All the targets with the carboxyl functionality were synthesised using methyl ester as 
the protecting group. However, problems arose when trying to remove the methyl 
ester when it was directly attached to the ring in the presence of the thiourea head 
group (96). The acid conditions (even aq. hydrochloric acid 1 M) appeared to be too 
harsh and so removal of the protecting group was tried using 30% NaOH (aq.) 
(Giordano et al 1982), this too was unsuccessful and so hydrobromic acid was tried. 
Removal of the methyl ester was achieved when 95 was stirred in 50% hydrobromic 
acid for 16 h.
The final step in the synthesis of methyl 3-(4,5-dihydrothiazol-2-ylamino)benzoate 
hydrochloride in which 97 was boiled under reflux with aq. hydrochloric acid ( 6  M) 
for 40 h gave a product which was difficult to purify. Attempts were made to purify 
the compound by recrystallisation but a suitable solvent proved hard to find due to 
the polarity of the compound. The methyl ester of the crude dihydrothiazole was 
made and deprotected with 50% aq. trifluoroacetic acid (under reflux for 16 h), 
which yielded the purified product in quantitative yield.
4-Aminomethylbenzoic acid was commercially available and so was used for the 
synthesis of targets 104 and 107 (scheme 3 .14).
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Scheme 3.14: Synthesis of targets 104 and 107. Reagents and conditions: i) SOCI2 , 
MeOH, 4 d; ii) CSC12, CHC13, 16 h; iii) NH3, CH2 C12; iv) hydrobromic acid (50%), 
16 h; v) 2-aminoethanol, acetone, reflux; vi) aq. HC1 6  M, 40 h, reflux, MeOH, 
SOCl2, 4 d.
As seen for the nitro group examples, when the nitro electron-withdrawing group 
was directly attached to the benzene ring a tetraoxazole was also formed in the 
reaction with 2-aminoethanol. This also occurred when the carboxyl electron- 
withdrawing group was in the para position giving rise to compound 105 in 
reasonable yield (43%). The reaction occurs by the same mechanism as shown in 
scheme 3.10. Once again the *H NMR spectra showed the characteristic oxazole 
triplets at 6  3.64 and 3.96 and the methyl group signal at 6  1.69. The FAB+ve ion 
mass spectra showed the [M + H] peak at 309.
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Synthetic routes to targets 21,110,112,114,117 119,121 and 123
Scheme 3.15: Synthesis of targets 21,110, 112 and 114. Reagents and conditions: i) 
CSCI2 , CHCI3 , 16 h; ii) NH3, CH2 CI2 ; iii) 2 -aminoethanol, acetone, reflux; iv) 
CF3 CO2 H.
The corresponding starting material for targets 112 and 110 was 3- 
methoxybenzylamine (108) and for targets 21 and 114 the starting material was 4- 
methoxybenzylamine (19). Due to the relatively unreactive properties (under the 
conditions used) of the methoxy group there was no need to add a protecting group to 
this functionality and so the synthetic pathways for these targets were reduced by 
several steps (schemes 3.15 and 3.16).
Target 112 was achieved by two different synthetic routes. The 1:1 addition of 3- 
methoxybenzylamine with 2-methylthio-4,5-dihydrothiazole (mechanism explained 
in scheme 3.1) was achieved in moderate yield (30%) of crystalline product. When 
the same target was synthesised by cyclising the intermediate 2 -hydroxyethyl 
thiourea 111 in trifluoroacetic acid, the product was attained in a higher yield (75%) 
but as an oil. On the basis of this information it would seem that the one-step 























Scheme 3.16: Synthesis of targets 117, 119, 121 and 123. Reagents and conditions: 
i) NH3 , CH2 CI2 ; ii) 2-aminoethanol, acetone, reflux; iii) CF3 CO2 H.
The number of steps involved in the synthesis of targets 117, 119, 121 and 123 were 
very few, as 3-methoxyphenylisothiocyanate (116) and 4- 
methoxyphenylisothiocyanate (1 2 0 ) were commercially available and all targets 
were achieved in one step and were of high crystalline yields (scheme 3.16).
All the steps involved in the synthesis of the methoxy targets were of good yield. In 
particular, the formation of the thiourea targets 114,110,121 and 117 were achieved 
in exceptional yields (99% or quantitative).
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Synthetic routes to targets 128,129 and 131
The synthetic route to targets 128,129 and 131 is given in Scheme 3.17.
NCS
in
h n ^ n h 2
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Scheme 3.17: Synthesis of targets 128, 129 and 131. Reagents and conditions: i) 
SOCl2, MeOH, 4 d; ii) CSC12, CHC13, 16 h; iii) NH3, CH2C12; iv) HBr in HO Ac 
(17.5%) 15 h; v) hydrobromic acid 16 h; vi) 2-aminoethanol, acetone, reflux; vii) aq. 
HC1, 6 M 40 h, reflux.
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Retrosynthetic analysis suggested that Ff-Cbz-lysine would be an ideal starting 
material. The carboxyl group was protected with ter/-butyl ester, which offers a 
degree of steric shielding. This makes the group resistant to attack by a wide range 
of nucleophiles (Kocienski 1994). The a-amino group was protected with the most 
popular amino-protecting group Boc. Cbz groups usually cleave easily with catalytic 
hydrogenation. However, repeated attempts to remove the e Cbz group gave no 
successful unprotected amine. Cbz-Lys-OH (124) was also commercially available 
and so this starting material was used instead. The carboxyl group was then 
protected as the methyl ester as the method was found to be slightly easier than 
introducing the butyl ester.
During the penultimate step in the synthesis of 131, involving 126 reacting with 2- 
aminoethanol, the methyl ester was exchanged with 2-aminoethanol(scheme 3.18).
OH OH:=s HN' HN
OH






Scheme 3.18: Mechanism showing the synthesis of 130.
Confirmation of the ester exchange came from the loss of the methyl signal around 8 
3.70 and the addition of two CH2 peaks, an NH and an OH peak, while the FAB+ve 
ion mass spectrum showed the [M + H] peak at 427.
Deprotection of the Cbz and methyl ester was achieved using hydrogen bromide in 
acetic acid, cleaving the Cbz protecting group followed by hydrobromic acid, to 
cleave the methyl ester. Both targets 128 and 129 were isolated as the 
dihydrobromide salts. The most obvious way of deprotecting Cbz groups is with 
Pd/C, however, in this synthesis deprotecting Cbz with Pd/C/H2 (in the final
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synthesis step) would have destroyed the head group as sulphur interferes with 
Pd/C/H2 . Another reason for deprotecting both protecting groups with hydrobromic 
acid is that the target would be isolated as the hydrobromide salt and not a mixture of 
different anions. In retrospect, the first starting material used (hf-Cbz-lysine); the 
Cbz protecting group could probably have been cleaved with hydrogen bromide in 
acetic acid instead of trying to remove the protecting group with Pd/C/H2 .
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Synthesis of 2-(3-(l(S), 2(S)-1-Amino-2, 3-dihydroxypropyl) 
phenylmethyl-4,5-dihydrothiazole (143)
This target compound was designed to incorporate many of the features believed to 
be beneficial for the inhibition of iNOS. The amine-diol functionality has been 
shown to be particularly beneficial to the selectivity o f iNOS inhibition. Hallinan et 
al 1998 showed that the dihydroxyethyl motif in 18 increased the selectivity for 
iNOS by 700 fold compared to 5. This group also showed that the chirality of the 
inhibitor was important, as the diasteroisomer showed a decrease of four times the 
potency in NOS inhibition. The dihydroxyethyl motif together with the benzene ring 
and dihydrothiazole head group should give rise to a potent and selective iNOS 
inhibitor. Scheme 3.19 shows the entire synthetic route that would have been taken 
to target 143 had time permitted, several of these steps were achieved and these 
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Scheme 3.19: Synthesis o f  target 143. Reagents and conditions: i)SOCl2, MeOH, 4 d; ii) propenoic acid, palladium (II) 
acetate, Et3N, propanenitrile, reflux 1 h; iii) propan-2-ol, cone H2S 0 4, reflux, 24 h; iv) K2[ 0 s 0 2(0 H )4], L i0H .H 20 ,  2-methyl- 
2-propanol, (DHQ)2PHAL, water, N-bromoacetamide, 4°C; v) PhP3, DEAD, acetic acid; vi) LiBH4, THF, Ar; vii) 2,2- 
dimethoxypropane, TSOH; viii) CF3CONH2, PhP3, DEAD; ix) NH3, MeOH; x) CSC12, CHC13, 16 h, xi) 2-aminoethanol, 
acetone, reflux; xii) aq.HCl, 6M, 40 h, reflux.
75
Chapter 3: Discussion
Retrosynthesis shows that the synthesis of 143 can be divided into three parts; i) the 
aromatic part, ii) the dihydrothiazole head group functionality and iii) the diol 
functionality. As mentioned before, the benzene ring was chosen to maintain the 
inhibitor in the correct conformation for binding to the active site. The different 
routes to synthesising the head group functionality were discussed in detail earlier. 
The addition-elimination reaction with 2-methylthio-4,5-dihydrothiazole at reflux 
(180°C for 4 h in the absence of solvent) was considered too harsh for this particular 
reaction. The pathway involving 1,2-dibromoethane was very low yielding and, as 
there would be many steps in the synthesis of 143, this would not be the most 
efficient pathway to take. The most suitable method for synthesising the 
dihydrothiazole head group would be to make the isothiocyanate, then the 2- 
hydroxyethylthiourea and finally cyclise the open chain thiourea under reflux in aq. 
hydrochloric acid or trifluoroacetic acid. The most important factor when 
synthesising the diol functionality was to ensure correct stereochemistry throughout 
the synthesis.
There are several methods for introducing stereogenic centres into compounds. The 
reagents and reaction conditions play a vital role in determining whether the two 
possible enantiomers are formed in equal amounts. Allylic alcohols can undergo 
Sharpless asymmetric epoxidation to yield epoxy alcohols. The opening of the 
epoxy alcohols can be carried out using sodium azide and ammonium chloride. This 
yields the corresponding azido diols in good regioselectivity (>10:1). The azido 
group can then be reduced with sodium borohydride to give the amino diols. The 
reduction can be carried out in the presence of di-tert butyl dicarbonate to give the 
Boc protected amino diol (Padron et al 1999).
Bruncko et al 1997 adapted a method of the asymmetric dihydroxylation which 
allows olefins to be converted to non-racemic protected amino alcohols in a single 
step. This method uses cinchona alkaloids as the ligand. The Hofmann 
rearrangement is often a competing reaction of alkali metal salts of N- 
chlorocarboxamides. Using the N-bromo derivative and lowering the temperature to 
4°C, this side reaction could be suppressed. Amines bind to OsC>4 in situ as chiral 
ligands, causing it to add asymmetrically. These ligands cause enantioselective 
addition as well as accelerating the rate of reaction giving regioselectivity values of
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>20:1. By lowering the reaction temperature and selecting the appropriate ligand, 
enantiomeric purity can be increased. This method was considered the most efficient 
and effective way of producing an asymmetric aminohydroxylation, obtaining the 
product in a one step reaction compared to three steps with the epoxidation method. 
Another advantage for this method is the stoichiometric amounts of oxidant that are 
used which enables the work-up and purification to be simplified greatly.
Isopropyl cinnamates are the best precursors for the asymmetric aminohydroxylation 
reaction, using the method as described by Bruncko et al 1997. The easiest way of 
introducing the isopropyl ester into the target would be to carry out an ester 
exchange. As shown in scheme 3.19, a suitable starting material for the synthesis of 
target 143 would be an iodobenzene. The carboxylic acid could be protected with a 
methyl ester and the iodide would provide a suitable starting material for introducing 
the double bond to the target. Double bonds can be introduced into the target in 
several different ways:
i) Arylation of alkenes by organopalladium compounds: The Heck reaction
ii) The condensation of aromatic aldehydes with anhydrides: The Perkin 
reaction
iii) The condensation of aldehydes or ketones, usually not containing an a  
hydrogen: The Knoevenagel reaction
The most appropriate method for the synthesis of 143 is to use is the Heck reaction. 
The Heck reaction can be used on simple alkenes or alkenes with a variety of 
functional groups. This reaction is stereospecific, yielding products from syn 
addition followed by syn elimination. Under the umbrella of the Heck reaction there 
are four different methods in which an arylpalladium reagent can be generated. They 
are;
i) by treatment of an aryl bromide with palladium-triarylphosphine 
complex.
ii) by treatment of an aryl iodide with palladium acetate in the presence of a 
base.
iii) by treatment of an aryl mercury compound.
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iv) by the reaction of an aromatic compound with palladium acetate or 
palladium metal and silver acetate in acetic acid.
As mentioned above, the iodide would provide a suitable starting material for the 
Heck reaction. Previous members of our group developed an adaptation to the Heck 
reaction which could be carried out without the need for sealed tubes. The starting 
iodide would be heated with propenoic acid, palladium acetate and propanenitrile 
and refluxed for 1.5 h, with a straightforward work up (Watson 1997). This 
procedure is a far simpler way of introducing double bonds via the Heck reaction 
into target compounds.
Once the diol functionality had been synthesised, the next step would be to reduce 
the isopropyl esters with lithium borohydride to give the diol at one end of the 
compound and an alcohol at the other end. In order to change the remote alcohol 
function to an amine, the diol must be protected. This would be achieved by reaction 
with 2,2-dimethoxypropane to give an acetonide, as this only protects diols. A 
Mitsunobu reaction enables the replacement of a hydroxyl group by a wide range of 
nucleophiles (Hughes 1992), including trifluoroacetamide. The resulting amide can 
be cleaved to an amine group with ammonia. The dihydrothiazole head group is then 
able to be assembled in the way as described previously. The final cyclisation step in 
boiling aq. hydrochloric acid (6 M) would cleave the N-acetyl and acetonide 
protecting groups as well.
The order in which the synthesis is carried out is very important. The diol 
functionality was to be synthesised first. This would then be protected while the 
head group was synthesised. The final cyclisation step for the head group synthesis 
would be carried out in aq. hydrochloric acid as the acetyl protecting group would 
also be cleaved, leaving the desired target as the dihydrochloride salt.
As mentioned earlier, 3-iodobenzoic acid would be a suitable starting material. The 
first step in the synthesis involved protecting the carboxyl functionality with a 
methyl ester. This was achieved in high yield (98%) of crystalline solid. The next 
step required a Heck arylation reaction in which propenoic acid was coupled onto 
133. There are four steps in the Heck arylation reaction. These are; i) oxidative
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Scheme 3.20: The four steps in the Heck arylation reaction; i) oxidative addition ii) 
olefin insertion iii) (3-elimination and iv) reductive elimination.
The propanenitrile acts as a ligand in this reaction and attaches to the palladium. 
During step one in the reaction, methyl 3-iodobenzoate (133) adds onto the 
palladium and ligand complex. Propenoic acid is inserted into the complex in step 
two and the product, methyl 3-(2-carboxyethenyl)benzoate (134) is (3-eliminated in 
step three. Step four is a reductive elimination step in which hydrogen iodide is lost 
and the palladium ligand complex is recycled (scheme 3.20). The product 134 was 
achieved in quantitative crystalline yield and was isolated as the trans isomer. This 
was confirmed by the coupling constants between the CH-Ar and CH-CO2H, J  — 16 
Hz.
The next step in the synthesis was to carry out an ester exchange on 134. This step is 
important as the asymmetric hydroxylation requires bulky esters to give the reaction 
better regioselectivity. The procedure for the asymmetric hydroxylation (Bruncko et
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al 1997) required isopropyl esters as the preceding step. The product was achieved 
in moderate yield (50%). The ]H NMR clearly showed the disappearance of the 
methyl ester and the appearance of the doublets from by the propyl esters at 5 1.32 
and 1.38.
Benzyl N-chlorocarbamate was the source of electrophilic nitrogen used in the 
asymmetric aminohydroxylation. This reagent would have to be synthesised as it is 
not commercially available. The advantage of using this compound would be that 
the amine functionality would be protected with a Cbz group which would easily 
cleave under the head group cyclisation conditions. The commercially available 
benzyl carbamate was monochlorinated by the procedure described by Bachand et al 
1974. However, purification of the crude reaction mixture proved difficult and so an 
alternative was used instead. This was N-bromoacetamide which was commercially 
available and would leave an acetyl functionality protecting the diol. It was hoped 
the acetyl protecting group would be cleaved during the cyclisation of the 
dihydrothiazole head group (final step in the synthesis).
The asymmetric aminohydroxylation of 135 was carried out in a one-step reaction 
using the procedure as described by Buncko et al 1997. The olefin was converted to 
a non-racemic protected amino alcohol using osmium(VIII) and a cinchona alkaloid 
derivative ((DHQ)2PHAL). The reaction was carried out at 4°C as this enhances the 
regioselectivity of the product. Compound 136 gave only one Rf value on TLC 
indicating that one diasteroisomer was present (Rf 0.4 (acetone/hexane 1:1)). Equal 
quantities of both enantiomers would give rise to [a]o20 values of zero, and since 136 
has an [a]o20 value of -12.5° this signifies that there is a larger percentage of one of 
the enantiomers. Further analysis however, is required to establish whether 136 is in 
the pure enantiomeric form. Due to the method followed being a procedure for the 







Most of the protons were readily assigned in the *H NMR spectrum of 136. 
However, the assignment of the four CH peaks, the NH and the OH peak can not be 
done by *H NMR spectrum alone. It is most likely that the two multiplets at 8 5.10 
and 5.24 correspond to the isopropyl CHs, while the doublet peak at 8 6.88 correlates 
to the NH peak. Assumptions are made in this assignment and so more evidence is 
needed to determine fully the structure of 136. *H COSY and *H NOESY spectra 
were taken of 136; these are given in figures 3.1 and 3.2, respectively. These spectra 
will help assign which peaks are correlated to each other and so assign fully the 
proton signals in the ]H NMR spectra of 136.
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Figure 3.1: A lH COSY spectrum of compound 136. The blue lines show the 
correlation between the propyl ester peaks and the corresponding CH peaks. The red 
lines show the correlation between the NH peak and the CH peak at 8 5.55.
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The acetyl peak is seen at 8 1.97 on ]H NMR. On the !H NOESY spectrum, 
through-space correlation is seen from this acetyl peak to a peak at 8 6.88. Since the 
acetyl is next to the NH, the peak at 8 6.88 must correspond to the NH. The lH 
COSY spectrum shows coupling from the NH peak to a peak at 8 5.55. The !H 
NOESY spectrum shows through-space correlation from the unassigned CH peak at 
8 5.55 to the singlet at 8 4.46 and to two aromatic peaks at 8 7.56 and 8.06.
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Figure 3.2: A NOESY spectrum of compound 136. The blue lines show the 
correlation between the acetyl peak and the NH peak. The red lines show the 
correlation between the singlet at 8 5.55 to the aromatic protons at 8 7.56 and 8.06.
Therefore it is possible to conclude that the doublet peak seen at 8 5.55 must 
correspond to the C//NH. This is because through-space correlation is seen to the
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two nearest aromatic peaks (Ar 2 and 6) the C//OH and also the acetyl peak. The 
broader singlet at 5 4.46 must correspond to the C//OH.
The lH COSY spectrum also shows that the two propyl ester peaks (6 1.28 and 1.39) 
are coupled with the multiplet peaks at 6 5.10 and 5.24. This indicates that the 
multiplets must be CH peaks of the propyl esters.
The critical step in the synthesis of target 143 was the asymmetric hydroxylation, 
which was achieved in a reasonable yield (32%). Had time permitted, the remainder 
of the synthetic pathway as described above would have been carried out.
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Synthetic routes to achieving the correct assignment of 
dihydrothiazole protons on 1H NMR Spectrum
Introduction
The dihydrothiazole head group is a five-membered ring which possesses two CH2 
units, one adjacent to a nitrogen atom and the other next to a sulphur atom. 
Difficulties have arisen in analysing the *H NMR spectra of the dihydrothiazole head 
group functionality. The CH2 units in the head group occur on the !H NMR spectra 
as two separate signals either as multiplets or triplets. However, due to the similar 
electronegativity properties of nitrogen and sulphur, it is unclear which of the CH2 
units resonates further downfield and which is more upfield. For example, in 123, 
the two dihydrothiazole unit signals are seen as multiplets at 5 3.60 and 3.75. In 
another example (67), the two CH2 signals are seen as triplets at 8 3.55 and 4.05. In 
both examples, it is unclear which signal corresponds to the CH2 which is next to the 
nitrogen atom and which is the CH2 adjacent to the sulphur. The aim of this study 
was to develop and synthesise compounds that would enable the two dihydrothiazole 
CH2 units to be differentiated in such a way that would lead to the correct assignment 
of the two CH2 signal peaks in the *H NMR spectra.
Several other advantages arise from achieving the aim of this study and they are;
i) Evidence for the mechanism of ring closure. The most likely mechanism 
involves the OH group being protonated first and then the sulphur acting 
as a nucleophile and attacking the CH2 adjacent to the OH2+ and so ring- 
closing the carbon chain in an Sn2 type reaction (scheme 3.3). However, 
SNl-like mechanisms are also possible.
ii) Information gained from the study of deuterated dihydrothiazoles can 
provide a good base for labelled studies with 3H or 14C.
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Results
A HETCOR spectrum enables the 13C NMR spectrum to be correlated with ]H NMR 
spectrum. Taking a HETCOR spectrum of one the dihydrothiazole target 
compounds would provide a very quick and simple way of assigning the CH2 peaks 
on the NMR spectrum. Compound 75 was considered a good example for this 
analysis as the target was isolated as the free base and not as a hydrochloride or 
trifluoroacetate salt. This means that any effects that the salt may have on the spectra
1 'i
would be eliminated. The assignment of the peaks in the C NMR spectrum of 75 
showed that the CH2S and CH2N were a considerable distance apart (CH2S at 8 35.7 
and the CH2N signal at 8 60.4) (Williams and Fleming 1980). A HETCOR spectrum 
was taken of this compound to see whether the CH2S and CH2N in the 13C NMR 
spectrum could be correlated to the dihydrothiazole CH2 triplets seen at 8 3.33 and 
4.02 in the !H NMR spectrum.
The HETCOR spectra shows that the CH2S signal in the 13C NMR spectrum strongly
correlates with the triplet at 8 3.33 while the CH2N signal at 8 60.4 is linked with the
triplet at 8 4.02 (figure 4.1). Although this information strongly suggests that the
dihydrothiazole peaks are assigned with the CH2N further downfield than the CH2S
assumptions are made about the correct assignment of the CH2S and CH2N peaks in 
1
the C NMR spectrum. Therefore, more evidence is needed to confirm the 
assignment of the two dihydrothiazole peaks. The HETCOR spectrum provides no 
knowledge of the mechanism of cyclisation and so further synthetic routes were 
designed to try and establish the mechanism and the correct assignment.
Compound 75
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Figure 4.1: HETCOR spectrum of compound 75. The blue line indicates the 
correlation between the CH2S signal on the 13C NMR spectrum and the triplet at 8 
3.33 seen on the *H NMR spectrum. The red line indicates the correlation between 
the CH2N signal at 8 60.4 on the 13C NMR spectrum and the triplet at 8 4.02 seen on 
the NMR spectrum.
The first synthetic approach to achieving the aim of this project was to synthesise 
(S)-2-(3-methoxyphenylamino)-5-methyl-4,5-dihydrothiazole (146). The theory 
behind using l-aminopropan-2-ol (144) was that the addition of the methyl unit into 
the dihydrothiazole head group would enable the dihydrothiazole CH2 signals to be 
easily differentiated. The introduction of the methyl group into the dihydrothiazole 
head group would hopefully not alter the dihydrothiazole CH2 signals too greatly 
from where they more commonly resonate. In addition, information could be gained
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about the mechanism of cyclisation and ascertain whether, in fact, the cyclisation 
reaction proceeds by a SnI or Sn2 type reaction.
H
146
Scheme 4.1: Reagents and conditions: i) Acetone, reflux 2 h; ii) aq. HC1 (6M), reflux 
24 h.
The synthesis of 146 was straightforward and easy to accomplish as it only involved 
two steps (scheme 4.1). The addition of 144 to 116 was achieved in reasonable yield 
(38%) by boiling under reflux in acetone for 2 h. The 'H NMR spectrum results 
showed that the CH2 was no longer seen either as triplet or a multiplet peak but as 
two separate multiplet peaks (5 3.64 and 3.94). This is due to the chiral centre that 
has been introduced. The chiral centre places both protons in the CH2 unit in 
different magnetic environments and so each proton is visualised as a separate peak.
The cyclisation of 145 was carried out under reflux for 24 h in aq. hydrochloric acid 
(6 M), which gave the product 146 in a quantitative yield. Confirmation of the 
cyclised product came from the mass spectrometry results (FAB+ve ion 223 [M + 
H]). The !H NMR spectrum showed a multiplet at 8 3.77, corresponding to one 
proton and a multiplet at 8 4.12, accounting for two protons. It is unclear whether 
the protons in the CH2 are seen separately as in 145 or together (as seen in all the 
other dihydrothiazole targets) at 8 4.12. A *H COSY spectrum enables the CH2 and 
the CH of the dihydrothiazole to be correctly assigned (figure 4.2). The two protons 
from the CH2 unit must be seen as two separate signals as coupling is observed from 
the signal at 8 4.12 to 8 3.77. If, however, the CH2 unit was assigned as the multiplet
11
87
Chapter 4: Synthesis o f deuterated dihydrothiazoles
seen at 8 4.12, coupling would not be observed; the !H COSY spectrum shows that 
this is not the case. The evidence suggests that the CH2S peak is further downfield 
from the CH2N. This is a surprising result as the HETCOR spectra (figure 4.1) seen 
from compound 75 suggests that the CH2N and CH2S would appear on the *H NMR 
spectrum the other way around. It is most likely that the methyl unit introduced into 
the dihydrothiazole ring has a larger effect on the NMR spectrum than 
anticipated. Therefore, other synthetic routes were explored to establish the aim of 
the project.
The chiral centre within 146 provides evidence for the mechanism of cyclisation. 
The mechanism of ring closure is most likely to proceed by an Sn2 type reaction. 
The methyl group and hydroxyl group in the open chain thiourea increase the steric 
bulk of the compound, which pushes the mechanism towards an SnI type reaction. 
The SnI type reactions give rise to racemic products as the carbocation in step two of 
the mechanism can be attacked from either the top side, yielding one enantiomer or 
from the bottom side yielding the other enantiomer. When racemisation occurs, the
90[a]o values of such compounds are zero. The mechanism of an Sn2 reaction of a 
pure enantiomer gives inversion of chirality. The nucleophile collides with the back 
side of the tetrahedral carbon (in this case the one with the hydroxyl and methyl 
group attached) causing the three groups attached to the carbon to flatten out into the 
transition state. The groups then flip over to the other side of the carbon giving rise 
to the opposite enantiomer as the product. The cyclised product 146 has an [a]o20 
value of -32.4° and, therefore, is it possible to conclude that the product has not 
racemised. Without further analysis it is unclear whether the reaction proceeds 
entirely by an S n 2 type mechanism or a mixture of S n I  and S n 2. However, on the 
evidence given the reaction is most likely to proceed by an Sn2 type mechanism. 
Although the synthesis of 2-(3-methoxyphenylamino)-5-methyl-4,5-dihydrothiazole 
has given evidence for the mechanism of ring closure, the correct assignment of the 
protons in the unsubstituted dihydrothiazole remains to be finally resolved.
Chapter 4: Synthesis o f deuterated dihydrothiazoles
CHN and CHS 
peak X
CHN
0 . 5 -
1 . 0-
1 . 5 -
2 . 0-
3 . 0 -
Coupling from 8 4.12 
to 8  3.77 '
4 . 0 -
4 . 0 3 . 5 2 . 5  2 . 0 1 . 5 1 . 0 0 . 5
F I  ( p p m )
Figure 4.2: A COSY spectrum of compound 146. The red line indicates the 
coupling observed from 8 4.12 to 5 3.77. The blue line shows the assignment of the 
CHN and CHS peaks.
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Scheme 4.2: Reagents and conditions: i) SOCI2 , MeOH, 4 d; ii) Boc20 , Et3N, 
CH2C12, 16 h; iii) LiBH4, THF, 16 h, Ar; iv) aq. HC1 (6 M), 10 min; v) Acetone, 
reflux 2 h.
Another approach to the aim of this study was to synthesise a dihydrothiazole head 
group with one of the CH2 units in the five-membered ring possessing a deuterium 
instead of hydrogen. Retrosynthesis showed that the simplest route to achieve a 
deuterated dihydrothiazole would be to make deuterated ethanolamine and add this 
onto a model isothiocyanate and cyclise the product in aq. hydrochloric acid 
following the same procedures for making dihydrothiazoles as before (scheme 4.2). 
The initial starting material used was a,a-dideuteroglycine (147) which was 
protected at the carboxyl terminal with a methyl ester. The product was obtained in a 
quantitative yield. The next step in the synthesis was to protect the amine; this was 
done using the most common amine protecting group, Boc. The reducing agent 
lithium borohydride was used to successfully reduce 149, as it is selective for esters 
in the presence of carbamates. The Boc protecting group was removed with aq. 
hydrochloric acid (6M) from the product, yielding deuterated ethanolamine as the 
hydrochloride salt. Compound 151 was then treated with the model 3- 
methoxyphenylisothiocyanate (116) (which was chosen as it was commercially 
available and had no other reactive functionality). This reaction, after repeated 
attempts, proved unsuccessful. !H NMR spectra and mass spectra analysis showed 
no signs that the deuterated ethanolamine had been added onto the isothiocyanate. 
This may have been due to the deuterated ethanolamine hydrochloride salt being too
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acidic to react with the isothiocyanate. Scheme 4.3 shows a similar synthesis but, 
instead of using Boc protecting group, Cbz was used. Cbz groups usually cleave 
easily with catalytic hydrogenation. However, this procedure gave no successful 
unprotected amine. The protecting group was removed with hydrogen bromide to 
give the deuterated ethanolamine hydrobromide. Once again, this was unsuccessful 
as the ]H NMR and IR spectra showed that whatever was happening mechanistically 
in the addition of 151 with 116 was being mimicked in the addition of 155 with 116. 
Clearly, a more basic approach was needed to couple the thiocyanate to the 
ethanolamine.
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Scheme 4.3: Reagents and conditions: i) SOCI2 , MeOH, 4 d; ii) benzyl 
chloroformate, Et3N, CH2C12, 16 h; iii) LiBH4, THF, 16 h, Ar; iv) Pd/C H2 16 h; v) 
HBr in HOAc (17.5%) 15 h; vi) Acetone, reflux 2 h.
Attempts were made in which 148 was added directly onto 116 and then reduced. 
This time, pyridine was used as the solvent instead of acetone and also triethylamine 
was added in two equivalents in order to make the reacting mixture more basic.
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These changes in the reaction conditions made no difference to the success of 
achieving the final product and so another approach was required.
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Scheme 4.4: Reagents and conditions: i) Acetone, reflux 16 h; ii) LiAlD4, THF, 16 h, 
Ar; iii) NaBD4, EtOH, 16 h.
Scheme 4.4 shows the next synthetic route that was attempted. The idea was to use 
glycine ethyl ester (not deuterated) which would be added onto the model 
isothiocyanate and then reduced with a deueterated reducing agent, hopefully 
yielding the deuterated dihydrothiazole. The addition of glycine ethyl ester (158) 
produced not the desired product but gave the aromatic enol. Evidence for the 
cyclised product was confirmed by mass spectra (El + 222 (M + H)). As scheme 4.4 
shows failed attempts were made to reduce the enolate with either sodium boro- 
deuteride or lithium aluminium deuteride. Basic conditions favour the enolate form 
and so these compounds are not electrophilic enough for the reduction of the 
carbonyl to the CH2. Once again another approach was needed.
92
















Scheme 4.5: Reagents and conditions: i) Acetone, reflux 2 h; ii) Dowex 50x8 H+, 
THF, reflux 16 h; iii) NaBD4, acetone, 60°C, 16 h.
Scheme 4.5 shows another approach to achieving the deuterated dihydrothiazole 
using 2,2-diethoxyethylamine (162). The initial step in the synthesis involved the 
addition of 162 to the model isothiocyanate (116). This novel compound was 
achieved in reasonable yield (50%). The aim of the following steps in the synthesis 
was to synthesise the corresponding aldehyde which would then be reduced with a 
deuterated reducing agent such as sodium borodeuteride and finally cyclised to the 
deuterated dihydrothiazole. The most common method for obtaining aldehydes from 
acetals requires hydrolysis in aq. hydrochloric acid followed by a complicated work­
up. This method was deemed unsuitable for the compounds involved in this 
synthesis. Another method for the hydrolysis of acetals is given by Webb and 
Threadgill (1990). This procedure involved a more gentle approach by boiling under 
reflux with Dowex 50x8 H+ resin in wet THF followed by a simple filtration work up 
to remove the Dowex. This method was applied to 159. Compound 159 was boiled 
under reflux with Dowex 50x8 H+ to form the aldehyde and then reduced with 
NaBD4. The reaction conditions were obviously too harsh for this compound as the 
!H NMR spectrum of the crude reaction mixture showed that the compound had 
decomposed.
93
Chapter 4: Synthesis o f deuterated dihydrothiazoles
Conclusions
Initially the synthesis of the methyldihydrothiazole 146 appeared to be a good 
strategy to assign the multiplets of the dihydrothiazole but the *H COSY spectrum 
suggests that the chiral centre introduced into the ring is believed to play a larger role 
than anticipated. The CH2N was no longer seen as either a multiplet or a triplet but 
as two separate singlet signals. Evidence from the !H COSY spectrum of 146 and 
the HETCOR spectra of 75 are not consistent with each other. The COSY 
spectrum provides evidence that the CH2N is further upfield of the CH2S while the 
HETCOR spectrum suggests the opposite. Target deuterated dihydrothiazoles from 
other synthetic routes were not achieved. This means that there is insufficient 
evidence to back up the conclusions from the HETCOR or the !H COSY spectrum. 
However, it is most likely that the assignments of the two CH2 peaks in the 
dihydrothiazole head group are consistent with the HETCOR spectrum, as the methyl 
group and the chiral centre introduced new variables into the project. Therefore, it is 
proposed, on the evidence given above, that the CH2S peak resides further upfield to 
the CH2N peak.
The synthesis of 146 did, however, provide evidence for the mechanism of ring 
closure for the dihydrothiazoles. The cyclisation of open-chain N-(2- 
hydroxyethyl)thioureas is believed to occur by an Sn2 type mechanism.
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Evaluation of Target Compounds as Nitric Oxide Synthase (NOS) 
inhibitors 
Introduction
There are several different methods used to determine NOS activity. Several 
techniques involve the measurement of the oxygenation products of NO. The Greiss 
reaction assays the nitrite ion, a chemical breakdown product of NO. NO interacts 
with naphthylethylenediamine (present in the Greiss reagent) in acid to produce a 
purple azo dye, which is measured at 548 nm on a uv/visible spectrophotometer. 
This method is particularly useful if the measurement of nitrate and nitrite is required 
(Ogden and Moore 1995). Thin-layer chromatography (TLC) exploits the fact that 
[ H]-arginine and citrulline migrate different distances on the TLC plate, within a 
specified buffer system. The products can then be quantified either by radiometric 
scanning of the TLC plate or by scintillation counting (Kumar et al 1999). Other 
methods include chemiluminescence (Ogden and Moore 1995) and high performance 
liquid chromatography (HPLC) (Bredt and Snyder 1989). The major disadvantage 
with the methods described above occur when large sample numbers are involved, 
the assay then becomes time consuming and difficult to manage.
The assay involving the conversion of radiolabelled arginine to citrulline is probably 
the most widely used and has the advantages of being suitable for crude homogenates 
or purified enzyme. The assay can be used on multiple samples and is relatively 
inexpensive. However, the disadvantages are that arginine may be converted to 
citrulline by different enzymes e.g. arginase and so care must be taken when carrying 
out the assay.
The procedure measures the conversion of L-[t/-14C]-arginine to L-[£/-14C]-citrulline 
and NO (Ogden and Moore 1995). A simple ion exchange separation of the substrate 
and product is carried out by batch addition of the Dowex -50W ((200-400), 8% 
cross-linked, Na+ form cation exchange resin (Collins et al 1998). The excess 
cationic L-arginine becomes bound to the resin whereas the labelled L-citrulline 
produced is zwitterionic and therefore does not bind to the resin and can be measured
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by liquid scintillation counting (Salter et al 1991). This method was used in 
evaluating target compounds for NOS inhibition.
NOS can be subdivided into two main groups: constitutive NOS and inducible NOS. 
Constitutive NOS consists of eNOS and nNOS and is Ca /CaM-dependent whereas 
inducible NOS (iNOS) is Ca2+/CaM-independent. The target compounds synthesised 
were evaluated as inhibitors of both iNOS and cNOS. cNOS was obtained from rat 
brain and iNOS was obtained from rat lung, or HT1080 iNOS transfected cell line.
Cell homogenates have been found to be an adequate source of NOS when screening 
compounds for isoform-selective inhibitors. The rat brain is the main source of the 
cNOS isoform whereas rat lung remains the largest source of the iNOS isoform 
(Ogden and Moore 1995). One drawback of using NOS isoforms derived from 
animal species is the fact that they may have different physical and pharmacological 
characteristics to the human NOS enzymes.
Materials and Methods 
Chemicals
Lipopolysaccharide (LPS), calmodulin, NADPH, calcium chloride, DL-dithiothreitol 
(DTT), bovine serum albumin (BSA), Dowex -50W ((200-400), 8% cross-linked, 
Na+ form cation exchange resin, L-arginine, L-citrulline, L-valine and the known 
NOS inhibitor L-NMMA (4) were all obtained from Sigma Chemical Co. (Poole, 




The enzymes were kindly extracted by Dr Edwin Chinje (University of Manchester). 
Enzyme induction in Rat tissues
Male Wistar rats (200 -  300 g), fed ad libitum, and were injected intraperitoneally 
with 4 mg Kg'1 trichloroacetic acid-extracted lipopolysaccharide (LPS). After 6 h, 
the rats were killed and the brain and lungs were removed and used directly or snap
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frozen in liquid nitrogen for subsequent preparations for NO synthase activity 
measurements.
Preparation of NOS Rat Tissue
Either freshly excised or frozen rat brain or lung were homogenised (Ultra-Turax 
T25 homogeniser) in 4 volumes of ice-cold buffer containing HEPES (10 mM, pH 
7.4), sucrose (320 mM), EDTA (0.1 mM), DL-dithiothreitol (0.5 mM), leupeptin (10 
pg ml'1) soybean trypsin inhibitor (10 pg ml’1) and aprotinin (2 pg ml'1), sonicated 
and then centrifuged using the TLA-100.3 Fixed Angle Rotor in Beckman TL-100 
Tabletop Ultracentrifuge at 15000 rpm at 4°C for 30 minutes. The resultant pellet 
was discarded and the post-mitochondrial supernatant (cytosol + microsomes) was 
then treated with previously activated cation exchange resin (Dowex -50W ((200- 
400), 8% cross-linked, Na+ form) to remove endogenous arginine. The supernatant 
was incubated with the resin for 5 minutes and centrifuged to settle the resin. This 
process was repeated twice after which the cytosol was assumed to be free of 
endogenous arginine. Several small aliquots in cryotubes were stored at -70°C until 
required.
Generation of iNOS-transfected clones
An optimised mammalian expression vector (pEFIRES-P, courtesy of Dr. S. Hobbs, 
CRC Centre for Cancer Therapeutics, ICR, London) was designed to express human 
iNOS (hiNOS) cDNA (courtesy of Prof. Ian Charles, University of London). 
Expression was linked with the selectable marker gene (pac) at the level of mRNA 
and antibiotic selection (puromycin) directly enforces expression of the cDNA. It 
was observed that this arrangement was effective at producing stable clones and 
because puromycin exerts selective pressure on the whole expression cassette, 
incremental doses led to generation of clones expressing increasing levels of enzyme 
activity. This vector has been used to transfect the human fibrosarcoma cell line, 
HT1080 and a series of iNOS-expressing clones were produced. To avoid loss of 
viability through the cytotoxic consequences of excessive NO production, clones 
were grown in the presence of a non-toxic dose of the NOS inhibitor, L-NNA (100 
pM). Routinely, clones were grown for 48 hours in the absence of puromycin and the 
NOS inhibitor prior to extracting the iNOS enzyme.
97
Chapter 5: Evaluation o f target compounds
Cells were grown to near confluence in T-175 cm flasks and harvested by 
trypsinisation. Cells were then washed twice in cold phosphate buffered saline 
(PBS) and homogenised in five volumes of ice-cold buffer containing HEPES (10 
mM, pH 7.4), sucrose (320 mM), EDTA (100 pM), dithiothreitol (50 pM), leupeptin 
(10 pg mL'1), soybean trypsin inhibitor (10 pg mL'1) and aprotinin (2 pg mL"1). The 
preparations were then sonicated using an MSE Soniprep 150 for 3 x 5s at a nominal 
frequency of 23 KHz and an oscillation amplitude between 5 and 10 pm. Samples 
were placed in ice between each sonication. These suspensions were allowed to stand 
in ice for a further 10 min, and then centrifuged at 9000 x g  for 15 min at 4°C. The 
resultant pellet was discarded and the post-mitochondrial supernatant (cytosol and 
microsomes) was treated with a strong cation exchange resin (Dowex -50W ((200- 
400), 8% cross-linked, Na+ form) to remove endogenous arginine. The supernatant 
was incubated with the resin for 5 min and centrifuged at 10000 rpm for 5 min in 
order to pellet the resin. This process was repeated twice, after which the cytosol was 
treated as free of endogenous arginine.
NOS Assay
The NOS enzyme was prepared from rat brain and lung tissue using the protocol as 
described by Knowles et al 1990.
Protocol
50 pi of either cNOS/iNOS crude tissue extract (diluted 1:3 with HEPES buffer) was 
added to 10 ml plastic tubes containing 100 pi containing 20 mM HEPES buffer pH 
7.4, L-valine (50 mM), NADPH (125 pM), L-citrulline (100 pM), L-arginine (10 
pM) and L-[f/-14C]-arginine (50 pCiml"1), 10 pM tetrahydropterin, calmodulin (400 
U m '1), DTT (375 mM), BSA (75 mg ml"1) and CaCb (0.25 mM). Samples were 
incubated at 37°C. The reaction was terminated by the addition of 1.5 ml 1:1 (v/v) 
H20/Dowex -50W ((200-400), 8% cross-linked, Na+ form); exchange was allowed to 
take place while samples were incubated for 20 min at rt. H2O (1.675 ml) was added 
and the resin was allowed to settle before 2 ml of supernatant was removed, to which 
4 ml of scintillation liquid was added and examined for the presence of L-[£/-14C]- 
citrulline by liquid scintillation counting (Beckman, LS380).
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The activity of the Ca2+-dependent NOS was determined from the difference between 
the L-[U-14C]citrulline generated from the control samples and samples containing 1 
mM ethylenebis(oxyethylenenitrilo)tetraacetic acid (EGTA). The background 
activity was obtained by adding EGTA (1 mM) and NOS inhibitor 4 (1 mM). The 
Ca -independent activity of the enzyme was determined by subtracting the 
background activity from the activity of samples containing 1 mM EGTA.
Pre-incubation
The known iNOS inhibitor 1400W (10) has been shown to be a slow tight binding 
inhibitor giving an optimum potency after a 10 min pre-incubation time (Garvey et al 
1997). Most of the targets synthesised are analogues of 10 and, therefore, pre­
incubation time may play an important role in the evaluation of the potency of the 
inhibitor. Compounds were initially screened at 100 pM, both with a 10 min pre­
incubation and without.
cNOS/iNOS preparation (40 pi) was added to 10 ml tubes containing the buffer 
mixture as above but without the arginine. The samples were pre-incubated at 37°C 
for pre-incubation time stated. Arginine mixture (10 pi) containing L-[t/-14C]- 
arginine (1 pl/tube) and arginine stock 10 mM was added. The samples were then 
incubated for 10 min and the procedure was conducted as before.
IC50 determinations
All target compounds were initially screened for their NOS inhibition at 100 pM 
concentration. The compounds which showed good inhibition (>70%) were assayed 
further to determine their IC50 values.
Each data point is expressed as a mean ± sd mean of duplicate determinations per 
experiment, unless otherwise stated.
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3-CH2NH2 35 34 ±0.6 44 ± 2 39 ± 5 47 ±0.1
4 -CH2NH2 40 29 ± 5 32 ± 4 11 ± 6 20 ± 2
3 -NH2 64 -58 ±1 9 ±0.5 -1 ± 6 9 ± 6
4 -NH2 71 -55 ±11 12 ±0.7 -0.3 ± 1 12 ± 2
3-OMe 110 35 ± 2 7 ± 3 -3 ± 1 6 ± 4
4-OMe 114 34 ± 13 2 ± 5 8 ± 1 14 ±0.2
3 -CO2H 96 -46 ± 5 7 ± 2 14 ±0.6 -0.4 ± 2
4 -CO2H 104 -56 ±12 3 ±0.5 -0.4 ±0.4 6 ±0.4
Table 5.1: % Inhibition results for thioureas against rat brain cNOS and hiNOS 
screened at 100 pM. Values are expressed as mean ± SEM (n=2). T=0 refers to 
no pre-incubation of the compound with the enzyme. T=10 refers to a ten- 
minute pre-incubation time of the compound with the enzyme.
Table 5.1 shows that pre-incubation time plays an important role in determining the 
optimum potency of the inhibitor. The most significant changes in NOS inhibition 
are seen in compounds 64, 71, 96 and 104; these compounds showed high 
stimulatory values for iNOS at time zero. After a ten-minute pre-incubation with the 
enzyme these compounds changed from exhibiting stimulatory properties to being 
weak inhibitors. These compounds may be acting at a site, which is distant from the 
L-arginine binding site of the NOS enzymes and may be somehow increasing the 
catalytic activity of the enzyme.
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Although 64, 71, 110 and 104 show stimulation with cNOS at time zero the 
percentage stimulation values are very low, indicating that they are more likely to be 
very weak inhibitors of cNOS rather than stimulators.
The two methoxy targets 110 and 114 showed a decrease in percentage inhibition 
with time for iNOS. Neither of these compounds showed any significant potency for 
either isoform.
A surprising result in this series of targets was that 35 and 40 were not as good 
inhibitors of iNOS and cNOS as previously predicted. Compound 40 was marginally 
better at inhibiting iNOS than 35 which is consistent with the results from Shearer et 
al (1997) that the para position around the aromatic ring gives rise to the most 
selective iNOS inhibitors. Compound 40 showed no significant increase in potency 
with time indicating that they are probably not slow-onset binding inhibitors.
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Table 5.2: % Inhibition results for thioureas against rat brain cNOS and hiNOS 
at 100 pM. Values are expressed as mean ± SEM (n=2). T=0 refers to no pre­
incubation time the compound with the enzyme. T=10 refers to a ten-minute pre­
incubation time of the compound with the enzyme.
The removal of the methylene unit from between the aromatic ring and thiourea head 
group increased the potency of inhibitors, compared to those in table 5.1. The para- 
substituted CH2NH2 functionality (56) showed no time-dependence as seen in 40. 
However, the meta-substituted CH2NH2 functionality (48) showed time-dependence 
towards the cNOS isoform but not the iNOS isoform. This was also seen in the 
homologous compound 35. Compound 48 was clearly the most potent inhibitor in 
this group of thioureas also displaying a degree of selectivity for the cNOS isoform.
As seen in the previous class of thiourea targets, the methoxy compounds showed no 
significant inhibition of either isoform.
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A high stimulation percentage was seen for iNOS for compound 80 at time zero. 
The CH2CO2H group appears to give rise to stimulatory compounds rather than NOS 
inhibitors, particularly when the aromatic ring was substituted in the meta position.
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3-CH2NH2 31 48 ±0.1 26 ± 3 55 ± 6 59 ±0.6
4 -CH2NH2 42 -30 ± 2 51 ± 2 33 ± 3 65 ± 2
3 -NH2 68 -36 ± 0.5 12 ± 2 5 ± 2 17 ± 5
4 -NH2 75 -47 ± 10 19 ± 2 8 ± 2 12 ±1
3-OMe 112 34 ± 4 8 ± 4 8 ± 1 14 ±0.2
4-OMe 21 26 ± 6 3 ±13 10 ± 2 13 ±0.1
3 -CO2H 99 -39 ± 1 34 ± 3 5 ± 3 13 ± 3
4 -CO2H 107 -45 ±0.1 5 ±0.4 0.4 ± 4 -11 ±0.1
Table 5.3: % Inhibition results for dihydrothiazoles against rat brain cNOS and
hiNOS at 100 pM. Values are expressed as mean ± SEM (n=2). T=0 refers to no
pre-incubation of the compound with the enzyme. T=10 refers to a ten-minute
pre-incubation time of the compound with the enzyme.
Compound 42 was the most potent inhibitor in this group of compounds showing 
reasonable potency but no selectivity for either isoform. The dihydrothiazole head 
group with the extra methylene unit is clearly more potent for both isoforms than the 
corresponding thiourea, as displayed by 42 and 40, respectively.
Dihydrothiazoles substituted with the amine and carboxylate functionality in both the 
meta and para positions gave rise to stimulatory compounds at time zero with iNOS. 
The same functional groups gave stimulatory values for the corresponding thioureas 
(table 5.1).
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Targets 112 and 21 showed a decrease in potency with time for the iNOS isoform 
and an increase in potency with time for the cNOS isoform. These results were also 
seen in the corresponding methoxyaryl thiourea targets 110 and 114 (table 5.1).
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Table 5.4: % Inhibition results for dihydrothiazoles against rat brain cNOS and 
hiNOS at 100 pM. Values are expressed as mean ± SEM (n=2). T=0 refers to no 
pre-incubation of the compound with the enzyme. T=10 refers to a ten-minute 
pre-incubation time of the compound with the enzyme.
Comparison of 31 and 50 show that the removal of the methylene unit from the 
dihydrothiazole target dramatically increases the potency of the inhibitor, especially 
for iNOS inhibition at the pre-incubation time of ten minutes (Compound 31 26%, 50 
86%). Although the potency of the inhibitor was increased, no isoform selectivity 
was seen in 50 or 58 (the second most potent target in this series).
Stimulatory values are seen once again with the carboxyl functionality, with the 
highest stimulatory values seen when the target is substituted in the para position, 
with the iNOS isoform at a pre-incubation time of zero.
As seen in previous tables, the methoxy substituted targets showed no potency or 
selectivity for either isoform.
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A 128 Me 77 ± 5  67 ±0.1 14 ±0.4  90 ± 2
A 129 H 98 ± 0.3 98 ± 1 98 ± 2 99 ± 3
B 131 H 64 ±0.1 37 ± 2 34 ± 2  12 ± 2
Table 5.5: % Inhibition results for lysine derivatives against rat brain cNOS and 
hiNOS at 100 pM. Values are expressed as mean ± SEM (n=2). T=0 refers to no 
pre-incubation of the compound with the enzyme. T=10 refers to a ten-minute pre­
incubation time of the compound with the enzyme.
The lysine derivatives showed a high potency for both iso forms. Compound 129 was 
the most potent but showed no time-dependent kinetics, whereas 128 showed a large 
increase in potency with time with the cNOS isoform.
Compound 131 was most selective for iNOS but, unlike most of the other targets 
tested this compound showed a reduction in potency with time with both cNOS and 
iNOS indicating that perhaps this compound is not a slow binding inhibitor.
Target 130 showed a decline in percentage inhibition when compared with the 
corresponding ornithine target 17. Adding the extra CH2 unit has a dramatic effect 
on potency of the inhibitor. Compound 17 gave IC5 0  values of 8.1 and 1.3 pM for 
iNOS and cNOS respectively (Ulhaq et al 1999), whereas 130 gave percentage 
inhibition values no greater than 64% at 100 pM for either isoform. It would appear 
that the shorter amino acid chain length gives rise to more potent inhibitors;
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however, 128 and 129 show that this is not necessarily the case. These two targets 
gave high percentage inhibition values indicating that the head group plays a vital 
role in binding to the active site and determining the potency of the inhibitor.
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A 111 3-OMe -58 ± 7 8 ±0.3 -1 ± 4 5 ± 1
A 115 4-OMe -25 ± 1 44 ± 5 -1 ± 1 5 ± 1
B 118 3-OMe -10± 1 -1 ± 1 0.03 ±  0.6 1 ± 0.8
B 122 4-OMe 6 ± 3 6 ± 2 2 ± 1 2 ± 3
Table 5.6: % Inhibition results for 2-hydroxyethyl thioureas against rat brain 
cNOS and hiNOS at 100 pM. Values are expressed as mean ± SEM (n=2). T=0 
refers to no pre-incubation of the compound with the enzyme. T=10 refers to a 
ten-minute pre-incubation time of the compound with the enzyme.
The methoxyisothiourea targets 110, 117, 114, 121 showed very little potency for 
either iNOS or cNOS with 110,117 and 121 showing negative values, indicating that 
the activity was being stimulated rather than inhibited. Targets 111, 115, 118, 122 
were synthesised to explore the SAR within the thiourea targets. The effects of chain 
length on the thiourea head group could then be discussed and determined whether 
this structural difference caused an inhibitory or stimulatory effect.
Targets which had the extra methylene unit between the head group and the aromatic 
ring (111 and 115) showed higher stimulatory values than those which had the head 
group directly attached to the ring (118 and 122), with the greatest stimulatory value 
seen in target 111.
Introducing the 2-hydroxyethyl motif to the methoxy targets switches the values 
from inhibitory to stimulatory. This is illustrated by comparing targets 110 and 114 
(table 5.1) with targets 111 and 115. The meta-substituted targets switch from 35%
109
Chapter 5: Evaluation o f target compounds
(110) inhibition, to 58% (111) stimulation, while the para-substituted targets switch 
from 34% (114) inhibition to 25% (115) stimulation. The same comparison can be 
made between the targets with the thiourea directly attached to the ring: 117 and 121 
(table 5.2) with 118 and 122.
The stimulatory effects are only seen in targets when screened against the iNOS 
isoform and not cNOS. The large stimulatory effects seen in this group of targets 
indicates that there are perhaps two separate binding sites; one for stimulation and 
another for inhibition. Had time permitted, it would have been interesting to test 
both the carboxyl and amine targets with the 2-hydroxyethyl motif.
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Compound iNOS (rat) hiNOS
Number T=0 T=0
35 23 ± 2 34 ±0.6
48 98 ± 0.5 35 ± 4
21 5 ± 3 26 ± 6
31 34 ± 0.4 48 ±0.1
50 34 ± 0.6 62 ± 2
131 21 ±0.3 64 ±0.1
Table 5.7: % Inhibition results for against rat lung iNOS and hiNOS at 100 pM. 
Values are expressed as mean ±  SEM (n=2). T=0 refers to no pre-incubation of the 
compound with the enzyme.
Initial studies of some target compounds were carried out using rat iNOS and rat 
cNOS with no pre-incubation. These results are given in table 5.7.
The majority of studies on NOS inhibition have been carried out in rodent iNOS. 
Table 5.7 shows a comparison between human and rat sources of iNOS. Most of the 
six target compounds showed an increase in percentage inhibition with the human 
source of iNOS, only compound 48 showed a decrease in percentage inhibition with 
the human source.
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Table 5.8: Comparison of IC5 0  values of compounds 48 and 50 against rat lung 
iNOS and rat brain cNOS. Values are expressed as mean ± SEM (n=3). IC5 0  
values taken without a pre-incubation time.
Compound 48 showed a nine-fold selectivity for the cNOS isoform over the rat iNOS 
isoform, while 50 only showed a two-fold selectivity. Table 5.11 shows that the 
selectivity displayed by these targets decreases when the human isoforms are used. 
Compound 48 shows only a five-fold selectivity, while 50 shows no selectivity for 
either human NOS isoform. Although 50 gives a more potent I C 5 0  with the human 
source the selectivity is lost, whereas 48 displays more potent I C 5 0  with the rat 
iso form (table 5.11).
This shows that each potential NOS inhibitor should be studied individually as their 
kinetics may be very different from each other.
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Time Study
The preliminary studies showed that five compounds gave high percentage inhibition 
values at 100 pM. These compounds (48, 50, 56, 128 and 129) were analysed 
further for IC50 results. Pre-incubating the target with the enzyme affects the potency 
of the inhibitor. To ensure the targets were assayed at their optimum pre-incubation 
time, time study curves were carried out in which the enzyme was pre-incubated with 
target at various time intervals. The five targets mentioned above were assayed with 
known inhibitors and against both cNOS and hiNOS isoforms.
As graphs 5.1 and 5.2 show pre-incubation time plays a large role in the potency of 
the inhibitor. The absence of pre-incubation time can lead to an under estimation of 
the potency of a slow-onset binding inhibitor. Exposure in vivo or in the clinical 
environment may be >30 min (Alderton et al 2001), so it is important to study time 
dependence in order to predict potency and selectivity of the inhibitor.
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Graph 5.1: % Inhibition results for compounds 48, 50, 56, 128, 129 and known 
inhibitors 4 and 12 against rat brain cNOS at 100 |liM, with varying times of pre- 
incubation (minutes) of the compound with the enzyme. Values are expressed as 
mean ± SEM (n=2).
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Graph 5.2: % Inhibition results for compounds 48, 50, 56, 128, 129 and known 
inhibitor 12 against hiNOS at 100 pM, with varying times of pre-incubation 
(minutes) of the compound with the enzyme. Values are expressed as mean ± SEM
(n=2).
Results and Conclusions
The optimum pre-incubation time chosen to assay targets with the hiNOS enzyme 
was fifteen minutes. Compounds 50 and 128 showed large increases in percentage 
inhibition after five minutes, while 48 showed a decline in percentage inhibition after 
five minutes. Compound 129 showed percentage inhibition values around 98% for 
all time points and, with hindsight, should have been assayed again at a lower
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concentration to see if time-dependence was evident. Compound 56 showed a 
decline in percentage inhibition after ten minutes; this result was repeated several 
times to eliminate any human or assay errors.
The optimum pre-incubation time chosen to assay targets with the cNOS isoform 
was fifteen minutes. Compound 128 showed similar high percentage inhibition 
results with cNOS and was seen with iNOS. As mentioned before, this compound 
should ideally have been assayed again at a lower concentration to see if time- 
dependence was evident.
Clearly time plays an important role in determining the optimum potency of the 
inhibitor and also gives an insight into whether the inhibitors display time-dependent 
kinetics. Ideally, each target should be assayed individually at their corresponding 
optimum time point; however, this may lead to difficulties in comparing the results 
for different analogues appropriately.
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A rginine C oncentration Study
The concentration of arginine used in published NOS assays varies immensely from 
0.2-10 pM (Garvey et al 1994), 10 pM (Ulhaq et al 1998), 30 pM (Rees et al 1990) 
and 50 pM (Sorrenti et al 2001). Therefore, to determine whether arginine 
concentration plays a significant role in the potency of the inhibitor and whether 10 
pM arginine gives the optimum percentage inhibition, a study was undertaken using 
the five most potent inhibitors as before and two known inhibitors.
Arginine concentration (% inhibition)
Compound
Number Type R 10 pM 5 pM 3 pM
48 A 3-CH2NH2 68 ± 1 71 ± 1 73 ± 2
56 A 4 -CH2NH2 61 ±0.2 62 ± 0.8 66 ± 3
50 B 3 -CH2 NH2 89 ±0.6 93 ± 3 91 ±0.6
128 C Me 86 ±0.1 91 ± 2 89 ± 2
129 C H 98 ±.04 98 ±0.5 98 ± 0.4
4 _ - 98 ± 0.2 98 ±0.1 97 ± 1
Table 5.9: % Inhibition results for compounds 48, 50, 56, 128, 129 and known 
inhibitor 4 against rat brain cNOS at 100 pM, at pre-incubation of fifteen minutes 
with varying arginine concentrations. Values are expressed as mean ± SEM (n=2).
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Arginine concentration (% inhibition)
Compound
umber Type R 10 pM 5 pM 3 pM
48 A 3-CH2NH2 40 ± 5 41 ± 4 61 ± 9
56 A 4 -CH2NH2 53 ± 4 51 ±1 50 ± 2
50 B 3 -CH2NH2 85 ± 3 77 ± 7 74 ± 7
128 C Me 73 ± 2 93 ±0.1 97 ± 3
129 C H 98 ± 1 98 ± 3 98 ±0.1
10 _ - 98 ± 1 _ 94 ± 0.5
Table 5.10: % Inhibition results for compounds 48, 50, 56, 128, 129 and known 
inhibitor 10 against hiNOS at 100 pM, at pre-incubation time of fifteen minutes with 
varying arginine concentrations. Values are expressed as mean ± SEM (n=2).
R esults and Conclusions
Table 5.9 shows that compounds 48, 50, 56 and 128 display no significant difference 
in percentage inhibition with different arginine concentrations. Compound 129 
shows percentage inhibition values >97% for all three arginine concentrations and 
was probably not assayed at the optimum concentration for that particular compound 
in this type of study. This is illustrated again in table 5.10 with 128 and 129. 
Compound 50 is the only one that shows any significant increase in percentage 
inhibition with decreasing arginine concentrations. It would seem that each 
compound should be assayed at their own optimum concentration to achieve the best 
results. However, this would lead to incompatibility within the data and each target 
would not be able to be compared with any of the others.
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The five most potent compounds were assayed for dose response curves using 10 pM 
arginine concentration and a fifteen minute pre-incubation time with both isoforms.
The fact that several of these compounds are unaffected by the changes in arginine 
concentration would suggest that they may be (at least partly) non-competitive 
inhibitors. It is obvious that more kinetic studies of these target compounds are 
needed to fully determine the nature and mechanisms of binding.
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Graph 5.3: Dose response curve for inhibition of hiNOS by compounds 50,128 and 
129. Values are expressed as mean ± SEM (n=3). Assay was carried out with a 
fifteen minute pre-incubation time of the compound with the enzyme.
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Graph 5.4: Dose response curve for inhibition of hiNOS by compounds 48 and 56. 
Values are expressed as mean ± SEM (n=3). Assay was carried out with a fifteen 
minute pre-incubation of the compound with the enzyme.
121






Graph 5.5: Dose response curve for inhibition of hiNOS by known inhibitors 4, 8, 
10 and 12. Values are expressed as mean ± SEM (n=3). Assay was carried out with 
a fifteen minute pre-incubation of the compound with the enzyme.
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Graph 5.6: Dose response curve for inhibition of rat brain cNOS by compounds 48, 
50, 56,128 and 129. Values are expressed as mean ± SEM (n=3). Assay was carried 
out with a fifteen minute pre-incubation of the compound with the enzyme.
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Graph 5.7: Dose response curve for inhibition of rat brain cNOS by known 
inhibitors 4, 8, 10 and 12. Values are expressed as mean ± SEM (n=3). Assay was 
carried out with a fifteen minute pre-incubation of the compound with the enzyme.
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Compound IC50IfMM)
Number hiNOS cNOS Selectivity
(cNOS/hiNOSl
50 19 ± 2 13 ± 2
48 260 ± 2 54 ± 1 5 (cNOS)
56 89 ± 2 41 ±2 2 (cNOS)
128 13 ±1 3 ±0.5 4 (cNOS)
129 18 ±0.6 8 ±0.4 2 (cNOS)
4 < 4 ± 0.5 9 ±0.5
12 24 ± 2 40 ±0.8
8 < 5 ± 0.5 17 ± 2
10 < 4 ± 0.5 12 ±1
Table 5.11: Comparison of IC50 values of compounds 48, 50, 56, 128, 129 and
known inhibitors; 4,12, 8 and 10 against hiNOS and rat brain cNOS. Values are
expressed as mean ± SEM (n=3). Assay was carried out with a fifteen minute
pre-incubation of the compound with the enzyme.
IC50 values for the known inhibitors 4, 10 and 8 can only be given as < 4, 5 and 4 
respectively as insufficient points on the dose response curve for hiNOS were 
determined close to the IC50.
The two lysine derivatives were the most potent NOS inhibitors. Both compounds 
showed better IC50 results than the known inhibitors 4 and 8 for cNOS. Ideally lead 
compounds should display at least 100-fold isoform selectivity and possess 
submicromolar IC50 values. As table 5.11 shows, none of the target compounds 
display selectivity within that range. However, selectivity values given do enable 
ideas to be considered about how inhibitor structure relates to selectivity and 
potency. The addition of the methyl ester into the lysine derivative increases the 
potency and selectivity of the inhibitor for this series. Compound 128 showed a 
four-fold selectivity for cNOS over iNOS compared to a two-fold selectivity
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displayed by 129. The methyl ester thiourea (128) was more potent than the target 
without the ester functionality (129). These results are the reverse of what is seen 
with compound 7 and its methyl ester 3. Compound 128 shows an increase in 
potency for both isoforms when compared to 129. The methyl ester seems to be an 
important feature in the design of potent amino acid analogue NOS inhibitors.
The dihydrothiazole target 50 was the most potent of the aromatic targets but showed 
no isoform selectivity (iNOS 19 pM, cNOS 13 pM). This target is a better non- 
selective NOS inhibitor than the known inhibitor 7NI. Target 17 (IC50 8.1 and 1.3 
pM for iNOS and cNOS respectively (Ulhaq et al 1999)) was a lead compound from 
which target compounds with the dihydrothiazole head group were based. 
Unfortunately, taking the dihydrothiazole head group and incorporating features of 
10 (such as the benzene ring) have not increased the potency and selectivity of the 
inhibitor.
The benzyl and phenyl thiourea head derivatives gave rise to the most potent NOS 
inhibitors when compared with the corresponding dihydrothiazoles. Targets 48 and 
56 in which the thiourea head group was attached to the benzene ring showed a 
decline in potency when compared to the lysine thiourea derivatives. Both targets 48 
and 56 with the thiourea head group displayed selectivity towards cNOS with the 
CH2NH2 group in the meta position giving rise to the most selective (five-fold 
compared to two-fold displayed by 56).
The CH2NH2 group gives rise to potent and selective inhibitors. The position and 
type of the functional group is very important in the design of potent and selective 
inhibitors. It appears that the dihydrothiazole head group gives rise more potent but 
non-selective inhibitors while the thiourea head group gives rise to more selective 
inhibitors. The bridge length between the head group and the remote amine does 
seem to be important in the design of potent NOS inhibitors. Those targets with 
seven-atom bridges (128 and 129) have given rise to the most potent inhibitors, 
whereas 50, 48 and 56 are less potent but display a higher degree of selectivity for 
cNOS. These findings are consistent with those for 15 which possesses a six-atom 
bridge and is selective for the nNOS isoform. Unfortunately, the corresponding 
thiourea with the seven-atom bridge (35) showed no potency or selectivity for iNOS
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as predicted. This indicates that the acetamidine head group in 10 plays an important 
role in the selectivity of the inhibitor.
The targets synthesised and tested have given rise to non-selective NOS inhibitors 
with some compounds (48, 56, 128) showing a degree of selectivity for the cNOS 
isoform. As mentioned in chapter one, the side-effects of cNOS inhibitors outweigh 
their benefits and so this class of inhibitor has very little use in therapeutics. 
However, such inhibitors are useful in gaining knowledge of structure-activity 
relationships and information about binding which enables the design of more 
selective inhibitors.
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Overall structure activity relationships
All three NOS isoforms function as homodimers which comprise two oxygenase 
domains, linked through interactions between haem domains, and one reductase 
domain (Siddhanta et al 1996). The zinc tetrathiolate centre at the dimer interface 
helps to stabilise the dimer and form the tetrahydrobiopterin-binding site.
The aromatic targets were based on the known iNOS selective inhibitor 10. This 
compound is known to bind to the haem active site through hydrogen-bond 
interactions with the amidine head group and amino acids Glu363 and Trp358. The 
benzene ring is positioned above the two propanoate groups of the haem. This is 
illustrated in figure 5.1.
Figure 5.1: Proposed binding of the NOS inhibitors 10 and 8, illustrating the co­
ordination of the amidine and thiourea head groups respectively to the haem.
Developing SAR pictures are particularly beneficial in understanding how target 
inhibitors may interact with the active site. Also information can be gained about 
which functional groups give rise to the strongest interactions with the enzyme.
Crystal structures of several different sources of iNOS and eNOS isoforms are 
available on database and so this information was used to obtain pictures of target 
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Due to their similarity in structure, compounds 48 and 56 are believed to inhibit NOS 
by binding to the L-arginine binding site in a similar conformation to 10. Figures 5.2 
and 5.3 clearly show the sulphur (yellow atom) of the thiourea head group on 
inhibitors 48 and 56 in close proximity to the haem domain. Target compounds 48 
and 56 lack the extra methylene unit between the aromatic ring and the head group 
functionality when compared with 10. As a consequence this could place the 
benzene ring closer to the two propanoate groups of the haem and may be one 
explanation why 48 and 56 give rise to lower IC50 values for cNOS than 10 (ref table 
1.5and 5.11).
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Figure 5.3: Proposed binding o f  compound 56 to the haem domain o f  eNOS iso form.
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Thiocitrulline binds to the haem domain by interacting with Glu371. The inhibitor is 
held in place by hydrogen bonds formed between the carboxyl oxygen atom of 
Glu371 and the sulphur atom in the thiourea group of 8 (Ware and King 2000) 
(figure 5.1). The sulphur atom is positioned above the haem iron. The lysine targets 
128 and 129 are structurally similar to thiocitrulline and so are thought to bind in a 
like manner. Figures 5.4 and 5.5 show how targets 128 and 129 may interact with 
the haem domain.
Figure 5.4 and 5.5 show that the amino acid moiety in the lysine targets are much 
closer to the propanoate groups in the haem active site than targets 48and 56 which 
may explain why they are more potent inhibitors. Clearly the head group 
functionality plays an important role in the potency of the inhibitor by forming 
interactions with the haem domain. Sulphur is a soft nucleophile and a good ligand 
for Fe, this may be one explanation why the thiourea targets have given rise to the 
most potent inhibitors in this series of compounds tested.
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Figure 5.4: Proposed binding o f  compound 128 to the haem  domain o f  eNOS iso form.
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Figure 5.5: Proposed binding o f  compound 129 to the haem domain o f  eNOS isoform.
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Conclusions
Target compounds 111, 89, 68, 75, 99, 107, 80, 96 and 104 showed the greatest 
stimulatory values. When the 2-hydroxyethyl motif was introduced into the 
methoxyarylthiourea targets an increase in the stimulatory values was seen with the 
iNOS isoform at a pre-incubation time of zero. It appears that this class of 
compounds can bind at more than one site under different conditions, one site being a 
stimulatory site (possibly a remote allosteric site) and the other an inhibitory site. 
Binding to the allosteric site would be stimulatory and fast (which gives rise to 
stimulation of NO synthesis without pre-incubation), whereas binding to substrate- 
binding site is slow and inhibitory. The 2-hydroxyethyl intermediates of the 
aromatic targets possessing the amine and carboxylate functionality would be a good 
series of compounds to test for NO stimulation. These compounds may have 
therapeutic use in the development of NO donors, however, the fact that they switch 
to weak inhibitors with time reduces their clinical potential.
The dihydrothiazole head group gave rise to the most potent NOS inhibitors. 
Compound 50 was more potent than the known NOS inhibitor 12 but showed no 
isoform selectivity (19 and 13 pM for iNOS and cNOS, respectively). Aromatic 
targets with the thiourea head group attached showed the most selectivity for the 
cNOS isoform. Compound 48 showed five-fold selectivity for the cNOS isoform 
and gave an IC50 value of 54 pM. The most potent and selective aromatic targets 
possessed the CH2NH2 functionality, with the most selective being substituted in the 
meta position. This functionality provides an optimum size for binding to the NOS 
active site.
The two lysine derivatives 128 and 129 were the most potent of all the targets tested 
with 128 displaying a four-fold selectivity for cNOS. Both targets were more potent 
than 8 and 5 (ref. table 1.2) when tested against the cNOS isoform and as good as 7 
when comparing the iNOS isoform (ref. table 1.2). The introduction of the methyl 
ester to the lysine thiourea target increased the potency of the inhibitor whereas, 3 
showed a reduction in potency when compared with 7.
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The therapeutic use of cNOS isoform-selective inhibitors is limited due to the 
systemic side-effects that could occur. However, such inhibitors are useful in 
determining SAR.
As seen with all the targets tested, time plays an important role in determining the 
optimum potency of the inhibitor and also gives an insight into whether the inhibitors 
display time-dependent kinetics. To develop this project further, it would be useful 
to determine the nature of inhibition of the most potent and selective inhibitors and 
ascertain whether they are for example irreversible or reversible with arginine and 





!H NMR data were recorded on either JEOL GX 270 or EX 400 spectrometers. 
Tetramethylsilane was used as an internal standard for ]H NMR samples dissolved in 
CDCI3 and (CD3 )2 SO. Multiplicities are indicated by s (singlet), d (doublet), t 
(triplet), q (quartet) and m (multiplet). IR was recorded on a Perkin-Elmer RXI FT- 
IR spectrometer either a liquid (film), Nujol mull (Nujol) or KBr disc (disc).
FAB Mass Spectra [matrix :-nitrobenzyl alcohol (mNBA)] were recorded at the 
University of Bath Mass Spectrometry service using a VG Analytical Mass 
Spectrometer. Microanalysis was carried out at the University of Bath microanalysis 
service. Thin layer chromatography (TLC) was performed on precoated plates 
(Merck TLC aluminium silica sheets 60 F 2 5 4 ,  Art no. 5554). Visualisation was 
carried out by dipping in ninhydrin (followed by heating) or by u.v. light were 
appropriate. Solutions in organic solvents were dried with MgSCL filtered evaporated 
under reduced pressure. Experiments were conducted at ambient temperature, unless 
otherwise stated. The aqueous NaHCC>3 and the brine were saturated. The stationary 
phase for the column chromatography was silica gel 33-70 pm.
Melting points were determined using a Reichert-Jung Thermo Galen Kofler block. 
Chemicals were purchased from the Aldrich Chemical companies unless otherwise 
stated.
2-(4-Methoxyphenylmethylamino)-4,5-dihydrothiazole 21
4-Methoxybenzylamine 19 (330 mg, 2.4 mmol) was heated with 2-methylthio-4,5- 
dihydrothiazole 20 (320 mg, 2.4 mmol) at 180°C for 4 h. Evaporation and 
chromatography (CH2 Cl2/MeOH 10:1) gave 21 (163 mg, 30%) as white crystals: mp 
77-79°C (lit. [Hirashima et al1992] mp 84-86°C); ‘H NMR (CDCh) 8  3.38 (2 H, t,
= 1A  Hz, thiazole 5-H2), 3.80 (3 H, s, CH3 ), 4.04 (2 H, t, J  = 1A  Hz, thiazole 4-H2),
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4.40 (2 H, s, CH2 Ar), 6.87 (2 H, d, 7 =  8 . 8  Hz, Ar 3,5-H2), 7.25 (2 H, d, 7 =  8 . 8  Hz, 
Ar 2,6-H2); IR vrax (disc) 1610 (C=N), 2780 (OCH3), 3207 (NH) c m 1; MS (FAB 
+ve ion) m/z2 3.0912 (M + H) (Cn Hi5N2OS requires 223.0905); Found C, 58.25:
H, 6.44; N, 12.35: Cn Hl4 N2 OS. 0.25H2O requires C, 58.29; H, 6.40; N, 12.36%.
I ,1 -Dimethylethyl jV-(3-(aminomethyl)phenyImethyl)carbamate 23
Di-terf-butyl dicarbonate (1.0 g, 4.9 mmol) was added slowly to l,3-bis(amino- 
methyl)benzene 2 2  (2 . 0  g, 15 mmol) and Et3N (2.9 g, 29 mmol) in CH2 CI2 (15 ml) at 
0°C and the mixture was stirred for 16 h. The solvent was evaporated. The residue, 
in CH2 CI2 , was washed with aq. NaHC0 3  and dried. Evaporation gave 23 (900 mg, 
78%) as white crystals: mp 61-64°C (lit. [Callahan et al 1989] oil); Rf 0.3 (CH2 CI2  
/MeOH 3:1); 'H NMR (CDC13) S 1.51 (9 H, s, Bu'), 1.67 (2 H, s, NH2), 3.90 (2 H, d, 
7 =  4.3 Hz, C //2 NHBoc), 4.34 (2 H, s, Ctf2 NH2), 5.10 (1 H, br, NH), 7.23-7.34 (4 H, 
m, Ar-H4); MS (FAB +ve ion) m/z237 (M + H), 181 (M -  Me2 C=CH2), 164 (M -  
Bu'O).
1,1-Dimethylethyl N-(3-(isothiocyanatomethyl)phenylmethyI)carbamate 27
Compound 23 (900 mg, 3.9 mmol), CaCC>3 (400 mg, 4.0 mmol), water (3 ml), 
thiophosgene (900 mg, 7.8 mmol) and CHCI3 (25 ml) were stirred vigorously for 16 
h. The mixture was extracted with CHCI3 and dried. Evaporation and 
chromatography (EtOAc/hexane 1:3) gave 27 (400 mg, 37%) as an oil (lit. [Smith et 
al 1996] mp 43°C); Rf 0.2 (EtOAc/hexane 1:3); ‘H NMR (CDC13) 8  1.46 (9 H, s, 
Bu'), 4.33 (2 H, d, 7 =  5.6 Hz, C //2 NHBoc), 4.70 (2 H, s, C //2 NCS), 4.91 (1 H, br, 
NH), 7.22-7.27 (3 H, m, Ar 2,4,6-H3), 7.34 ( 1  H, t, 7  = 7.8 Hz, Ar 5-H); IR vmax 
(film) 1670 (C=0), 2060 (N=C=S), 3353 (NH) c m 1; MS (FAB +ve ion)
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279.1163 (M + H) (C 1 4H 19N2 O2 S requires 279.1167), 223 (M -  Me2 C=CH2), 179 (M 
-B oc), 164 (M -BocN H ).
1,1-Dimethylethyl N-(3-(thioureidomethyI)phenylmethyl)carbamate 28
Ammonia was passed through 27 (400 mg, 1.5 mmol) in CH2 CI2 (40 ml) for 30 min. 
The mixture was then stirred for 3 h at 0°C. Evaporation and chromatography 
(EtOAc/hexane 4:1) gave 28 (300 mg, 72%) as white crystals: mp 70-72°C; Rf 0.7 
(EtOAc/hexane 4:1); 'H NMR (CDC13) 5 1.40 (9 H, s, Bu1), 4.18 (2 H, br, CH2), 4.62
Ar-H4  + NH); IR vm„  (disc) 1164 (C=S), 1608 (C=0), 3308 (NH) cm'1; MS (FAB 
+ve ion) m/z296.1426 (M + H) (C 1 4H2 2 N 3 O2 S requires 296.1433), 240 (M -  
Me2 C=CH2); Found C, 56.50: H, 7.11: Ci4 H2 2 N 3 0 2S requires C, 56.50; H, 7.09%.
1,1-Dimethylethyl N-(3-(N’-(2-hydroxyethyl)thioureidomethyl)phenylmethyl)- 
carbamate 30
Compound 27 (210 mg, 1.0 mmol) in acetone (1 ml) was added dropwise during 30 
min to 2-aminoethanol (60 mg, 1.0 mmol) in acetone (1 ml). The mixture was boiled 
under reflux for 4 h. Evaporation and chromatography (EtOAc/hexane 1:1) gave 30 
(90 mg, 30%) as an oil; Rf 0.2 (EtOAc/hexane 1:1); *H NMR ((CD3)2 SO) 6  1.45 (9
1170 (C=S), 1642 (C=0), 3413 (NH) cm '1; MS (FAB +ve ion) m/z 340.1697 (M +
BocHN.
S
(2 H, br, CH2), 5.30 (1 H, br, N//CSNH2), 6.01 (2 H, br, NH2), 7.16-7.29 (5 H, m,
BocHN.
s
H, s, Bu1), 1.63 (1 H, br, NH), 3.59 (1 H, br, NH), 3.75 (2 H, m, CH2 NH), 4.01 (2 H, 
t, J  = 6.2 Hz, CH2 OH), 4.26 (2 H, m, CH2 Ar), 4.85 (2 H, d, J  = 4.7 Hz, 
ArC//2NBoc), 5.40 (1 H, br, OH) 7.16-7.33 (5 H, m, Ar-H4  + NH); IR v ^  (film)
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Compound 30 (83 mg, 0.24 mmol) in aq. HC1 ( 6  M, 4 ml) was boiled under reflux 
for 36 h. Evaporation gave 31 (59 mg, 47%) as an hygroscopic gum; JH NMR 
( C D C I 3 )  6  3.63 (2 H, t, J=  7.4 Hz, thiazole 5-H2), 3.99 (2 H, t, J = 7.4 Hz, thiazole 4- 
H2), 4.06 (2 H, brq, J=  5.9 Hz, C //2 N+H3), 4.77 (2 H, d, J  = 6.2 Hz, CH2 Ar), 7.47- 
7.58 (4 H, m, Ar-H4), 8.70 (3 H, br, N+H3), 10.89 (2 H, s, 2 x NH); IR v™* (film) 
1632 (C=N), 3429 (NH) cm'1; MS (FAB +ve ion) m/z 222.1067 (M + H)
(CiiHi6N3S requires 222.1065).
N-(3-(Aminomethyl)phenylmethyl)thiourea bis(trifluoroacetate) salt 35
2.CF3C02
©  f  I  H ©
H3 * k > ^ J\ ^ NY NH3
S
Compound 28 (100 mg, 0.3 mmol) was stirred in trifluoroacetic acid (3 ml) for 5 
min. Evaporation gave 35 (140 mg, quant.) as an hygroscopic gum; Rf 0.2 
(EtOAc/hexane 4:1); 'H NMR ((CD3 )2 SO) 5 4.00 (2 H, m, C //2 NH3+), 4.65 (2 H, br, 
Ctf2 NH), 7.15 (3 H, br, NH3+), 7.30-7.34 (4 H, m, Ar-H4), 8.10 (4 H, br, NH + 
NH3+); IR vrax (film) 1172 (C=S), 1780 (C=0), 3200 (NH) c m 1; MS (FAB +ve ion) 






Di-tert-butyl dicarbonate (1.0 g, 4.9 mmol) was added slowly to a solution of 1,4-bis- 
(aminomethyl)benzene 36 (2.0 g, 15 mmol) and Et3N (2.9 g, 29 mmol) in CH2 CI2  (35 
ml) at 0°C and the mixture was stirred for 16 h. The solvent was evaporated. The 
residue, in CH2 CI2 , was washed with aq. NaHCC>3 and dried. Evaporation gave 37 
(930 mg, 80%) as an oil: (lit. [Smith et 1996] oil); R f 0.7 (EtOAc); 'H NMR 
(CDCI3 ) 8  1.46 (9 H, s, Bu'), 1.52 ( 2  H, br, NH2), 3.85 (2 H, s, C //2 NH2), 4.29 ( 2  H, 
d, J  = 6.0 Hz, C //2N H B oc), 5.89 (1 H, br, NH), 7.24-7.28 (4 H, m, Ar-H4); MS (FAB 
+ve ion) m/z237 (M + H), 181 (M -  Me2 C=CH2), 164 (M -  Bu’O).
1,1-Dimethylethyl N-(4-isothiocyanatomethyl)phenylmethyl)carbamate 38
BocHN
Compound 37 (900 mg, 3.8 mmol), CaCC>3 (0.36 g, 3.6 mmol), water (4 ml), 
thiophosgene ( 1 . 1  g, 9.2 mmol) and CHCI3 (30 ml) were stirred vigorously for 16 h. 
The mixture was extracted with CHCI3 and dried. Evaporation and chromatography 
(EtOAc/hexane 1:3) gave 38 (860 mg, 81%) as yellow crystals: mp 80-82°C (lit. 
[Smith et al1996] mp 74°C); Rf 0.4 (EtOAc/hexane 1:3); 'H NMR (CDCI3 ) 5 1.46
(9 H, s, Bu'), 4.33 (2 H, m, C //2 NHBoc), 4.70 (2 H, s, CH2 Ar), 4.88 (1 H, br NH), 
7.24-7.35 (4 H, m, Ar-H4); IR vm„  (disc) 1682 (C=0), 2091 ( N O S ) ,  3358 (NH) 





Ammonia was passed through 38 (300 mg, 1.1 mmol) in CH2 CI2 (50 ml) for 2 h. The 
mixture was then stirred for 3 h at 0°C. Evaporation and chromatography (EtOAc) 
gave 39 (250 mg, 71%) as pale yellow crystals: mp 104-106°C; Rf 0.4 (EtOAc); ]H 
NMR ((CD3 )2 SO) 5 1.38 (9 H, s, Bu1), 4.08 (2 H, d, J=  6.0 Hz, CH2NHBoc), 4.57 (2 
H, br, CH2 Ar), 7.20 ( 6  H, m, Ar-H4  + NH2), 7.37 (1 H, br, NH), 7.98 (1 H, br, NH); 
IR Vmax (disc) 1171 (C=S), 1686 (C=0), 3355 (NH) cm'1; MS (FAB +ve ion) m/z 
296.1423 (M + H) (C 1 4H2 1N 3 O3 S requires 296.1421), 591 (2 M + H), 249 (M -  
Me2 C=CH2); Found C, 56.6: H, 7.09; N, 13.90: C 1 4H2 2 N 3 O2 S requires C, 56.72; H, 
7.16; N, 14.23%.
N-(4-(Aminomethyl)phenylmethyl)thiourea bis(trifluoroacetate) salt 40
Compound 39 (130 mg, 0.4 mmol) was stirred in trifluoroacetic acid (5 ml) and was 
stirred for 2 h. Evaporation gave 40 (240 mg, quant.) as white crystals: mp 197- 
199°C; Rf 0.2 (EtOAc); JH NMR ((CD3 )2 SO) 5 3.99 (4 H, s, 2 x CH2), 4.64 (3 H, br, 
NH3+), 7.29 (1 H, br, NH), 7.30 (2 H, d, J = 8.0 Hz, Ar 3,5-H2), 7.37 (2 H, d, J = 8.0 
Hz, Ar 2,6-H2), 8.16 (3 H, br, NH3+); IR vmax (disc) 1188 (C=S), 3293 (NH) cm'1; 
MS (FAB +ve ion) m/z 196.0920 (M + H) (C9 H 14N 3 S requires 196.0908), 349 (M + 




Compound 37 (300 mg, 1.0 mmol) in acetone (1.3 ml) was added dropwise during 30 
min to 2-aminoethanol (61 mg, 1.0 mmol) in acetone (1.3 ml). The mixture was 
boiled under reflux for 4 h. Evaporation gave 41 (140 mg, 41%) as an oil; R f 0.3
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(EtOAc); 'H NMR (CDC13)8  1.44 (9 H, s, Bu’), 3.57 (2 H, br, C //2 NH), 3.68 (2 H, t, 
J  = 4.7 Hz, C/72 OH), 4.24 (2 H, d, / =  5.4 Hz, C //2NHBoc), 4.67 (2 H, s, CH2 Ar), 
5.04 (1 H, s, OH), 6 . 8 8  (1 H, br, NH), 7.18 (1 H, br, NH), 7.20 (2 H, d, 7.0 Hz, 
Ar 3,5-H2), 7.26 (3 H, m, Ar 2,6-H2 + NH); IR vmx (film) 1171 (C=S), 1682 (C=0), 
3297 (NH + OH) cm'1; MS (FAB +ve ion) 340.1684 (M + H) (CisH^NjOjS 
requires 340.1695), 679 (2 M +H), 284 (M -  Me2 C=CH2).
2-(4-(Aminomethyl)phenyImethylamino)-4,5-dihydrothiazole dihydrochloride 
42
2.Cle  / ^ X  H
$ T \ - T \
H
Compound 41 (100 mg, 0.29 mmol) in aq. HC1 ( 6  M, 6  ml) was boiled under reflux 
for 36 h. Evaporation and recrystallisation (propan-2-ol) gave 42 (40 mg, 47%) as 
pale yellow crystals: mp 198-200°C; ]H NMR ((CD3 )2 SO) 6  3.64 (2 H, t, J=  7.4 Hz, 
thiazole 5-H2), 4.04 (2 H, m, thiazole 4-H2), 4.14 (2 H, m, CH2 Ar), 4.61 (2 H, s, 
C7/2NH3+), 7.44 (2 H, m, Ar 3,5-H2), 7.53 (2 H, m, Ar 2,6-H2); IR vmax (disc) 1654 
(C=N), 3425 (NH) cm'1; MS (FAB +ve ion) m/z 222.1061 (M + H) (CnH,6N3S 
requires 222.1065), 443 (2 M +H), 375 (M + mNBA), 205 (M -  NH3).
1,1-Dimethylethyl N-(3-nitrophenylmethyl)carbamate 44
n o 2
Di-terr-butyl dicarbonate (1.7 g, 7.8 mmol) was added slowly to 3-nitrobenzylamine 
43 (1.0 g, 6 . 6  mmol) and Et3N (1.1 g, 11 mmol) in CH2 C12  (25 ml) at 0°C and the 
mixture was stirred for 16 h. The solvent was evaporated and the residue, in CH2 C12, 
was washed with aq. NaHC03 and dried. Evaporation and chromatography (CH2 C12) 
gave 44 (900 mg, 56%) as white crystals: mp 124-126°C (lit. [Collins et al 1998] no 
mp given); Rf 0.3 (EtOAc/hexane 1:1); 'H  NMR (CDCI3 ) 8  1.39 (9 H, s, Bu‘), 4.35 




7.54 (1 H, d, J = 7.8 Hz, Ar 6 -H), 8.03 (1 H, d, J =  8.9 Hz, Ar 4-H), 8.04 (1 H, s, Ar 
2-H); MS (FAB +ve ion) m/z 253.1184 (M + H) (C 1 2H 17N 2 O4  requires 253.1188), 
197 (M - Me2 C=CH2); Found C, 57.30: H, 6.35; N, 11.20: C 1 2H 15N2 O4  requires C, 
57.14; H, 6.35; N, 11.11%.
1,1-Dimethylethyl N-(3-aminophenylmethyl)carbamate 45
n h 2
Compound 44 (900 mg, 3.7 mmol) and SnCl2 .2 H2 0  (2.6 g, 10 mmol) in EtOH ( 8  ml) 
were boiled under reflux for 30 min under N2 . The solution was cooled to 0°C and 
made basic with 5% aq. NaHCCh, before being extracted with EtOAc. The extract 
was washed with brine and dried. Evaporation gave 45 (250 mg, 31%) as an oil (lit. 
[Collins et al1998] oil); R f 0.4 (EtOAc/CHCl3 1:1); ‘H NMR (CDC13) 5 1.40 (9 H, 
s, Bu1), 3.59 (2 H, br, NH2), 4.15 (2 H, d, J  = 5.7 Hz, CH2), 4.70 (1 H, br, NH), 6.55 
(3 H, m, Ar 2,4,6-H3), 7.06 (1 H t, J  = 7.7 Hz, Ar 5-H); MS (FAB +ve) m/z 222 (M), 
167 (M -Me2 C=CH2), 121 (M - Boc), 106 (M - BocNH).
1,1-Dimethylethyl A-(3-isothiocyanatophenylmethyl)carbamate 46
NCS
Compound 45 (200 mg, 0.9 mmol), CaC0 3  (77 mg, 0.8 mmol), water (1 ml), 
thiophosgene (200 mg, 1.8 mmol) and CHCI3 (5 ml) were stirred vigorously for 48 h. 
The mixture was extracted with CHCI3 and dried. Evaporation and chromatography 
(EtOAc/hexane 1:3) gave 46 (130 mg, 70%) as white crystals: mp 70-72°C; Rf 0.5 
(EtOAc/hexane 1:3); 'H NMR ((CD3 )2 SO) 5 1.39 (9 H, s, Bu1), 4.12 (2 H, d, 5.9 
Hz, CH2), 7.23 (3 H, m, Ar 2,4,6-H3), 7.43 (1 H, t, 7.7 Hz, Ar 5-H), 7.46 (1 H, br, 
NH); IR Vmax (disc) 1675 (C=0), 2100 (N=C=S), 3180 (NH) cm'1; MS (FAB +ve 
ion) m/z265.1012 (M + H) (Ci3 H nN2 0 2S requires 265.1011), 209 (M -  







Ammonia was passed through 46 (200 mg, 0.8 mmol) in CH2 CI2  (20 ml) for 30 min. 
The mixture was then stirred for 3 h at 0°C. Evaporation and chromatography 
(EtOAc/hexane 4:1) gave 47 (85 mg, 38%) as yellow crystals: mp 198-200°C; Rf 0.2 
(EtOAc/hexane 4:1); !H NMR (CDCI3 ) 6  1.37 (9 H, s, Bu'), 4.01 (2 H, d, J = 7.4 Hz, 
CH2), 6.96 (1 H, t, J = 1A  Hz, NH), 7.23 (1 H, d, J=  7.8 Hz, Ar-H), 7.28-7.35 (5 H, 
m, Ar-H3 + NH2), 9.78 (1 H, s, NH); IR Vmax (disc) 1173 (C=S), 3291 (NH) cm'1, MS 
(FAB +ve ion) m/z 282.1295 (M + H) (C1 3H2 0 N 3 O2 S requires 282.1276), 226 (M -  
Me2 C=CH2).
N-(3-Aminomethylphenyl)thiourea bis(trifluoroacetate) salt 48
©
2.CF3CO2
Compound 47 (85 mg, 0.3 mmol) was taken up in trifluoroacetic acid (3 ml) and was 
stirred for 5 min. Evaporation gave 48 (75 mg, quant.) as an hygroscopic gum; *H 
NMR ((CD3 )2 SO) 5 4.02 (2 H, brq, J = 5.9 Hz, CH2), 7.09 (3 H, br, NH3+), 7.20 (1 H, 
m, Ar 4-H), 7.40 (2 H, m, Ar 5,6-H2), 7.50 (1 H, s, Ar 2-H), 8.16 (3 H, br, N ^ ) ,  
9.87 (1 H, s, NH); 13C NMR ((CD3 )2 SO) 6  42.3 (CH2), 123.4 (C-2) 123.5 (C-6 ),
124.8 (C-4), 129.1 (C-5), 134.5 (C-l), 139.5 (C-3), 181.1 (C=S); IR vmax (film) 1170 
(C=S), 3407 (NH) cm'1; MS (FAB +ve ion) m/z 182.0768 (M + H) (C8 H 12N3S 






Compound 46 (200 mg, 0.7 mmol) in acetone (1.0 ml) was added dropwise during 30 
min to 2-aminoethanol (43 mg, 0.7 mmol) in acetone (1.0 ml). The mixture was 
boiled under reflux for 2 h. Evaporation and chromatography (EtOAc) gave 49 (103 
mg, 43%) as an oil; R f 0.3 (EtOAc); *H NMR ((CD3 )2 SO) 8  1.39 (9 H, s, Bu1), 3.50 
(2 H, br, C //2NH), 3.52 (2 H, m, C //2 OH), 4.04 (2 H, d, J  = 6 . 6  Hz, CH2NHBoc), 
4.80 (1 H, s, OH), 6.96 (1 H, d, J =  7.4 Hz, Ar 4-H), 7.23 (2 H, m, NH + Ar 2-H), 
7.36 (2 H, m, Ar 5,6-H2), 7.66 (1 H, br, NH), 9.60 (1 H, br, NH); IR vmax (film) 1164 
(C=S), 1693 (C=0), 3380 (NH); MS (FAB +ve ion) m/z 326.1541 (M + H) 
(Ci5 H2 4 N3 0 3 S requires 326.1538), 651 (2 M + H), 270 (M -  Me2 C=CH2).
2-(3-(Aminomethyl)phenylamino)-4,5-dihydrothiazole dihydrochloride 50
H
Compound 49 (830 mg, 2.6 mmol) was taken up in aq. HC1 ( 6  M, 3 ml) and was 
boiled under reflux for 43 h. Evaporation gave 50 (820 mg, quant.) as buff crystals: 
mp 208-210°C; 'H NMR ((CD3 )2 SO) 5 3.65 (2 H, t, 7.7 Hz, thiazole 5-H2), 4.01 
(2 H, t, J=  7.7 Hz, thiazole 4-H2), 4.11 (2 H, m, C //2 NH3+), 7.39 (1 H, d, 7.5 Hz, 
Ar 4-H), 7.56 (2 H, m, Ar 5,6-H2), 7.62 (1 H, s, Ar 2-H), 8 . 6 6  (3 H, s, N+H3), 10.5 (1 
H, br, NH), 12.7 (1 H, br, NH); IR v™, (disc) 1640 (C=N), 3432 (NH) cm '; MS 
(FAB +ve ion) m/z 208.0918 (M + H) (CioHi4 N3S requires 208.0908); Found C, 




2-(3-Aminomethylphenylamino-4,5-dihydrothiazole bis(trifluoroacetate) salt 
50a
Compound 49 (103 mg, 0.3 mmol) was taken up in trifluoroacetic acid (3 ml) and 
was stirred for 5 min. Evaporation gave 50a (138 mg, quant.) as an hygroscopic 
gum; ‘H NMR ((CD3 )2 SO) 6  3.62 (2 H, t, 7.7 Hz, thiazole 5-H2), 4.0 (4 H, m,
NTHj), 9.73 (1 H, br, NH); IR vmK (film) 1674 (C=N), 3398 (NH); MS (FAB +ve 
ion) m/z208.0915 (M + H) (CI0 H,4N3S requires 208.0908), 191 (M - NH3+).
1,1-Dimethylethyl N-(4-nitrophenylmethyl)carbamate 52
Di-ter/-butyl dicarbonate (3.3 g, 15 mmol) was added slowly to 4-nitrobenzylamine 
51 (2 . 0  g, 1 1  mmol) and Et3N (2 . 1  g, 2 1  mmol), in CH2 C12 (25 ml) at 0°C and the 
mixture was stirred for 16 h. The solvent was evaporated. The residue, in CH2 C12, 
was washed with aq. NaHC0 3 and dried. Evaporation gave 52 (2.4 g, 91%) as white 
crystals: mp 111-114°C (lit. [Tanaka et al 1988] mp 109-110°C); R f 0.6 
(EtOAc/hexane 2:1); ‘H NMR (CDC13) 8  1.53 (9 H, s, Bu'), 4.42 (2 H, 5.9 Hz, 
CH2), 5.05 (1 H, br, NH), 7.44 (2 H, d, J  = 8. 6  Hz, Ar 2,6-H2), 8.19 (2 H, d, 8 . 6
Hz, Ar 3,5-H2); MS (FAB +ve) m/z505 (2 M + H), 406 (2 M + H -  Boc), 275 (M + 











Compound 52 (2.0 g 7.8 mmol) was boiled under reflux with SnCl2 .2 H2 0  (7.4 g, 39 
mmol) in EtOH (17 ml) for 1 h. The solution was cooled to 0°C, made basic with 5% 
aq. NaHC03, extracted with EtOAc, washed with brine and dried. Evaporation gave 
53 (250 mg, 31%) as an oil: (lit. [Liu et al 1998] mp 87-88°C); R f 0.5 (EtOAc/hexane 
2:1); *H NMR (CDC13) 8  1.45 (9 H s Bu1), 3.8 (2 H, br, NH2), 4.18 (2 H, d, J  = 5.1 
Hz, CH2), 4.73 (1 H, br, NH), 6.64 (2 H, d, J=  8.2 Hz, Ar 2,6-H2), 7.07 (2 H, d, J  =




Compound 53 (900 mg, 3.9 mmol), CaC0 3 (0.4 g, 0.4 mmol) water (3 ml) and 
thiophosgene (400 mg, 7.8 mmol) and CHC13 (25 ml) were stirred vigorously for 16 
h. The mixture was extracted with CHC13 and dried. Evaporation and 
chromatography (EtOAc/hexane 1:3) gave 54 (260 mg, 26%) as a pale yellow 
powder: mp 113-115°C; R f0.4 (EtOAc/hexane 1:3); 'H  NMR (CDC13) 5 1.46 (9 H, 
s, Bu‘), 4.29 (2 H, d ,J =  5.6 Hz, CH2), 4.91 (1 H, br, NH), 7.18 (2 H, d 8 . 6  Hz, 
Ar 2,6-H2), 7.27 (2 H, d, J =  8. 6  Hz, Ar 3,5-H2); IR v „  (disc) 1683 (C=0), 2123 
( N O S ) ,  3366 (NH) cm '1; MS (FAB +ve ion) 265.1006 (M + H) (Ci3 H 1 7N2 0 2S 
requires 265.1011), 529 (2 M +H), 209 (M -  Me2 C=CH2); Found C, 58.10: H, 5.92; 
N, 10.30: C 1 3H ,6N 2 0 2S 0.25 H20  requires C, 58.08; H, 6.19; N, 10.42%.
1,1-Dimethylethyl N-(4-thioureidophenylmethyI)carbamate 55
f yiH
BocHN '  H
Ammonia was passed through a solution of 54 (400 mg, 1.5 mmol) in CH2 CI2 (40 
ml) for 30 min. The mixture was then stirred for 3 h at 0°C. Evaporation and 
chromatography (EtOAc/hexane 4:1) gave 55 (250 mg, 6 6 %) as white crystals: mp
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89-91°C; Rf 0.3 (EtOAc/hexane 4:1); ‘H NMR (CDCI3 ) 8  1.46 (9 H, s, Bu1), 4.30 (2 
H, d, J =  6.0 Hz, CH2), 5.03 (1 H, br, NH), 6.25 (2 H, br, NH2), 7.19 (2 H, d, 8.2
Hz, Ar 3,5-H2), 7.33 (2 H, d, J  = 8.2 Hz, Ar 2,6-H2), 8.39 (1 H, br, NH); IR vmax 
(disc) 1187 (C=S), 1690 (C=0), 3298 (NH) cm '1; MS (FAB +ve ion) m/z 282.1276 
(M + H) (Ci3 H 2 0 N3 O2S requires 282.1276), 226 (M -  Me2 C=CH2); Found C, 54.40: 
H, 6.73; N, 14.20: Ci3 H,9 N 3 0 2S 0.5 H20  requires C, 53.87; H, 6.78; N, 14.49%.
N-(4-Aminomethylphenyl)thiourea bis(trifluoroacetate) salt 56
2 .CF3CO2
Compound 55 (52 mg, 0.18 mmol) was stirred in trifluoroacetic acid (3 ml) for 2 h. 
Evaporation gave 56 (880 mg, quant.) as an hygroscopic gum; 'H NMR ((CD3 )2 SO) 
8  3.96 (2 H, q, J=  5.6 Hz, CH2), 7.38 (2 H, d, J = 8.2 Hz, Ar 2,6-H2), 7.51 (2 H, d, J  
= 8.2 Hz, Ar 3,5-H2), 7.51 (3 H, br, NH3+), 8.11 (3 H, br, NH3+), 9.83 (1 H, s, NH); 
IR vmax (film) 1173 (C=S), 3369 (NH) cm'1; MS (FAB +ve ion) m/z 182.0748 (M + 





Compound 54 (120 mg, 0.5 mmol) in acetone (0.6 ml) was added dropwise during 30 
min to 2-aminoethanol (28 mg, 0.5 mmol) in acetone (0.6 ml). The mixture was 
boiled under reflux for 4 h. Evaporation and chromatography (EtOAc) gave 57 (67 
mg, 45%) as an oil; Rf 0.5 (EtOAc); ]H NMR ((CD3 )2 SO) 8  1.39 (9 H, s, Bu1), 3.32 
(2 H, m, C //2 NH), 3.52 (2 H, m, C //2 OH), 4.07 (2 H, d, /  = 6.2 Hz, C //2 NHBoc),
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4.94 (1 H, br, OH), 7.15 (2 H, d, 7 =  8.2 Hz, Ar 3,5-H2), 7.33 (2 H, d, 7  = Hz, Ar 
2,6-H2), 7.38 (1 H, br, NH), 7.65 (1 H, br, NH), 9.57 (1 H, br, NH); IR vrax (film) 
1166 (C=S), 1689 (0=0), 3323 (NH + OH) c m 1; MS (FAB +ve ion) m/z 326.1552 
(M + H) (Ci5 H2 4 N3 0 3S requires 326.1538).
2-(4-(Aminomethylphenyl)-4,5 dihydrothiazole) bis(trifluoroacetate) salt 58
1CF>CV \ 5  
H $r\=r )=s0
Compound 57 (57 mg 0.18 mmol) was stirred in trifluoroacetic acid (3 ml) for 2 h. 
Evaporation gave 58 (880 mg quant.) as an hygroscopic gum; JH NMR ((CD3 )2 SO) 8  
3.60 (2 H, t, J=  1A  Hz, thiazole 5-H2), 4.00 (2 H, t, J=  1A  Hz, thiazole 4-H2), 4.03 
(2 H, q, J=  6.0 Hz, C //2NH3), 4.59 (1 H, br, NH), 7.37 (2 H, d, J  = 8.2 Hz, Ar 2,6- 
H2), 7.54 (2 H, d, J  = 8.2 Hz, Ar 3,5-H2), 8.26 (3 H, br, NH3+); IR v ^  (film) 1643 
(C=N), 3400 (NH) c m 1; MS (FAB +ve ion) 208.0914 (M + H) (C,0 H 14N3S 
requires 208.0908), 191 (M -N H 3).
3-Nitrophenylmethylisothiocyanate 62
NCS
Compound 43 (500 mg, 3.3 mmol), CaC0 3 (0.3 g, 3.0 mmol), water (4 ml) 
thiophosgene (700 mg, 6 . 6  mmol) and CHC13 (25 ml) were stirred vigorously for 16 
h. The mixture was extracted with CHC13 and dried. Evaporation and 
chromatography (EtOAc) gave 62 (390 mg, 61%) as yellow crystals: mp 65-67°C 
(lit. [Hirashima et al1992] oil); Rf 0.7 (EtOAc); 'H NMR (CDC13) 6  4.82 (2 H, s, 
CH2), 7.62(1 H, t, 7 = 7 .8  Hz, Ar 5-H), 7.69(1 H, d ,7 = 7 .8 , Hz, Ar4-H), 8.20(1 H, 
s, Ar 2-H), 8.21 (1 H, d, 7 =  7.8 Hz, Ar 6 -H); IR v™  (disc) 1347 (N 02), 1526 (N 02), 





Ammonia was passed through 62 (150 mg, 0.7 mmol) in CH2 CI2  (20 ml) for 40 min. 
The mixture was then stirred for 3 h at 0°C. Evaporation and chromatography 
(EtOAc) gave 63 (110 mg, 6 8 %) as yellow crystals: mp 143-145°C; Rf 0.5 (EtOAc); 
*H NMR (CDCI3 ) 6  4.77 (2 H, s, CH2), 7.20 (2 H, br, NH2), 7.64 (1 H, dd, J =  8.2,
7.8 Hz, Ar 5-H), 1.1 A (1 H, d, J =  7.8 Hz, Ar 4-H), 8.10 (1 H, s, Ar 2-H), 8.11 (1 H, 
d, J  = 8.2 Hz, Ar 6 -H); IR vmax (disc) 1159 (C=S), 1347 (N 02), 1529 (N 02), 3292 
(NH) c m 1; MS (FAB +ve ion) m/z 212.0498 (M + H) (C g H ^ O z S  requires 
212.0494), 365 (M + mNBA), 196 (M -  NH2).
N-(3-AminophenylmethyI)thiourea 64
Compound 63 (90 mg 0.4 mmol) was boiled under reflux with SnCl2 .2 H2 0  (0.2 g,
1.2 mmol), in EtOH (5 ml) for 1 h. The solution was cooled to 0°C, made basic with 
5% aq. NaHCOs, extracted with EtOAc, washed with brine and dried. Evaporation 
and chromatography (EtOAc/hexane 5:1) gave 64 (40 mg, 55%) as buff crystals: mp 
141-143°C; R f 0.3 (EtOAc/hexane 5:1); 'H  NMR (CD3 OD) 5 3.34 (2 H, s, CH2), 
4.25 (1 H, br, NH), 4.58 (2 H, br, NH2), 6.62 (3 H, m, Ar 2,4,6-H3), 6 . 6 8  (1 H, br, 
NH), 7.05 (1 H, t , J =  7.8 Hz, Ar 5-H); IR vm«  (disc) 1166 (C=S), 3289 (NH) cm'1; 





65 and N-(2-hydroxyethyl)-N’-(3-nitrophenylmethyl)thiourea 66
(6 6 ) (65)
Compound 62 (200 mg, 1.0 mmol) in acetone (1.2 ml) was added dropwise during 30 
min to 2-aminoethanol (61 mg, 1.0 mmol) in acetone (1.2 ml). The mixture was 
boiled under reflux for 4 h. Evaporation and chromatography (EtOAc) gave 65 (50 
mg, 19%) as an oil; R f 0.6 (EtOAc); and 6 6  (180 mg, 70%) as buff crystals: mp 79- 
81°C; Rf 0.4 (EtOAc);
Compound 65
*H NMR ( C D C I 3 )  5 1.80 ( 6  H, s, 2 x CH3), 3.82 (2 H, br, oxazole 4-H2), 4.05 (4 H, t, 
J = 6 . 6  Hz, oxazole 5-H2), 5.02 (2 H, d, J = 5.4 Hz, CH2 Ar), 5.70 (1 H, br, NH), 7.55 
(1 H, dd, J=  8.2, 7.8 Hz, Ar 5-H), 7.72 (1 H, d, J = 8.0 Hz, Ar 4-H), 8.15 (1 H, d, J  =
8.0 Hz, Ar 6 -H), 8.16 (1 H, s, Ar 2-H); IR Vmax (film) 1144 (C=S), 1346 (N 02), 1534 
(N 02), 3413 (NH) cm '1; MS (FAB +ve ion) m/z 296.1066 (M + H) (C 1 3H 1 8N3 O3 S 
requires 296.1069), 449 (M + mNBA).
Compound 66
‘H NMR (CDCI3 ) 6 3.61 (2 H, br, C //2NH), 3.82 (2 H, t, J  = 4.7 Hz, C //2OH), 4.89 
(2 H, d, J=  5.4 Hz, CH2Ar), 6.78 (1 H, br, OH), 7.28 (1 H, br, NH), 7.50 (1 H, t, J  = 
1A Hz, Ar 5-H), 7.77 (1 H, d, J  = 1A Hz, Ar 4-H), 8.11 (1 H, d, J=  7.4 Hz, Ar 6-H),
8.16 (1 H, s, Ar 2-H); IR Vmax (disc) 1144 (C=S), 1348 (N 02), 1531 (N 02), 3402 (NH 
+ OH) cm'1; MS (FAB +ve ion) m/z 256.0753 (M + H) (C 1 0HMN3 O3 S requires 
256.0756), 409 (M + mNBA).
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2-(3-NitrophenyImethylamino)-4,5-dihydrothiazole trifluoroacetate salt 67
©
Compound 65 (120 mg, 0.47 mmol) was taken up in trifluoroacetic acid (5 ml) and 
stirred for 16 h. Evaporation gave 67 (170 mg, quant.) as an oil: (lit. [Hirashima et al 
1992] mp 91-92°C); R f 0.6 (EtOAc); *H NMR (CDC13) 5 3.55 (2 H, t, J =  7.8 Hz, 
thiazole 5-H2), 4.05 (2 H, t, J  = 7.8 Hz, thiazole 4-H2), 4.59 (2 H, d, J  = 4.7 Hz, 
CH2 Ar), 7.61 (1 H, dd, J  = 8.2, 7.8 Hz, Ar 5-H), 7.69 (1 H, d, J  = 7.8 Hz, Ar 6 -H),
8.17 (1 H, s, Ar 2-H), 8.21 (1 H, d, J =  8.2 Hz, Ar 4-H), 11.94 (1 H, br, NH), 12.32 
(1 H, br NH); IR vmax (film) 1352 (N 02), 1532 (N 02), 1679 (O N ), 3170 (NH) cm '1; 
MS (FAB +ve ion) m/z 238.0640 (M + H) (Ci0 Hi2 N3 O2S requires 238.0650), 475 (2 
M + H).
2-(3-Aminophenylmethylamino)-4,5-dihydrothiazole 68
Compound 67 (150 mg, 0.6 mmol) was boiled under reflux with SnCl2 .2H20  (0.3 g 
1.7 mmol), in EtOH ( 8  ml) for 2 h. The solution was cooled at 0°C, made basic with 
5% aq. NaHC03, extracted with EtOAc, washed with brine and dried. Evaporation 
gave 68 (150 mg, quant.) as an oil; ]H NMR (CD3 OD) 5 3.30 (2 H, m, thiazole 5- 
H2), 3.90 (2 H, m, thiazole 4-H2), 4.30 (2 H, br, CH2 Ar), 6.62 (2 H, m, Ar 4,6-H2), 
6.67 (1 H, s, Ar 2-H), 7.04 (1 H, t, J = 7.4 Hz, Ar 5-H); IR vmax (film) 1618 (C=N); 
3391 (NH) cm '1; MS (FAB +ve ion) m/z 208.0905 (M + H) (Ci0 H 14N3S requires 





Compound 51 (1.0 g, 6.5 mmol), CaCOs (500 mg, 5.0 mmol), water (4 ml) 
thiophosgene (1.2 g, 11 mmol) and CHCI3 (40 ml) were stirred vigorously for 16 h. 
The mixture was extracted with CHCI3 and dried. Evaporation gave 69 (700 mg, 
56%) as an oil: (lit. [Molina et al1982] mp 111-112°C); R f 0.7 (EtOAc); ‘H NMR 
(CDCb) 5 4.88 (2 H, s, CH2), 7.52 (2 H, d, 8.9 Hz, Ar 2,6-H2), 8.25 (2 H, d
8.9 Hz, Ar 3,5-H2); IR Vmx (film) 1347 (N 02), 1531 (N 02), 2070 (N=C=S), 3079 
(NH) cm '1; MS (FAB +ve ion) m/z 195 (M + H).
N-(4-Nitrophenylmethyl)thiourea 70
Ammonia was passed through 69 (250 mg, 1.3 mmol) in CH2 CI2 (40 ml) for 2 h. The 
mixture was then stirred for 3h at 0°C. Evaporation and chromatography (EtOAc) 
gave 70 (190 mg, 69%) as an oil: (lit. [McKay et 1958] oil) Rf 0.5; ‘H NMR 
(CDC13) 5 4.82 (2 H, br, CH2), 5.82 (2 H, br, NH2), 7.26 (1 H, s, NH), 7.50 (2 H, d, J  
= 8 . 6  Hz, Ar 2,6-H2), 8.21 (2 H, d, J  = 8. 6  Hz, Ar 3,5-H2); IR vmx (film) 1159 (C=S), 
1344 (N 02), 1563 (N 02), 3213 (NH) cm '1; MS (FAB +ve ion) 212.0490 (M + H) 
(C8HioN30 2S requires 212.0494), 422 (2 M +H), 364 (M + mNBA), 196 (M -  NH2).
N-(4-Ammophenylmethyl)thiourea 71
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Compound 70 (150 mg, 0.7 mmol) was boiled under reflux with SnCl2 .2 H2 0  (400 
mg 1.8 mmol), in EtOH (9 ml) for 3 h. The solution was cooled to 0°C, made basic 
with 5% aq. NaHCC>3 , extracted with EtOAc, washed with brine and dried. 
Evaporation and chromatography (EtOAc/acetic acid/hexane 10:1:1) gave 71 (120 
mg 95 %) as pale orange crystals: mp >270°C; R f 0.4 (EtOAc/acetic acid/hexane 
10:1:1); !H NMR (CD3 OD) 5 4.54 (2 H, s, CH2), 6.69 (2 H, d, J =  8.2 Hz, Ar 3,5- 
H2), 7.06 (2 H, d, J =  8.2 Hz, Ar 2,6-H2); IR vmax (disc) 1179 (C=S), 3422 (NH) 
cm'1; MS (FAB +ve ion) m/z MS (FAB +ve ion) m/z 182.0746 (M + H) (C8 H,2N3S 
requires 182.0752), 164 (M -  NH3).
2,2-Dimethyl-3-(N-(4-nitrophenylmethyl)aminothiocarbonyl)tetrahydrooxazole 
72 and N-(2-hydroxyethyl)-N’-(4-nitrophenylmethyl)thiourea 73
(73) (72)
Compound 69 (350 mg, 2.3 mmol) in acetone (2.8 ml) was added dropwise during 30 
min to 2-aminoethanol (140 mg, 2.3 mmol) in acetone (2.8 ml). The mixture was 
boiled under reflux for 4 h. Evaporation and chromatography (EtOAc) gave 72 (90 
mg, 13%) as an oil; Rf 0.6 (EtOAc); and 73 (200 mg, 34%) as an oil; Rf 0.4 (EtOAc)
Compound 72
'H NMR (CDC13) 6  1.79 ( 6  H, s, 2 x CH3), 3.82 (2 H, m, oxazole 4-H2), 4.05 (2 H, t, 
J=  6.2 Hz, oxazole 5-H2), 5.03 (2 H, d, J =  5.4 Hz, CH2 Ar), 5.67 (1 H, br, NH), 7.49 
(2 H, d, J  = 8 . 8  Hz, Ar 2,6-H2) 8.17 (2 H, d, J =  8 . 8  Hz, Ar 3,5-H2); IR vmax (film) 
1143 (C=S), 1346 (N 02), 1541 (N 02), 3380 (NH) cm'1; MS (FAB +ve ion) m/z 




'H  NMR (CDCI3 ) 5 3.62 (2 H, br, CH2 NH), 3.82 (2 H, t, 5.0 Hz, CH2 OH), 4.90 
(2 H, d, J  = 5.8 Hz, CH2 Ar), 6.54 (1 H, br, OH), 7.10 (1 H, br, NH), 7.26 (1 H, br 
NH), 7.50 (2 H, d, J  = 8.9 Hz, Ar 2,6-H2), 8.19 (2 H, d, 8.9 Hz, Ar 3,5-H2); IR 
vmax (film) 1160 (C=S), 1346 (N 02), 1562 (N 02), 3368 (NH + OH) cm '1; MS (FAB 
+ve ion) m/z256.0755 (M + H) (C8 Hi0N 3O2S requires 256.0756), 409 (M + mNBA).
2-(4-Nitrophenylmethylamino)-4,5-dihydrothiazole trifluoroacetate salt 74
H
02
Compound 73 (200 mg, 0.78 mmol) was stirred under reflux in trifluoroacetic acid (5 
ml) for 15 h. Evaporation gave 74 (240 mg, quant.) as an hygroscopic gum: (lit. 
[Hirashima et al 1992] no mp given); Rf 0.6 (EtOAc); *H NMR (CDC13) 6  3.54 (2 H, 
t, J = 7.8 Hz, thiazole 5-H2), 4.04 (2 H, t ,J =  7.8 Hz, thiazole 4-H2), 4.59 (2 H, d, J -
5.1 Hz, CH2 Ar), 7.49 (2 H, d, J  = 8 . 6  Hz, Ar 2,6-H2), 8.23 (2 H, d, J =  8 . 6  Hz, Ar
3,5-H2), IR Vmax (film) 1347 (N 02), 1524 (N 02), 1678 (C=N), 3173 (NH) cm'1; MS 
(FAB +ve ion) m/z 238.0639 (M + H) (Ci0 H 12N 3 O2S requires 238.0650), 222 (M -  
NH2).
2-(4-Aminophenylmethylamino)-4,5-dihydrothiazole 75
Compound 74 (200 mg, 0.8 mmol) was boiled under reflux with SnCl2 .2H20  (460 
mg 2.4 mmol) in EtOH (12 ml) for 90 min. The solution was cooled to 0°C, made 
basic with 5% aq. NaHC03, extracted with EtOAc, washed with brine and dried. 
Evaporation gave 75 (70 mg, 38%) as an oil; 'H NMR (CDCI3 ) 6  3.33 (2 H, 7.4 
Hz, thiazole 5-H2), 3.64 (2 H, br, NH2), 4.02 (2 H, t, = 7.4 Hz, thiazole 4-H2), 4.34 
(2 H, s, CH2 Ar), 6.64 (2 H, d, J  = 8. 6  Hz, Ar 3,5-H2), 7.11 (2 H, d, = 8 . 6  Hz, Ar
2,6-H2); ,3C NMR 35.7 (CH2 S), 49.2 (CH2 Ar), 60.4 (CH2 N), 115.4 (Ar 3,5-C2),
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129.0 (Ar 1-C), 129.3 (Ar 2,6-C2), 146.0 (Ar 4-C), 161.9 (C=N); IR vmax (film) 1609 
(C=N), 3324 (NH) cm'1; MS (FAB +ve ion) m/z 208.0911 (M + H) (Ci0 H,4 N3S 
requires 208.0908), 361 (M + mNBA).
Methyl 3-aminophenylacetate hydrochloride 77
3-Aminophenylacetic acid 76 (2.0 g, 13.2 mmol) was stirred with MeOH (350 ml) 
and SOCI2 ( 2 0  ml) for 4 d. Evaporation gave 77 (2 . 6  g, quant.) as an hygroscopic 
gum: (lit. [Jacobs et al 1917] mp 167-170°C) Rf 0.5 (EtOAc); *H NMR ((CD3 )2 SO) 6
3.60 (2 H, s, CH2), 3.41 (3 H, br, NH3+), 3.74 (3 H, s, CH3), 7.15 (3 H, m, Ar-H3), 
7.41 (1 H, m, Ar 5-H); MS (FAB +ve ion) m/z 166 (M + H), 319 (M + mNBA).
Methyl 3-isothiocyanatophenylacetate 78
Compound 77 (2.0 g, 12 mmol), CaC0 3 (1.2 g, 12.0 mmol) water (5 ml), 
thiophosgene (2.8 g, 24 mmol) and CHC13 (80 ml) were stirred vigorously for 16 h. 
The mixture was extracted with CHC13 and dried. Evaporation and chromatography 
(EtOAc/hexane 1:1) gave 78 (1.9 g, 77%) as a pale yellow liquid; Rf 0.8 
(EtOAc/hexane 1:1); 'H  NMR ((CD3 )2 SO) 6  3.61 (2 H, s, CH2), 3.71 (3 H, s, CH3), 
7.26 (3 H, m, Ar-H3), 7.30 (1 H, t, 7 = 7 .8  Hz, Ar 5-H); IR v™  (film) 1738 (C=0), 
2119 (N=C=S) cm'1; MS (FAB +ve ion) 208.0432 (M + H) (C |0 H 1 0NO2S 




Ammonia was passed through 78 (150 mg, 0.7 mmol) in CH2 CI2 (20 ml) for 1 h. The 
mixture was then stirred for 3 h at 0°C. Evaporation and chromatography 
(EtOAc/hexane 1:1) gave 79 (60 mg, 99%) as yellow crystals: mp 131-133°C; Rf 0.2 
(EtOAc/hexane 1:1); 'H  NMR ((CD3 )2 SO) 5 3.61 (3 H, s, CH3), 3.65 (2 H, s, CH2),
7.00 (1 H, d, J  = 1AHz, Ar 4-H), 7.23 (1 H, dd, = 8 .6 , 7.4 Hz, Ar 5-H), 7.25 (1 H, 
s, Ar 2-H), 7.33 (1 H, d, J  = 8. 6  Hz, Ar 6 -H), 7.35 (1 H, br, NH), 9.71 (1 H, s, NH); 
13C NMR ((CD3 )2 SO) 8  40.1 (CH2), 51.8 (CH3), 121.6 (C-2), 123.8 (C-4), 125.4 (C- 
6 ), 128.7 (C-5), 134.9 (C-l) 139.2 (C-3), 171.5 (C=S), 181.1 (0=0); IR v™  (disc) 
1160 (C=S), 1730 (C=0), 3409 (NH) cm '1; MS (FAB +ve ion) 225.0694 (M +
H) (C,oH,3N 2 0 2 S) requires 225.0698), 377 (M + H + mNBA).
3-Thioureidophenylacetic acid hydrochloride 80
ho2̂ X I nXn§3
H
Compound 79 (50 mg, 0.2 mmol) was stirred in aq. HC1 (1 M, 3 ml) for 9 d. 
Evaporation gave 80 (40 mg, 8 6 %) as white crystals: mp 159-161°C (lit. [Richter et 
al 1974] mp 174-176°C); ]H NMR (CD3 OD) 6  3.67 (2 H, s, CH2), 7.15 (1 H, d, J  = 
1A  Hz, Ar 4-H), 7.23 (1 H, d, J  = 8 . 6  Hz, Ar 6 -H), 7.25 (1 H, s, Ar 2-H), 7.35 (1 H, 
dd, J =  8 .6 , 7.4 Hz, Ar 5-H); IR vmax (disc) 1157 (C=S), 1730 (C=0), 2500 (OH), 
3337 (NH) cm'1; MS (FAB +ve ion) m/z 211.0541 (M + H) (C9 HHN2 O2 S requires 
211.0531), 364 (M + mNBA).
Methyl 3-(N’-(2-hydroxyethyl)thioureido)phenylacetate 81
H H
Compound 78 (500 mg, 2.6 mmol) in acetone (3.2 ml) was added dropwise during 30 
min to 2-aminoethanol (160 mg, 2.6 mmol) in acetone (3.2 ml). The mixture was 
boiled under reflux for 4 h. Evaporation and chromatography (EtOAc) gave 81 (400 
mg, 64%) as an oil; Rf 0.4 (EtOAc); 'H  NMR ((CD3 )2 SO) 6  3.34 (2 H, m, CH2 N),
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3.52 (2 H, br, CH2 Ar), 3.59 (3 H, s, CH3), 3.63 (2 H, m, CH2 0), 4.70 (1 H, s, OH), 
6.97 (1 H, d, J  = 1AHz, Ar 4-H) 7.24 (1 H, dd, 7.8,6.3 Hz, Ar 5-H), 7.28 (1 H,
s, Ar 2-H), 7.33 (1 H, d, J  = 6.3 Hz, Ar 6 -H), 7.69 (1 H, s, NH), 9.60 (1 H, br, NH); 
IR Vmax (film) 1061 (C=S), 1732 (C=0), 3293 (NH + OH) c m 1; MS (FAB +ve ion) 
m/z269.0953 (M + H) (Ci2 H |7 N2 0 3S requires 269.0960), 537 (2 M + H).
3-(4,5-Dihydrothiazol-2-ylamino)phenylacetic acid hydrochloride 82
©
H
Compound 81 (200 mg, 0.8 mmol) was boiled under reflux for 40 h in aq. HC1 ( 6  M, 
10 ml). Evaporation gave 82 (200 mg, quant.) as an hygroscopic gum; Rf 0.2 
(EtOAc); *H NMR ((CD3 )2 SO) 6  3.55 (2 H, t, J = 7.6 Hz, thiazole 5-H2), 3.93 (2 H, t, 
J =  7.6 Hz, thiazole 4-H2), 5.75 (2 H, s, CH2 Ar), 7.25 (3 H, m, Ar-H3), 7.44 (2 H, m, 
Ar-H + NH); 13C NMR ((CD3 )2 SO) 5 31.0 (CH2 -S), 40.5 (CH2 -Ar), 48.7 (CH2 -N),
122.0 (C-4), 124.3 (C-2), 129.1 (C-6 ), 129.8 (C-5), 135.8 (C-l) 136.8 (C-3), 171.2 
(O N ), 173.6 (C=0); IR vmax (film) 1633 (C=N), 1714 (C=0), 2600 (OH), 3450 
(NH) cm'1; MS (FAB +ve ion) m/z 237.0698 (M + H) (Cn H 1 3N2 0 2S requires 
237.0698).
Methyl 4-aminophenylacetate hydrochloride 84
    Cl0
M e02C 0
4-Aminophenylacetic acid 83 (2.0 g, 13.2 mmol) was stirred with MeOH (350 ml) 
and SOCl2 (20 ml) for 4 d. Evaporation gave 84 (2.6 g quant.) as off-white crystals: 
mp 118-120°C (lit. [De Graw and Engstrom 1975] no mp given); R f 0.5 (EtOAc); *H 
NMR ((CD3 )2 SO) 6  3.47 (3 H, br, NH3+), 3.59 (3 H, s, CH3), 3.68 (2 H, s, CH2), 7.19 
(2 H, d, J = 8 . 6  Hz, Ar 3,5-H2), 7.30 (2 H, d, J  = 8 . 6  Hz, Ar 2,6-H2); MS (FAB +ve 




Compound 84 (1.0 g, 6.0 mmol), CaCC>3 (900 mg, 9.0 mmol), water (5 ml), 
thiophosgene (1.3 g, 12.0 mmol) and CHCI3 (60 ml) were stirred vigorously for 16 h. 
The mixture was extracted with C H C I 3  and dried. Evaporation gave 85 (1.0 g, 83%) 
as an oil; (lit. [Shridhar et al1985] oil); R f 0.7 (EtOAc); 'H NMR ((CD3 )2 SO) 5 3.61 
(3 H, s, CH3), 3.73 (2 H, s, CH2), 7.34 (2 H, d, = 8 . 6  Hz, Ar 2,6-H2), 7.39 (2 H, d,
= 8 . 6  Hz, Ar 3,5-H2); IR vmax (disc) 1738 (C=0), 2120 (N=C=S) cm '1; MS (FAB +ve 
ion) m/z208 (M + H), 192 (M -  Me).
Methyl 4-thioureidophenylacetate 86
r < y \M e02C ^ = S
h 2n
Ammonia was passed through 85 (150 mg, 0.7 mmol) in CH2 CI2  (50 ml) for 1 h. The 
mixture was then stirred for 3 h at 0°C. Evaporation and chromatography (EtOAc) 
gave 8 6  (150 mg, 93%) as a white powder mp: 121-123°C; Rf 0.5 (EtOAc); lH NMR 
((CD3 )2 SO) 6  3.59 (3 H, s, CH3), 3.62 (2 H, s, CH2), 7.18 (2 H, d, J =  8.2 Hz, Ar 3,5- 
H2), 7.31 (2 H, d, J = 8.2 Hz, Ar 2,6-H2), 7.43 (2 H, br, NH2), 9.65 (1 H, s, NH); IR 
vmax (disc) 1718 (C=0), 3168 (OCH3), 3341 (NH) cm '1; MS (FAB +ve ion) 
225.0687 (M + H) (Ci0 H 1 3N2 O2S requires 225.0698), 378 (M + mNBA).
4-Thioureidophenylacetic acid hydrochloride 87
h o 2c  ^ —r y=  s




Compound 8 6  (50 mg, 0.2 mmol) was stirred for 16 h in aq. HC1 ( 6  M, 5 ml). 
Evaporation gave 87 (60 mg, quant.) as white crystals: mp 198-200°C (lit. [Richter et 
al 1974] mp 200-203°C); 'H NMR (CD3 OD) 5 3.65 (2 H, s, CH2), 7.26-7.32 (4 H, m, 
Ar-H4); IR Vmax (disc) 1181 (C=S), 1699 (C=0), 2900 (C 0 2 H), 3313 (NH) cm'1; MS 





M e02C \ = H
Compound 85 (200 mg, 1.0 mmol) in acetone (1.2 ml) was added dropwise during 30 
min to 2-aminoethanol (60 mg, 1.0 mmol) in acetone (1.2 ml). The mixture was 
boiled under reflux for 4 h. Evaporation and chromatography (EtOAc) gave 8 8  (70 
mg, 27%) as yellow crystals: mp 53-55°C; R f 0.3 (EtOAc); 'H NMR (CDC13) 6  2.35 
(1 H, br, OH), 3.64 (2 H, s, CH2 Ar), 3.72 (3 H, s, CH3), 3.80 (4 H, m, 2 x CH2), 6.56 
(1 H, br, NH), 7.20 (2 H, d, J =  7.8 Hz, Ar 3,5-H2), 7.33 (2 H, d, 7.8 Hz, Ar 2,6- 
H2), 7.94 (1 H, br, NH); IR v „ ,  (disc) 1169 (C=S), 1730 (C=0), 3325 (NH), 3480 
(OH) cm'1; MS (FAB +ve ion) m/z269.0933 (M + H) (Ci2 Hl6N 2 0 3S requires 
269.0960), 537 (2 M +H), 422 (M + mNBA).
4-(4,5-Dihydrothiazol-2-ylamino)phenylacetic acid hydrochloride 89
Compound 8 8  (110 mg, 0.2 mmol) was stirred in aq HC1 ( 6  M, 6  ml) for 16 h. 
Evaporation gave 89 (60 mg, quant.) as an hygroscopic gum; *H NMR (CD3 OD) 8  
3.67 (4 H, m, thiazole 5-H2 + CH2 Ar), 4.04 (2 H, m, thiazole 4-H2), 7.30 (2 H, d, J  =
8.2 Hz, Ar 3,5-H2), 7.43 (2 H, d, J = 8.2 Hz, Ar 2,6-H2); IR Vmax (disc) 1633 (C=N),
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1736 (C=0), 2600 (C 0 2 H), 3423 (NH) cm'1: MS (FAB +ve ion) 237.0697 (M + 
H) (CiiH,3 N 2 0 2S requires 237.0698).
Methyl 3-cyanobenzoate 91
3-Cyanobenzoic acid 90 (2.0 g, 13.6 mmol) was stirred with MeOH (180 ml) and 
SOCI2 ( 1 0  ml) for 4 d. Evaporation gave 91 (920 mg, 42%) as white crystals: mp 38- 
40°C (lit. [Tanaka et al1998] oil); R f 0.7 (EtOAc); 'H NMR (CDCI3 ) 5 3.96 (3 H, s, 
CH3), 7.95 (1 H, t, J =  7.8 Hz, Ar 5-H), 7.84 (1 H, d, = 7.8 Hz, Ar 4-H), 8.27 (1 H, 
d, J  = 7.8 Hz, Ar 6 -H), 8.34 (1 H, s, Ar 2-H); IR vmax (disc) 1720 (C=0), 2228 (CN) 
c m 1; MS (FAB +ve ion) m/z 162 (M + H), 315 (M + mNBA), 147 (M -  CH3).
Methyl 3-(aminomethyl)benzoate 92 and 
Bis(3-methoxycarbonylphenylmethyl)amine 93
(92) (93)
Compound 91 (900 mg, 5.6 mmol) in MeOH (30 ml) was treated with Pd/C (10%), 
and H2 for 16 h. Evaporation and chromatography (EtOAc) gave 92 (330 mg 36%) as 
white crystals: mp 37-39°C (lit. [Ashton et al 1998] no mp given); Rf 0.1 (EtOAc) 
and 93 (150 mg, 8 . 6  %) as an oil (lit. [Ashton et al 1998] oil); R f 0.5 (EtOAc);
Compound 92
'H NMR (CDClj) 8  3.92 (3 H, s, CH3), 3.95 (2 H, s, CH2), 7.40 (1 H, t , J =  7.8 Hz, 
Ar 5-H), 7.53 (1 H, d, J =  7.8 Hz, Ar 4-H), 7.92 (1 H, 7.8 Hz, Ar 6 -H), 8.01 (1 
H, s, Ar 2-H); IR vmx (film) 1719 (C O ), 3453 (NH) cm'1; MS (FAB +ve ion) m/z 




'H  NMR (CDCI3 ) 5 3.84 (4 H, s, 2 x CH2), 3.91 ( 6  H, s, 2 x CH3), 7.40 (2 H, t,
7.8 Hz, 2 x Ar 5-H), 7.52 (2 H, d, J =  7.8 Hz, 2 x Ar 4-H), 7.93 (2 H, d, 7.8 Hz, 2 
x Ar 6 -H), 8.02 (2 H, s, 2 x Ar 2-H); IR vmax (film) 1721 (C=0), 3336 (NH) c m 1; 
MS (FAB +ve ion) m/z314 (M + H), 467 (M + mNBA).
Methyl 3-(isothiocyanatomethyl)benzoate 94
NCS
Compound 92 (270 mg, 1.6 mmol), CaCC>3 (160 mg, 1.6 mmol), water (3 ml), 
thiophosgene (360 mg, 3.2 mmol) and CHCI3 (20 ml) were stirred vigorously for 16 
h. The mixture was extracted with CHCI3 and dried. Evaporation and 
chromatography (EtOAc) gave 94 (170 mg, 51%) as an oil; R f 0.7 (EtOAc); *H 
NMR (CDCI3 ) 5 3.94 (3 H, s, CH3), 4.79 (2 H, s, CH2), 7.50 (1 H, t, J =  7.8 Hz, Ar
5-H), 7.54 (1 H, d, J=  7.8 Hz, Ar 4-H), 8.0 (1 H, d, J=  7.8 Hz, Ar 6 -H), 8.03 (1 H, s, 
Ar 2-H); IR vmax (film) 1722 (C=0), 2101 ( N O S )  cm '1; MS (FAB +ve ion) m/z 




Ammonia was passed through 94 (60 mg, 0.3 mmol) in CH2 C12 (20 ml) for 1 h. The 
mixture was then stirred for 3 h at 0°C. Evaporation and chromatography (EtOAc) 
gave 95 (80 mg, quant.) as pale yellow crystals: mp 123-125°C; JH NMR (CD3 OD) 6
3.89 (3 H, s, CH3), 4.88 (2 H, s, CH2), 7.44 (1 H, t, J=  7.8 Hz, Ar 5-H), 7.56 (1 H, d, 
J = 7.8 Hz, Ar 4-H), 7.90 (1 H, d, J=  7.8 Hz, Ar 6 -H), 8.03 (1 H, s, Ar 2-H); IR vmax 
(disc) 1202 (C=S), 1710 (C=0), 3418 (NH) cm'1; MS (FAB +ve ion) m/z 225.0708 
(C ,0H ioN 0 2S requires 225.0698), 208 (M + H), 149 (M -  NCS), 225 (M + H), 378 
(M + mNBA), 449 (2 M + H), 211 (M -  CH3).
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3-(Thioureidomethyl)benzoic acid hydrobromide 96
HO
s
Compound 95 (80 mg, 0.4 mmol) was stirred in hydrobromic acid (50%, 5 ml) for 16 
h. Evaporation gave 96 (70 mg, 98%) as an hygroscopic gum; ’H NMR (CD3 OD) 8
3.89 (2 H, s, CH2), 7.45 (1 H, t, J =  7.8 Hz, Ar 5-H), 7.57 (1 H, d, J = 7.8 Hz, Ar 4- 
H), 7.91 (1 H, d, J =  7.8 Hz, Ar 6 -H), 8.08 (1 H, s, Ar 2-H); IR vmax (film) 1704 




Compound 8 8  (80 mg, 0.4 mmol) in acetone (0.6 ml) was added dropwise during 30 
min to 2-aminoethanol (20 mg, 0.4 mmol) in acetone (0.6 ml). The mixture was 
boiled under reflux for 2.5 h. Evaporation and chromatography (EtOAc) gave 97 (80 
mg, 77%) as an oil; R f 0.2 (EtOAc); 'H NMR (CD3 OD) 8  3.60 (2 H, m, C //2 NH),
3.66 (2 H, m, C //2 OH), 3.89 (3 H, s, CH3), 4.80 (2 H, s, CH2 Ar), 7.44 (1 H, t, 7.8 
Hz, Ar 5-H), 7.56 (1 H, d, J  = 7.8 Hz, Ar 4-H), 7.88 (1 H, d, = 7.8 Hz, Ar 6 -H), 
7.96 (1 H, s, Ar 2-H); IR Vmax (film) 1197 (C=S), 1715 (C=0), 3355 (NH + OH) 
cm '1; MS (FAB +ve ion) m/z269.0955 (M + H) (C 1 2H 1 7N2 O3 S requires 269.0960), 
537 (2 M + H).
Methyl 3-(4,5-dihydrothiazol-2-ylamino)benzoate hydrochloride 98
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Compound 97 (70 mg, 0.3 mmol) was boiled under reflux for 40 h in aq. HC1 ( 6  M, 5 
ml). Evaporation gave crude 3-(4,5-dihydrothiazol-2-ylamino)methyl benzoic acid 
hydrochloride as an hygroscopic gum. This material (70 mg, 0.3 mmol) was stirred 
with MeOH (70 ml) and SOCI2 (0.5 ml) for 4 d. Evaporation gave 98 (50 mg, 67%) 
as an oil; *H NMR (CDC13) 8  3.51 (2 H, m, thiazole 5-H2), 3.92 (3 H, s, CH3), 4.02 
(2 H, m, thiazole 4-H2), 4.54 (2 H, s, CH2 Ar), 7.47 (1 H, t, J =  7.4 Hz, Ar 5-H), 7.57 
(1 H, d ,J =  1A  Hz, Ar 4-H), 7.95 (1 H, s, Ar 2-H), 7.99 (1 H, d, J =  1A  Hz, Ar 6 -H),
10.40 (1 H, br, NH), 10.93 (1 H, br, NH): IR vmax (film) 1640 (C=N), 1718 (C=0), 
3398 (NH) cm’1; MS (FAB +ve ion) m/z 251.0859 (M + H) (Ci2 H 14N2 0 2S requires 
251.0854).
3-(4,5-Dihydrothiazol-2-ylaminomethyl)benzoic acid trifluoroacetate salt 99
Compound 98 (70 mg, 0.3 mmol) was stirred in aq. trifluoroacetic acid (50%, 5 ml) 
under reflux for 16 h. Evaporation gave 99 (70 mg, quant.) as an hygroscopic gum; 
'H NMR (CD3 OD) 5 3.65 (2 H, t , J =  7.8 Hz, thiazole 5-H2), 4.04 (2 H, t, 7.8 Hz, 
thiazole 4-H2), 4.60 (2 H, m, CH2 Ar), 7.54 (3 H, m, Ar-H3), 8.02 (1 H, m, Ar-H); IR 
Vmax (disc) 1645 (C=N), 1696 (C=0), 2600 (C 0 2 H), 3433 (NH) c m 1; MS (FAB +ve 
ion) m/z237.0698 (M + H) (Cn Hl3 N2 0 2S requires 237.0698).
Methyl 4-(aminomethyl)benzoate hydrochloride 101
4-Aminomethylbenzoic acid 100 (2.0 g, 13.2 mmol), was stirred with MeOH (350 
ml) and SOCl2 (20 ml) for 4 d. Evaporation gave 101 (2.2 g, 99%) as white crystals: 
mp 153-155°C (lit. [Milkiewicz et al2000] no mp given); R f 0.5 (EtOAc); 'H NMR 
((CD3 )2 SO) 5 3.84 (3 H, s, CH3), 4.08 (2 H, s, CH2), 7.64 (2 H, 8.2 Hz, Ar 3,5-
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H2), 7.96 (2 H, d, J=  8.2 Hz, Ar 2,6-H2), 8.62 (3 H, br, NH3); MS (FAB +ve ion) m/z 
319 (M + mNBA), 166 (M + H), 150 (M -  NH2).
Methyl 4-(isothiocyanatomethyl)benzoate 102
NCS
Compound 101 (1.0 g, 6.0 mmol), CaC0 3 (900 mg, 9.0 mmol), water (5 ml), 
thiophosgene (1.3 g, 1 2  mmol) and CHC13 (60 ml) were stirred vigorously for 16 h. 
The mixture was extracted with CHC13 and dried. Evaporation gave 102 (1.0 g, 
83%) as a pale yellow liquid: (lit. [Emerson and Heimsch 1950] bp 138-152°C; Rf 
0.6 (EtOAc); 'H NMR ((CD3 )2 SO) 5 3.88 (3 H, s, CH3), 5.05 (2 H, s, CH2), 7.49 (2 
H, d , J =  8.4 Hz, Ar 3,5-H2), 7.98 (2 H, d ,J =  8.4 Hz, Ar 2,6-H2); IR vmx (film) 1715 
(C=0), 2089 ( N O S )  cm'1; MS (FAB +ve ion) 360 (M + mNBA), 208 (M + H), 
192 (M -M e).
Methyl 4-(thioureidomethyl)benzoate 103
Ammonia was passed through compound 102 (150 mg, 0.7 mmol) in CH2 C12 (20 ml) 
for 1 h. The mixture was then stirred for 3 h at 0°C. Evaporation and 
chromatography (EtOAc/hexane 1:1) gave 103 (60 mg, 99%) as white crystals: mp 
131-133°C; R f 0.2 (EtOAc/hexane 1:1); *H NMR ((CD3 )2 SO) 6  3.82 (3 H, s, CH3), 
4.70 (2 H, s, CH2), 7.18 (2 H, br, NH2), 7.38 (2 H, d, 8.2 Hz, Ar 3,5-H2), 7.90 (2 
H, d, J  = 8.2 Hz, Ar 2,6-H2), 8.06 (1 H, br NH); IR v™  (disc) 1179 (C=S), 1711




4-(Thioureidomethyl)benzoic acid hydrobromide 104
Compound 103 (40 mg, 0.2 mmol) was stirred in hydrobromic acid (50%, 8 ml) for 
16 h. Evaporation gave 104 as an hygroscopic gum (40 mg, quant.); ]H NMR 
(CD3OD) 6 3.88 (2 H, s, CH2), 7.41 (2 H, d, J =  8.3 Hz, Ar 3,5-H2), 7.97 (2 H, d, J  =
8.3 Hz, Ar 2,6-H2); v™* (disc) 1176 (C=S), 1705 (C=0), 3031 (C 02H), 3382 (NH) 






Compound 102 (500 mg, 2.4 mmol) in acetone (3.0 ml) was added drop wise during 
30 min to 2-aminoethanol (160 mg, 2.4 mmol) in acetone (3.0 ml). The mixture was 
boiled under reflux for 4 h. Evaporation and chromatography (EtOAc) gave 105 
(280 mg, 43%) as white crystals: mp 105-107°C; Rf 0.3 (EtOAc); and 106 (400 mg, 
64%) as buff crystals: mp 75-77°C; Rf 0.6 (EtOAc);
Compound 105
'H NMR ((CD3)2SO) 5 1.69 (6 H, s, 2 x CH3), 3.82 (3 H, s, OCH3), 3.64 (2 H, t, /  =
6.3 Hz, oxazole 4-H2), 3.96 (2 H, t, J =  6.3 Hz, oxazole 5-H2), 4.82 (2 H, d,
Hz, CH2Ar), 7.39 (2 H, d, J -  8.2 Hz, Ar 3,5-H2), 7.88 (2 H, d, = 8.2 Hz, Ar 2,6- 
H2), 7.84 (1 H, br, NH); IR Vmax (disc) 1199 (C=S), 1701 (C=0), 3359 (NH) cm’1; 




'H  NMR ((CD3 )2 SO) 8  3.47 (4 H, m, 2  x CH2), 3.82 (3 H, s, CH3), 4.74 (3 H, m, 
CH2Ar + OH), 7.38 (2 H, d , J =  8.2 Hz, Ar 3,5-H2), 7.89 (2 H, d, = 8.2 Hz, Ar 2,6- 
H2), 7.58 (1 H, br, NH), 8.01 (1 H, br, NH); IR vmax (film) 1194 (C=S), 1714 (C=0), 
3351 (NH + OH) cm"1; MS (FAB +ve ion) 269.0961 (M + H) (Ci2Hi6 N2 0 3S 
requires 269.0960).
4-(4,5-Dihydrothiazol-2-ylaminomethyl)benzoic acid hydrochloride 107
Cl©
Compound 106 (70 mg, 0.3 mmol) was boiled under reflux for 40 h in aq. HC1 ( 6  M, 
5 ml). Evaporation gave 107 (200 mg, quant.) as yellow crystals: mp 138-140°C; Rf 
0.2 (EtOAc); *H NMR ((CD3)2 SO) 8  3.57 (2 H, t, J =  7A  Hz, thiazole 5-H2), 3.92 (2 
H, t, J =  7.4 Hz, thiazole 4-H2), 4.73 (2 H, s, CH2 Ar), 7.46 (2 H, d, J  = 8.2 Hz, Ar
3,5-H2), 7.95 (2 H, d, J =  8.2 Hz, Ar 2,6-H2), 10.66 (1 H, br, NH), 13.05 (1 H, br, 
NH); IR vmax (film) 1656 (O N ), 1697 (C=0), 2600 (OH), 3430 (NH) cm’1; MS 




3-Methoxybenzylamine 108 (1.5 g, 11 mmol), CaC0 3 (1.0 g, 1.0 mmol), water ( 8  
ml), thiophosgene (1.1 g, 9.2 mmol) and CHC13 (80 ml) were stirred vigorously for 
16 h. The mixture was extracted with CHC13 and dried. Evaporation and 
chromatography (EtOAc/hexane 1:1) gave 109 (800 mg, 40%) as an oil: (lit. 
[Ettlinger and Lundeen 1956] oil); Rf 0.6 (EtOAc/hexane 1:1); *H NMR (CDC13) 6
3.82 (3 H, s, CH3), 4.68 (2 H, s, CH2), 6.87 (3 H, m, Ar 2,4,6-H3), 7.30 (1 H, t, J  =
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7.8 Hz, Ar 5-H); IR v™, (film) 2094 ( N O S )  cm'1; MS (FAB +ve ion) m/z 
180.0460 (M + H) (C9 H 1 0NOS requires 180.0483), 121 (M -  NCS).
N-(3-Methoxyphenylmethyl)thiourea 110
s
Ammonia was passed through compound 109 (300 mg, 1.7 mmol) in CH2 CI2 (50 ml) 
for 1 h. The mixture was then stirred for 3 h at 0°C. Evaporation and 
chromatography (EtOAc) gave 110 (340 mg, quant.) as an oil: (lit. [Ettlinger and 
Lundeen 1956] mp 101-103°C) Rf 0.5 (EtOAc); ’H NMR (CDC13) 5 3.80 (3 H, s, 
CH3), 4.20 (1 H, br, NH), 4.77 (2 H, m, CH2), 5.83 (2 H, s, NH2), 6 . 8 6  (3 H, m, Ar
2,4,6-H3), 7.27 (1 H, m, Ar 5-H); IR v^x (film) 1046 (C=S), 2835 (OCH3), 3273 
(NH) cm '1; MS (FAB +ve ion) m/z 197.0751 (M + H) (C9 H 13N2OS requires 
197.0749), 1 2 1  (M -N H C SN H 2).
N-(2-Hydroxyethyl)-N’-(3-methoxyphenyImethyl)thiourea 111
N Y  O H
S
Compound 109 (100 mg, 0.5 mmol) in acetone (0.6 ml) was added dropwise during 
30 min to 2-aminoethanol (30 mg, 0.5 mmol) in acetone (0.6 ml). The mixture was 
boiled under reflux for 4 h. Evaporation and chromatography (EtOAc) gave 111 
(100 mg, 85%) as an oil; R f 0.3 (EtOAc); *H NMR ((CD3 )2 SO) 5 3.36 (4 H, m, 2 * 
CH2), 3.67 (3 H, s, CH3), 4.55 (2 H, m, CH2 Ar), 4.78 (1 H, s, OH), 6.80 (1 H, dd, J  = 
7 A, 2.1 Hz, Ar 6 -H), 6 . 8 6  (1 H, dd, J  = 7.4, 2.1 Hz, Ar 4-H), 6.85 (1 H, s, Ar 2-H), 
7.23 (1 H, t, J  = 1A Hz, Ar 5-H), 7.52 (1 H, br, NH), 7.92 (1 H, br, NH); ,3C NMR 
((CD3 )2 SO) 5 46.7 (CH2), 48.5 (CH2), 55.3 (CH2 -Ar), 112.9 (C-2) 113.2 (C-3), 119.7 
(C-5,6), 129.7 (C-1,3), 159.6 (C=S); IR vmax (film) 1167 (C=S), 3292 (NH + OH)
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cm '1; MS (FAB +ve ion) m/z 241.1009 (M + H) (C 1 1H 1 7N2 O2 S requires 241.1011), 
393 (M + mNBA).
2-(3-Methoxyphenylmethylamino)-4,5 dihydrothiazole 112
Compound 110 was stirred in trifluoroacetic acid (5 ml) for 2 h. Evaporation and 
chromatography (EtOAc/MeOH 5:1) gave 112 (200 mg, 75%) as an oil; Rf 0.2 
(EtOAc/MeOH 5:1); 'H NMR (CDC13) 5 3.46 (2 H, t, 7.6 Hz, thiazole 5-H2),
(1 H, s, NH); 13C NMR (CDCI3 ) 5 31.1 (CH2 S), 48.7 (CH2 N), 51.3 (CH2Ar), 55.2 
(CH3), 112.9 (Ar 2-C), 114.0 (Ar 4-C), 119.6 (Ar 6 -C), 130.0 (Ar 5-C), 136.5 (Ar 1- 
C), 160.0 (Ar 3-C), 174.6 (C=N); IR vmax (film) 1681 (C=N), 3200 (NH) c m 1; MS 
(FAB +ve ion) m/z2 3.0890 (M + H) (C ,,H ,5 N2OS requires 223.0905).
2-(3-Methoxyphenylmethylamino)-4,5-dihydrothiazole 112
Compound 108 was heated with 20 (320 mg, 2.4 mmol) at 180°C for 4 h. 
Evaporation and chromatography (EtOAc/MeOH 5:1) gave 112 (163 mg, 30%) as 
white crystals: mp 94-96°C; Rf 0.2 (EtOAc/MeOH 5:1); 'H NMR (CDC13) 5 3.59 (2
H, m, Ar 5-H); IR vmax (disc) 1653 (C=N), 3420 (NH) cm'1; MS (FAB +ve ion) m/z 
223.0902 (M + H) (Ci,H 1 5N2OS requires 223.0905).
3.82 (3 H, s, CH3), 3.95 (2 H, t, J=  7.6 Hz, thiazole 4-H2), 4.43 (2 H, d, J=  5.6 Hz, 
CH2 Ar), 6.87 (3 H, m, Ar 2,4,6-H3), 7.28 (1 H, m, Ar 5-H), 12.25 (1 H, s, NH), 12.36
Me
H, t, J  = 7.4 Hz, thiazole 5-H2), 3.80 (3 H, s, CH3), 4.04 (2 H, t, J=  1A Hz, thiazole




Compound 19 (1.0 g, 7.3 mmol), CaCC>3 (0.7 g, 0.7 mmol), water (5 ml), 
thiophosgene (1.6 g, 15 mmol) and CHCI3 (50 ml) were stirred vigorously for 16 h. 
The mixture was extracted with CHCI3 and dried. Evaporation and chromatography 
(EtOAc/hexane 1:1) gave 113 (1.0 g 80%) as a pale yellow liquid: (lit. [Buckley and 
Oppenheimer 1994] liquid); R f 0.7 (EtOAc/hexane 1:1); ‘H NMR (CDC13) 8  3.81 (3 
H, s, CH3), 4.63 (2 H, s, CH2), 6.93 (2 H, d, 8.2 Hz, Ar 3,5-H2), 7.22 (2 H, d , J  =
8.2 Hz, Ar 2,6-H2); IR vTOX (film) 2087 ( N O S )  cm'1; MS (FAB +ve ion) 179 
(M), 121 (M-NCS).
N-(4-Methoxyphenylmethyl)thiourea 114
Ammonia was passed through compound 113 (600 mg, 3.2 mmol) in CH2 CI2  (50 ml) 
for 30 min. The mixture was then stirred for 3 h at 0°C. Evaporation and 
chromatography (EtOAc/hexane 1:1) gave 114 (600 mg, 99%) as white crystals: mp 
124-126°C (lit. [Huter 1947] mp 135°C); 'H NMR (CDC13) 8  3.87 (3 H, s, CH3), 4.38 
(2 H, br, CH2), 5.75 (2 H, br, NH2), 6 . 8 8  (1 H, br, NH), 6.90 (2 H, d, = 8.4 Hz, Ar
3,5-H2), 7.23 (2 H, d, J  = 8.4 Hz, Ar 2,6-H2); IR vmax (disc) 1177 (C=S), 2800 
(OCH3), 3165 (NH) c m 1; MS (FAB +ve ion) 197.0749 (M + H) (C9 H,3 N2OS 
requires 197.0751), 393 (2 M + H), 350 (M + mNBA), 121 (M -  CH3N2 S); Found C, 




Compound 113 (400 mg, 2.2 mmol) in acetone (2.7 ml) was added dropwise during 
30 min to 2-aminoethanol (134 mg, 2.2 mmol) in acetone (2.7 ml). The mixture was 
boiled under reflux for 2 h. Evaporation and chromatography (EtOAc) gave 115 
(250 mg, 47%) as an oil; Rf 0.3 (EtOAc); ‘H NMR (CDCI3 ) 6  3.49 (3 H, s, CH3 ),
3.66 (2 H, br, CH2NH), 3.81 (2 H, m, CH2 OH), 4.58 (2 H, s, CH2 Ar), 6.48 (1 H, br, 
NH), 6.74 (1 H, br, NH), 6.87 (2 H, d, J =  8. 6  Hz, Ar 3,5-H2), 7.25 (2 H, d, = 8 . 6  
Hz, Ar 2,6-H2); IR vmax (film) 1171 (C=S), 3336 (NH + OH) c m 1; MS (FAB +ve 
ion) m/z241.1011 (M + H) (Cn H,7N 2 0 2S requires 241.1018), 394 (M + mNBA).
N-(3-Methoxyphenyl)thiourea 117
Ammonia was passed through 3-methoxyphenylisothiocyanate 116 (500 mg, 3.0 
mmol) in CH2 CI2 (75 ml) for 1 h. The mixture was then stirred for 3 h at 0°C. 
Evaporation gave 117 (600 mg, quant.) as white crystals: mp 160-162°C (lit. 
[Rasmussen et al1988] mp 109°C); Rf 0.5 (EtOAc); ‘H NMR (CDCI3 ) 8  3.73 (3 H, 
s, CH3), 6.67 (1 H, d, J =  8.2 Hz, Ar 4-H), 6.90 (1 H, d, 7.6 Hz, Ar 6 -H), 7.10 (1 
H, s, Ar 2-H), 7.23 (1 H, dd, J  = 8.2, 7.6 Hz, Ar 5-H), 7.53 (2 H, br, NH2) 9.62 (1 H, 
s, NH); l3C NMR ((CD3 )2 SO) 8  55.1 (CH3), 108.6 (C-2) 110.0 (C-6 ), 115.0 (C-4), 
129.6 (C-5), 140.3 (C-l), 159.3 (C-3), 180.9 (C=S); IR vmax (disc) 1166 (C=S), 3149 
(NH) cm '1; MS (FAB +ve ion) m/z183.0598 (M + H) (C8 HnN2OS requires 
183.0592), 336 (M + mNBA), 365 (2 M +H); Found C, 52.50: H, 5.53; N, 15.40; 
C8 H,0 N2OS requires C, 52.72; H, 5.53; N, 15.37%.
N-(2-Hydroxyethyl)-N’-(3-methoxyphenyl)thiourea 118
Compound 116 (500 mg, 3.0 mmol) in acetone (3.5 ml) was added dropwise during 
30 min to 2-aminoethanol (183 mg, 3.0 mmol) in acetone (3.5 ml). The mixture was
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boiled under reflux for 2 h. Evaporation gave 118 (570 mg, 84%) as white crystals: 
mp 129-131°C; Rf 0.4 (EtOAc); 'H NMR ((CD3)2SO) 5 3.52 (4 H, m, 2 x CH2), 3.70 
(3 H, s, CH3), 4.80 (1 H, br, OH), 6.65 (1 H, 7.8 Hz, Ar 6-H), 6.90 (1 H,
7.8 Hz, Ar 4-H), 7.20 (2 H, m, Ar 2,5-H2), 7.71 (1 H, br, NH), 9.41 (1 H, s, NH); IR 
vmax (disc) 1149 (C=S), 2900 (OCH3), 3186 (NH) cm '1; MS (FAB +ve ion) 
227.0846 (M + H) (C,0H15N2O2S requires 227.0854), 452 (2M + H); Found C, 53.4: 




MeCT 'N  
H
Compound 118 was stirred in trifluoroacetic acid (5 ml) for 3 h. Evaporation and 
chromatography (EtOAc) gave 119 (130 mg, 70%) as buff crystals: mp 80-82°C; Rf 
0.2 (EtOAc); NMR ((CD3)2SO) 6 4.17 (3 H, s, CH3), 3.92 (2 H, t, J  = 7.6 Hz, 
thiazole 5-H2), 4.35 (2 H, t, J =  7.6 Hz, thiazole 4-H2) 7.24 (1 H, d, J =  8.2 Hz, Ar 4- 
H), 7.34 (1 H, d, J = 8.2 Hz, Ar 6-H), 7.41 (1 H, s, NH), 7.73 (1 H, t, J =  8.2 Hz, Ar
5-H), 7.74 (1 H, s, Ar 2-H); IR vmax (disc) 1674 (O N ), 2850 (OCH3), 3238 (NH) 
cm'1; MS (FAB +ve ion) m/z 209.0749 (M + H) (Ci0Hi3N2OS requires 209.0743), 
362 (M + mNBA).
N-(4-Methoxyphenyl)thiourea 121
s
jf— \} - N H 2 
MeO—^  y—N
Ammonia was passed through 4-methoxyphenylisothiocyanate 120 (500 mg, 3.0 
mmol) in CH2C12 (75 ml) for 1 h. The mixture was then stirred for 3 h at 0°C; 
Evaporation gave 121 (340 mg, quant.) as white crystals: mp 198-200°C (lit. 
[Rasmussen et al1988] mp 155-157°C); R f 0.5 (EtOAc); ‘H NMR (CDC13) 5 3.71 
(3 H, s, CH3), 6.89 (2 H, d, J  = 8.8 Hz, Ar 3,5-H2), 7.21 (2 H, d, 8.8 Hz, Ar 2,6-
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H2), 7.23 (2 H, br, NH2), 9.47 (1 H, s, NH); IR vm»  (disc) 1171 (C=S), 2838 
(OCH3), 3154 (NH) cm '1; MS (FAB +ve ion) 183.0592 (M + H) (C8 H 10N2OS 
requires 183.0592), 335 (M + mNBA).
N-(2-Hydroxyethyl)-N’-(4-methoxyphenyI)thiourea 122
OH
Compound 120 (500 mg, 3.0 mmol) in acetone (3.5 ml) was added dropwise during 
30 min to 2-aminoethanol (183 mg, 3.0 mmol) in acetone (3.5 ml). The mixture was 
boiled under reflux for 90 min. Evaporation and chromatography (EtOAc) gave 122 
(600 mg, 8 8 %) as buff crystals: mp 145-147°C (lit. [Adock and Lawson 1965] 146- 
147°C); R f 0.5 (EtOAc); 'H NMR ((CD3 )2 SO) 8  3.35 (3 H, s, CH3), 3.73 (4 H, m, 2 x 
CH2), 4.79 (1 H, br, OH), 6 . 8 8  (2 H, d, J  = 8. 6  Hz, Ar 3,5-H2), 7.24 (2 H, d, = 8 . 6  
Hz, Ar 2,6-H2), 7.46 (1 H, br, NH), 9.41 ( 1  H, s, NH); IR vm  (disc) 1165 (O S ), 
2835 (OCH3), 3189 (NH), 3646 (OH) cm '1; MS (FAB +ve ion) 227.0850 (M + 
H) (Cl0 Hl5N 2 O2S requires 227.0854), 380 (M + mNBA); Found C, 53.0: H, 6.17; N, 
12.2: C iiHI4 N2 0 2S requires C, 53.08; H, 6.24; N, 12.38%.
2-(4-Methoxyphenylamino)-4,5-dihydrothiazole trifluoroacetate salt 123
Compound 122 (200 mg, 0.88 mmol) was stirred in trifluoroacetic acid (5 ml) under 
reflux for 15 h. Evaporation gave 123 (220 mg, quant.) as white crystals: mp 101- 
103°C (lit. [Tisler et al 1958] mp 127.5°C for free base); Rf 0.6 (EtOAc/MeOH 1:1); 
‘H NMR ((CD3 )2 SO) 5 2.29 (3 H, s, CH3), 3.60 (2 H, m, thiazole 5-H2) 3.75 (2 H, m, 
thiazole 4-H2), 7.02 (2 H, d, J  = 6.9 Hz, Ar 3,5-H2), 7.25 (2 H, d, 6.9 Hz, Ar 2,6- 
H2), 7.97 (1 H, br, NH); IR Vrrax (disc) 1674 (C=N), 2750 (OCH3), 3409 (NH) cm'1;
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MS (FAB +ve ion) m/z 209.0758 (M + H) (Ci0 Hi3N2OS requires 209.0749), 362 (M 
+ mNBA).




Cbz-Lys-OH 124 (2.1 g, 7.5 mmol) was stirred with MeOH (100 ml) and SOCl2  (11 
ml) for 4 d. Evaporation gave 125 (1.5 g, 65%) as an hygroscopic gum: (lit. 
[Ranganathan et al 1993] mp 113-115°C for free base); Rf 0.5 (EtOAc/MeOH 5:1); 
'H NMR ((CD3 )2 SO) 5 1.35 (2 H, m, Lys y-H2), 1.45-1.80 (4 H, m, Lys, P,5-H4), 
2.75 (2 H, m, Lys e-H2), 3.68 (3 H, s, CH3), 4.00 (1 H, m, Lys <x-H), 5.03 (2 H, m, 
PhCH2), 7.38-7.45 (5 H, m, Ph-H5), 7.75 (1 H, d, 7.8 Hz, NH), 7.99 (1 H, br, 
NH3+); [a ] D 2 0  = -10.6° (c = 1.6 mg ml’1, MeOH); MS (FAB +ve ion) m/z 295.1662 




Compound 125 (1.0 g, 3.4 mmol), CaC0 3 (400 mg, 4.4 mmol), water (5 ml), 
thiophosgene (780 mg, 6 . 8  mmol) and CHC13 (40 ml) were stirred vigorously for 16 
h. The mixture was extracted with CHC13 and dried. Evaporation gave 126 (600 mg, 
52%) as an oil; R f 0.5 (EtOAc/hexane 1:1); ]H NMR (CDC13) 6  1.48 (2 H, m, 4-H2),
1.66 (4 H, m, 3,5-H4), 3.51 (2 H, t, J  = 6.2 Hz, 6 -H2), 3.76 (3 H, s, CH3), 4.40 (1 H, 
m, 1-H), 5.03 (2 H, s, CH2 Ar), 5.35 (1 H, d, J = 7.8 Hz, NH), 7.36-7.38 (5 H, m, Ar- 
H5); 13C NMR ((CD3 )2 SO) 6  22.6 (C-4), 28.8 (C-3), 28.8 (C-5), 44.8 (C-6 ), 51.9
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(CH3), 53.6 (C-2), 126.9 (CH2 -Ar), 126.9 (Ar-4), 127.7 (Ar-2), 128.2 (Ar-3), 128.5 
(Ar-5), 128.7 (Ar-6 ), 136.8 (Ar-1 ), 155.9 (C=S), 172.5, 173.5 (2 x C=0); IR vmax 
(film) 1721 (C=0), 2109 (N=C=S), 3348 (NH) cm '1; MS (FAB +ve ion) m/z 
337.1218 (M + H) (C 1 6H2 1 N2 O4 S requires 337.1222), 673 (2 M + H).
Ne-Aminothiocarbonyl-Na-phenylmethoxycarbonyl-L-lysine methyl ester 127
sx
r o r " N H 2
CbzHN C 02Me
Ammonia was passed through 126 (300 mg, 0.9 mmol) in CH2 CI2  (30 ml) for 1 h. 
The mixture was then stirred for 3 h at 0°C. Evaporation and chromatography 
(EtOAc/MeOH 5:1) gave 127 (180 mg, 59%) as a yellow oil; Rf 0.3 (EtOAc/MeOH 
5:1); *H NMR ((CD3)2SO) 8 1.40 (2 H, m, Lys y-H2), 1.65 (4 H, m, Lys, P,8-H4), 
3.05 (1 H, m) and 3.56 (1 H, m) (Lys c-H2), 3.75 (3 H, s, CH3), 4.34 (1 H, m, Lys a- 
H), 5.03 (2 H, s, CH2Ar), 6.89 (1 H, br NH), 7.34-7.37 (7 H, m, Ar-H5 + NH2) 7.74 
(1 H, s, NH); IR vmax (film) 1159 (C=S), 3200 (NH) cm '1; MS (FAB +ve ion) m/z 
354.1497 (M + H) (Ci6H24N30 4S requires 354.1488).
N8-Aminothiocarbonyl-L-lysine methyl ester dihydrobromide 128
S
A©h n ^ n h 3
J  2.Br0  
C 02Me
Compound 127 (100 mg, 0.3 mmol) was stirred in HBr in HOAc (17.5%, 4 ml) for 
15 h. Dry Et20  (10 ml) was added, the mixture was stirred for 5 min and then Et20 
was decanted; this was repeated 8 times. Drying gave 128 (78 mg, quant.) as a
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colourless hygroscopic gum; Rf 0.4 (MeOH); 'H NMR ((CD3)2SO) 5 1.43-1.90 (6 H,
3030 (NH) cm '1; MS (FAB +ve ion) m/z 220.1119 (M + H) (C8HigN30 2S requires 
220. 1120).
NE-Aminothiocarbonyl-L-lysine dihydrobromide 129
Compound 128 (50 mg, 0.2 mmol) was stirred in hydrobromic acid (5 ml) for 16 h. 
Evaporation gave 129 (60 mg, quant) as a colourless hygroscopic gum; !H NMR 
(CD3OD) 6 1.5-2.0 (6 H, m, Lys P,y,5-H6), 2.96 (2 H, t, J =  7.8 Hz, Lys e-H2), 4.01 
(1 H, t, J=  6.6 Hz, Lys ct-H); 13C NMR 6 22.3 (C-y), 27.4 (C-P), 30.1 (C-5), 43.9 (C- 
e), 52.7 (C-a), 128.8 (C=0), 170.4 (C=S); IR vmax (film) 1194 (C=S), 1739 (C=0), 




Compound 125 (500 mg, 1.5 mmol) in acetone (2 ml) was added dropwise during 30 
min to 2-aminoethanol (82 mg, 1.4 mmol) in acetone (2 ml). The mixture was boiled
m, Lys p,y,S-H6), 3.29 (2 H, m, Lys e-H 2), 3.67 (3 H, s, CH3), 4.01 (1 H, m, Lys cx- 
H), 7.52 (1 H, br NH), 8.34 (1 H, s, NH); IR (film) 1240 (C=S), 1742 (C=0),
S
CbzHN u u i\tt(u n 2;2uii
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under reflux for 4 h. Evaporation and chromatography (EtOAc/MeOH 5:1) gave 130 
(340 mg, 53%) as an oil; Rf 0.6 (EtOAc/MeOH 5:1); *H NMR ((CD3)2SO) 6 1.43 (6 
H, m, Lys P,y,5-H6), 3.15 (2 H, m, Lys s-H2), 3.35 (4 H, m) and 3.44 (2 H, m) and 
3.94 (2 H, m) (2 x CH2CH20), 3.94 (1 H, m, NHCbz), 4.25 (1 H, t, J =  7.4 Hz, NH),
4.67 (1 H, t, J  = 5.5 Hz, Lys <x-H), 5.01 (2 H, s, PhCH2), 7.10 (1 H, br, NH), 7.34-
7.40 (5 H, m, Ar-H5), 7.87 (1 H, br, NH); IR vmax (film) 1148 (O S ), 1711 (O O ), 
3370 (NH) cm '1; MS (FAB +ve) m/z 875 (2 M + Na), 853 (2 M + H), 449 (M + Na), 
427 (M + H), 91 (Bn).
A|C-(4,5-Dihydrothiazol-2-yl)lysine dihydrochloride 131
Compound 130 (330 mg, 0.91 mmol) was boiled under reflux for 36 h in aq. HC1 (6 
M, 4 ml). Evaporation gave 131 (160 mg, 76%) as an hygroscopic gum; 'H NMR 
((CD3)2SO) 5 1.44 (6 H, m, Lys P,y,5-H6), 2.80 (2 H, m, Lys e-H2), 3.35 (2 H, m, 
thiazole 5-H2), 3.49 (1 H, m, Lys a-H), 3.58 (2 H, m, thiazole 4-H2), 8.10 (3 H, br, 
N+H3) 8.50 (2 H, br, 2 x NH); 13C NMR ((CD3)2SO) 8 21.6 (C-8), 29.5 (C-8), 30.9 
(C-P), 38.6 (CH2-S), 44.8 (C-e), 51.8 (C-a), 57.6 (CH2-N), 169.6 (C=N), 171.0 
(C=0); IR vmax (film) 1651 (C=N), 1750 (C=0), 2600 (C 02H), 3413 (NH) c m 1; MS 





3-Iodobenzoic acid 132 (30 g, 120 mmol), was stirred with MeOH (600 ml) and 
SOCI2  (90 ml) for 4 d. Evaporation gave 133 (31 g, 98%) as white crystals: mp 47- 
49°C (lit. [Chaikovski et al2000] mp: 52-54°C); R f 0.7 (EtOAc); ‘H NMR (CDC13) 
6  3.92 (3 H, s, CH3), 7.17 (1 H, t, J=  7.8 Hz, Ar 5-H), 7.88 (1 H, dd 1.0, 7.8 Hz, 
Ar 6 -H), 7.98 (1 H, dd, J =  1.0, 7.8 Hz, Ar 4-H), 8.38 (1 H, s, Ar 2-H); MS (El +ve 
ion) m/z262 (M).
Methyl 3-(2-carboxyethenyl)benzoate 134
Compound 133 (1 g, 4 mmol), propenoic acid (360 mg, 5 mmol), palladium(II) 
acetate (85 mg, 0.4 mmol), EtsN (250 mg, 2.5 mmol) in propanenitrile (3 ml) were 
boiled under reflux for 1 h. aq. HC1 (100 ml, 2 M) was added to the cooled mixture. 
The precipitate, in hot ethanol, was filtered and the filtrate was allowed to cool 
slowly. The solid was collected and dried to give 134 (850 mg, quant.) as off-white 
crystals: mp: 145-147°C; R f 0.4 (EtOAc); ‘H NMR ((CD3 )2 SO) 5 3.87 (3 H, s, CH3),
6.61 (1 H, d, J =  16.0 Hz, CHC0 2H), 7.56 (1 H, t 7.8 Hz, Ar 5-H), 7.66 (1 H, d,
J =  16.0 Hz, CH-Ar), 7.97 (1 H, d , J =  7.8 Hz, Ar 4-H), 7.98 (1 H, d, = 7.8 Hz, Ar
6 -H), 8.18 (1 H, s, Ar 2-H); MS (FAB +ve ion) m/z 207.0659 (C nH n0 4  requires 
207.0657), 162 ( M - C 0 2 H).
Prop-2-yl 3-(3-(prop-2-yloxy(carbonyl)phenyl)propanoate 135
Compound 134 (200 mg, 1.0 mmol) in propan-2-ol (20 ml) and conc. H2 SO4  (1 ml) 
was heated under reflux for 24 h. The mixture was cooled, poured onto ice and then 
extracted with diethyl ether. The extracts were dried. Evaporation and
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chromatography gave 135 (140 mg, 50%) as an oil; Rf 0.8 (EtOAc); 'H NMR 
(CDCI3 ) 5 1.32 ( 6  H, d, J  = 6.3 Hz, 2 x CH3), 1.38 ( 6  H, d, = 6.3 Hz, 2 x CH3), 
1.39 (3 H, s, CH3), 5.16 (1 H, m, CH), 5.24 (1 H, m, CH), 6.48 (1 H, d, 16.1 Hz, 
CHCO2 H), 7.46 (1 H, t, J =  7.8 Hz, Ar 5-H), 7.68 (1 H, d, = 7.8 Hz, Ar 4-H), 7.69 
(1 H, d, J =  16.0 Hz, CH-Ar), 8.02 (1 H, d, 7.8 Hz, Ar 6 -H), 8.18 (1 H, s, Ar 2-
H); MS (FAB +ve ion) m/z 277.1427 (Ci6 H2 iO requires 277.1440).
Prop-2-yl 2(/J), 3(5)-3-acetamido-2-hydroxy-3-(3-prop-2-yloxycarbonyl)phenyl) 
propanoate 136
Y
K2 [0 s0 2 (0 H)4] (15 mg, 0.04 mmol) was dissolved in 3 ml LiOH.H20  (43 mg, 4.0 
mmol). 2-Methylpropan-2-ol ( 6  ml) was added followed by (DHQ)2PHAL (40 mg, 
0.05 mmol) and the mixture was stirred for 10 min to give a clear solution. Water ( 6  
ml) was added and the mixture was immersed in a cooling bath 4°C. After the 
addition of 135 (280 mg, 1 mmol), N-bromoacetamide (152 mg, 1.1 mmol) was 
added in one portion and the mixture was stirred at 4°C. The reaction was monitored 
by TLC and pH (pH 7 indicating that the reaction was complete). After 24 h, 
Na2 SC> 3 (5.0 g, 4.0 mmol) was added and the mixture was stirred for 30 min at 20°C. 
EtOAc (5 ml) was added and the organic layer was extracted, washed with brine and 
dried. Evaporation and chromatography (acetone/hexane 1:1) gave 126 (113 mg, 
32%) as an oil; Rf 0.4 (acetone/hexane 1:1); *H NMR (CDCI3 ) 5 1.28 ( 6  H, d, J=  6.3 
Hz, 2 x CH3), 1.39 ( 6  H, d, / =  6.3 Hz, 2 x CH3), 1.97 (3 H, s, CH3), 4.46 (1 H, s, 
C//OH), 5.10 (1 H, m, CH), 5.24 (1 H, m, CH), 5.55 (1 H, d, J  = 8.9 Hz, CENH), 
6 . 8 8  (1 H, d, J = 9.4 Hz, NH), 7.38 (1 H, t, J=  7.8 Hz, Ar 5-H), 7.56 (1 H, d, J=  7.8 
Hz, Ar 6 -H), 7.94 (1 H, d, / =  7.8 Hz, Ar 4-H), 8.06 (1 H, s, Ar 2-H); ; [a ] D 2 0  = - 







3-Methoxyisothiocyanate (116) (500 mg. 3.0 mmol) in acetone (2.1 ml) was added 
dropwise during 30 min to (R)-(-)-l-Aminopropan-2-ol (420 mg, 4.0 mmol) in 
acetone (2.1 ml). The mixture was boiled under reflux for 2 h. Evaporation and 
chromatography (EtOAc/hexane 1:1) gave 145 (270 mg, 38%) as an oil; Rf 0.3 
(EtOAc/hexane 1:1); *H NMR (CDC13) 5 1.22 (3 H, d, J  = 6.3 Hz, CH3), 3.46 (1 H, 
m, CHNH), 3.81 (3 H, s, OCH3), 3.94 (1 H, m, C//NH), 4.02 (1 H, C//OH), 6.64 (1 
H, br, NH), 6.78 (3 H, m, Ar 2,4,6-H3), 7.33 (1 H, t, J =  8.2 Hz, Ar 5-H), 7.76 (1 H, 
br, NH); IR vmax (film) 1180 (C=S), 2850 (OCH3), 3369 (NH) cm '1; [a ] D 2 0  = -7.2° (c 
= 1.4 mg 1 m l'1, MeOH); MS (FAB +ve ion) m/z 241.1007 (C 1 1H 17N2 O2 S requires 
241.1011).
(S)-2-(3-Methoxyphenylamino)-5-methyl-4,5-dihydrothiazole 146
Compound 145 (80 mg, 0.3 mmol) was boiled under reflux for 24 h in aq. HC1 ( 6  M, 
4 ml). Evaporation gave 146 (70 mg, quant.) as an oil; 'H NMR (CDCI3 ) 8  1.51 (3 
H, d, J =  5.9 Hz, thiazoleCHj), 3.72 (1 H, m, CHNH), 3.81 (3 H, s, OMe), 3.94 (1 H,
m, CHNH),4.11 (2 H, m, CHNH + CHS), 6.81 (1 H, m, Ar 6 -H), 6 . 8 8  (1 H, d, J = 8.2 
Hz, Ar 4-H), 7.30 (1 H, s, Ar 2-H), 7.32 (1 H, t, = 8.2 Hz, Ar 5-H), 10.67 (1 H, br, 
NH), 12.29 (1 H, br, NH); IR vmax (film) 1629 (C=N), 3434 (NH) c m 1; [ct] D 2 0  = - 




a,a-Dideuteroglycine methyl ester hydrochloride 148
Cl© D
C02Me
a,a-Dideuteroglycine 147 (300 mg, 3.9 mmol) was stirred with MeOH (50 ml) and 
SOCI2 (3 ml) for 4 d. Evaporation gave 148 (460 mg, quant.) as white crystals: mp 
113-115°C (lit. [Tiley et al1994] mp 174-176°C; 'H NMR ((CD3 )2 SO) 6  3.36 (3 H, 
s, CH3), 8.35 (2 H, br, NH2); IR vmax (disc) 1748 (C=0), 2170 (CD2), 3400 (NH) 
cm '1: MS (FAB +ve ion) m/z92 (M + H), 245 (M+ mNBA).
a,a-Dideutero-N-(l,l-dimethylethoxycarbonyl)glycine methyl ester 149
D
BocHN^ x  C02Me 
D
Di-tert-butyl dicarbonate (950 mg, 4.4 mmol) was added slowly to compound 148 
(400 mg, 4.4 mmol) and Et3N (730 mg, 7.2 mmol) in CH2 CI2  (15 ml) at 0°C and the 
mixture was stirred for 16 h. The solvent was evaporated. The residue, in CH2 CI2 , 
was washed with aq. NaHC0 3  and dried. Evaporation and chromatography 
(EtOAc/hexane 1:1) gave 149 (260 mg, 31%) as an oil (lit. [Elemes and Ragnarson 
1996] mp 87.5-88.5 °C); R f 0.6 (EtOAc/hexane 1:1); ’H NMR (CDC13) 6  1.45 (9 H, 
s, Bul), 3.75 (3 H, s, CH3), 5.00 (1 H, br, NH); IR vmax (disc) 1747 (C=0), 2362 
(CD2), 3451 (NH) cm'1: MS (FAB +ve ion) m/z 192 (M + H), 345 (M + mNBA).
1,1-Dimethylethyl N-(l,l-dideutero-2-hydroxyethyl)carbamate 150
BocH
Compound 149 (200 mg, 1.0 mmol) was taken up in dry THF (5 ml). LiBH4  (2 M 
solution in THF, 1.2 ml, 2.4 mmol) was added and the mixture was stirred for 16h
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under Ar. The mixture was quenched with water and extracted with EtOAc. 
Evaporation and chromatography (EtOAc/hexane 1:1) gave 150 (120 mg, 73%) as an 
oil; R f 0.3 (EtOAc/hexane 1:1); 'H NMR (CDC13) 6  1.45 (9 H, s, Bu‘), 2.44 (1 H, br, 
OH), 3.70 (2 H, d, J  = 4.3 Hz, CH2), 4.94 (1 H, br, NH); IR vmax (film) 1716 (C=0), 
2123 (CD2), 3348 (NH) c m 1: MS (FAB +ve ion) 164.1261 (M + H)







Compound 150 (100 mg, 0.6 mmol) was stirred in aq. HC1 (6 M, 5 ml,) for 10 min. 
Evaporation gave 151 (100 mg, quant.) as white crystals; mp 148-150 °C (lit. [Tiley 
et al1994] free base bp l 0  68-75°C); Rf 0.1 (EtOAc); 'H NMR ((CD3 )2 SO) 6  3.57 (2 
H, t, J  = 5.3 Hz, CH2), 4.21 (1 H, br, OH), 8.09 (3 H, br, NH3+); IR vmax (disc) 2358
(CD2), 3433 (NH); MS (FAB +ve ion) m/z64 (M + H), 217 (M + mNBA).




Benzyl chloroformate (380 mg, 2.2 mmol) was added slowly to 148 (200 mg, 2.2 
mmol) and Et3N (560 mg, 5.5 mmol) in CH2 C12 (30 ml) at 0°C and the mixture was 
stirred for 16 h. The solvent was evaporated. The residue, in CH2 C12, was washed 
with aq. NaHC0 3 and dried. Evaporation and chromatography (EtOAc/hexane 1:1) 
gave 153 (220 mg, 44%) as white crystals mp 175-177°C; Rf 0.4 (EtOAc/hexane 
1:1); 'H  NMR (CDC13) 6  3.76 (3 H, s, CH3), 5.13 (2 H, s, CH2), 7.36 ( 6  H, m, Ph-H5 
+ NH); IR Vmax (disc) 1666 (0=0), 2554 (CD2), 3436 (NH) cm-1; MS (FAB +ve ion) 







Compound 153 (210 mg, 0.9 mmol) was taken up in dry THF (2 ml). 0.1ml UBH 4  
was added and the mixture was stirred for 16h under Ar. The mixture was quenched 
with water and extracted with EtOAc. Evaporation and chromatography (EtOAc) 
gave 154 (150 mg, 82%) as white crystals: mp 60-62°C; (lit. [Hamada et al 1987] mp 
60-62°C for unlabelled); R f 0.4 (EtOAc); 'H NMR (CDC13) 5 2.80 (1 H, br, OH),
H5); IR (film) 1668 (0=0), 2300 (CD2), 3421 (NH + OH) cm '1; MS (FAB +ve 
ion) m/z 198.1101 (M + H) (CioHnD2 N0 3  requires 198.1130).
2-Amino-2,2-dideuteroethanol bromide 155
Compound 154 (70 mg, 0.4 mmol) was stirred in HBr in HOAc (17.5%, 2 ml) for 15 
h. Dry Et2 0  (10 ml) was added, the mixture was stirred for 5 min and then Et2 0  was 
decanted; this was repeated 6  times. Drying gave 155 (30 mg, quant.) as pale purple 
crystals: mp 62-64°C; ‘H NMR (CD3 OD) 8  4.28 (1 H, br, OH), 4.62 (2 H, s, CH2); 
MS (FAB +ve ion) m/z64 (M + H); 217 (M + mNBA).
2-(3-Methoxyphenylamino)thiazole-5-one 159
Compound 116 (500 mg. 3.0 mmol) in acetone (2.1 ml) was added dropwise during 
30 min to glycine ethyl ester (420 mg, 4.0 mmol) in acetone (2.1 ml). The mixture






was boiled under reflux for 16 h. Evaporation and chromatography (EtOAc/hexane 
1:1) gave 159 (420 mg, 52%) as an oil; Rf 0.5 (EtOAc/hexane 1:1); *H NMR 
((CD3 )2 SO) 6  3.78 (3 H, s, CH3), 4.27 (2 H, s, CH2), 6.85 (2 H, d, J=  8.2 Hz, Ar 6 - 
H2), 7.01 (2 H, d, J=  8.2 Hz, Ar 4-H2), 7.35 (1 H, t, J = 8.2 Hz, Ar 5-H), 7.40 (1 H, 
s, Ar 2-H); 13C NMR ((CD3 )2 SO) 5 49.6 (CH2), 55.8 (CH3), 114.6 (C-2), 115.3 (C-6 ), 
121.6 (C-4), 129.9 (C-5), 135.1 (C-3), 159.9 (C-l), 172.6 (C=N), 183.8 (O O ); IR v 
max (film) 1694 (C=N), 1761 (C=0), 3244 (NH) cm'1; MS (El +) m/z 222.0464 (M) 
(CioH1 0N2 0 2S requires 222.0463), 378 (M + mNBA).
N-(2,2-Dimethoxyethyl)-N’-(3-methoxyphenyl)thiourea 163
Compound 116 (500 mg. 3.0 mmol) in CH2 C12  (2 ml) was added to 2,2- 
dimethoxyethylamine (280 mg, 3.0 mmol) in CHC12 (2 ml). The mixture was boiled 
under reflux for 1 h. Evaporation and chromatography (EtOAc/hexane 1:1) gave 163 
(420 mg, 52%) as an oil; R f 0.5 (EtOAc/hexane 1:1); 'H  NMR (CD3 OD) 8  3.40 ( 6  H, 
s, 2  x CH3), 3.70 ( 2  H, d, J  = 5.5 Hz, CH2), 3.79 (3 H, s, CH3), 4.61 ( 1  H, t, 5.5 
Hz, CH), 6.75 (2 H, ddd, J  = 0.8, 2.7, 8.5 Hz, Ar 6 -H), 6.84 (2 H, ddd, 0.8, 2.0, 
8.2 Hz, Ar 4-H), 7.01 (1 H, dd, J =  2.0, 2.7 Hz, Ar 5-H), 7.25 (1 H, t, J =  7.8 Hz, Ar 
2-H); IR vmax (film) 1125 (C=S), 2834 (OCH3), 3369 (NH) c m 1; MS (FAB +ve ion) 
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Pharmacological actions of two NOS inhibitors: N-(3- 
aminomethyl)phenylmethylthiourea and L-NAME on 
in vitro longitudinal muscle of rat ileum
Introduction
Nitric oxide has been found to be involved in the relaxation of smooth muscle. 
Evidence comes from in vitro studies which show that nitric oxide is involved in the 
nonadrenergic-noncholinergic response in circular and longitudal muscle of rat ileum 
and causes an increase in cGMP which leads to a relaxation of smooth muscle 
(Allescher et al 1992). Ninety percent of the total NOS found in rat ileum is nNOS 
and iNOS, with iNOS being predominant.
L-NAME has been shown to cause frequent intestinal muscular contractions in rats 
when administered intravenously. These contractions were inhibited by L-arginine 
and therefore suggest NOS inhibition plays a role in this response. The constriction 
of vascular smooth muscle is thought to occur by inhibition of nNOS while 
contraction of the gastrointestinal tract occurs through inhibition of nNOS and iNOS.
Aim
The aim of this study was to evaluate the pharmacological effects of N-(3- 
aminomethyl)phenylmethyl)thiourea (35) on longitudinal muscle in isolated rat 
ileum, compared to the known NOS inhibitor L-NAME (3).
Methods
These experiments were carried out by MPharm undergraduate project students 
Laura Baber and Georgina Watson.
Preparation of ileal segments
Male Wistar rats were killed and the ileum was dissected into approximately 3 cm 
segments which were washed with Tyrode solution and suspended vertically in their 
longitudinal direction at a load of 1 g in a 30 ml organ bath. The organ bath 
contained Tyrode solution at 37°C and gassed with 5% CO2 in O2 . The tissues were
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allowed to equilibrate for 30 min. Initial organ bath concentrations used for the
O
cumulative dose response curves for 35 and 3 were 1 x 10 '  M.
Recording of response of ileal longitudinal muscle
The activity of the longitudinal muscle of the rat ileum segments was recorded on 
isotonic transducers and the data was transferred and recorded on the computer 
software program, Powerlab. Relaxation was defined as the lengthening of the 
preparation and was recorded on Powerlab as a decrease in voltage. Contraction was 
defined as shortening of the preparation and was recorded on Powerlab as an increase 
in voltage.
Results
Compounds 3, 35 and isoprenaline all caused the longitudinal muscle of rat ileum 
segments to relax. EC50 values could not be obtained for the NOS inhibitors, as there 
was a limited supply of both inhibitors. Therefore threshold values at which the 
compounds elicited a relaxation response were calculated.
Compound added to 







35 20 1.6 X 10'5 2.5 X 10‘5
3 8 3.1 x 10‘5 3.4 x 10'5
Isoprenaline 14 4.2 x 10‘8 5.1 x 10'8
Table 7.1: Mean threshold values for NOS inhibitors 35 and 3.
The table above shows the mean threshold values obtained. Compound 35 required 
the highest concentration to elicit a response; however, there was no statistical
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difference between 35 and 3 but, there were statistically significant differences 
between isoprenaline and 3 and isoprenaline and 35. Figure 5.6 shows the relaxation





















Figure 7.1: shows a) response (relaxation) of pre-contracted rat ileum following the 





The two NOS inhibitors used in this study, 3 and 35, elicited a relaxation response in 
pre-contracted rat ileum. These data conflicts with other studies involving 3, 
(Allescher et al 1992 and Calignano et al 1992) in which the compound has been 
shown to cause a contraction both in vitro and in vivo. However, the methods used 
in previous studies differ from those used in this study.
The differences in the methods used may explain why a relaxation response was 
observed and not a contractile response. The NOS enzymes were not activated in the 
resting smooth muscle cells and, therefore, inhibition of the NOS enzymes with 3 or 
35 did not elicit a contractile response in the rat ileum. Alternatively, if  NOS 
enzymes were active, a contractile response may not have been observed because 3 
and 35 were not allowed sufficient time to equilibrate in order to inhibit the NOS 
enzymes.
This study has shown that both NOS inhibitors 3 and 35 can elicit a relaxation 
response that is unrelated to their inhibitory action of the NOS enzymes. The 
mechanism by which this relaxation occurs remains unknown.
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Human tumours have high levels of NO, the main source deriving from iNOS. NO is 
responsible for the increase in blood flow to the tumour. The administration of the 
iNOS inhibitor 1400W (1) has been shown to reduce the rate of solid tumour growth 
in mice (Thomsen et al 1997). Selective inhibition of tumours should cause collapse 
of the tumour vasculature, which may be an antitumour event in itself but which will 
also increase tumour hypoxia and potentiate the cytotoxicity of bioreductively 
activated drugs.
N5-(4,5-dihydrothiazol-2-yl)-L-omithine (2), £-2-amino-5-(imidazol-1 -yl)pentanoic 
acid (3) and (1) have been used as lead compounds in the design of potent and 
selective NOS inhibitors. Both 2 and 3 were potent but not isoform-selective; 2 has 
IC50 values of 32 pM, 19 pM and 13 pM for iNOS, nNOS and cNOS, respectively. 
Compound 3 has IC50 values of 8 pM, 4 pM and 1 pM for iNOS, nNOS and cNOS, 
respectively. New compounds have been designed using the potent thiazole head 
group and incorporating features of the selective iNOS inhibitor 1 (Ki 0.14 pM 
iNOS) with the aim of giving rise to both potent and selective inhibitors.
N-(3-Aminomethyl)phenylmethyl)thiourea (4) was synthesised from 3- 
nitrobenzylamine. Boc protection and reduction of the nitro group, followed by 
treatment with thiophosgene, gave the isothiocyanate. Reaction with ammonia gave 
the thiourea and deprotection with trifluoroacetic acid gave the target. The 2,4- 
dihydrothiazole head group was added to methoxybenzylamine under harsh 
conditions, (180°C, 4 h) using 2-methylthio-4,5-dihydrothiazole. Other structurally 
related targets were synthesised analogously. All compounds were initially screened 
at one concentration (100 pM) in the presence of 10 pM arginine, for inhibition of 
rat brain cNOS and rat lung iNOS; results below are expressed as % inhibition. 
Wherever preliminary screening results showed good inhibition, the IC50 values were 
determined.
Compound 4 was the most potent inhibitor against iNOS and cNOS. (IC5 0  30 pM 
and 6 pM for iNOS and cNOS, respectively). The compounds tested showed limited 
isoform selectivity, of which the greatest selectivity for iNOS was seen for 5 (iNOS 
55%, cNOS 25%) and 6 (iNOS 46%, cNOS 21%) after five minutes pre-incubation. 
In contrast, 4 showed the greatest selectivity for cNOS (iNOS 27%, cNOS 88%), 
especially after a five minute pre-incubation. The selectivity for iNOS in 1 is thought 
to be based on the 7-atom bridge between the remote Fe-binding amidine N and the 
N+H3 . The 4,5-dihydrothiazole and thiourea head groups may be important in the 
potency of the inhibitor. The pre-incubation time appears to be important in the 
isoform selectivity of the compounds, suggesting that slow-binding inhibition may be 
involved.
4: X = CH2NHCSNH2 
N-.
7: X = CH2NH— ("gj 
8: X = NHCSNH2
